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Zusammenfassung: 
 
G-Protein gekoppelte Rezeptoren (GPCRs) bilden die größte Hauptklasse innerhalb 
jener Gruppe von Transmembranproteinen, die ein extrazelluläres Signal in eine spezifische 
intrazelluläre Reaktion (Signaltransduktion) umwandeln. Etwa 3% des humanen Genoms 
codieren für GPCRs, wobei diese wiederum den Angriffspunkt für 40-50% der zurzeit auf 
dem Markt befindlichen Pharmaka bilden. Diese Angaben unterstreichen die Wichtigkeit 
der GPCR-Superfamilie und verdeutlichen die Notwendigkeit für ein tief greifendes 
Verständnis ihrer Funktionsweise. Die externen Stimuli, die über GPCRs eine spezifische 
intrazelluläre Reaktion auslösen können, sind sehr vielfältig. Sie reichen von Licht, 
Geruchs- und Geschmacksstoffen über Amine, Peptide, Lipiden und Nukleotiden bis hin zu 
Ionen wie etwa  Ca
2+. Die ligandeninduzierte Konformationsänderung des Rezeptors 
überträgt das Signal auf ein cytosolisches Guanin-Nukleotide bindendes Protein (G-
Protein), das daraufhin seinerseits eine Kaskade zellulärer Reaktionen startet. 
 
Während in den letzten Jahrzehnten vielfältigste biochemische und 
pharmakologische Daten über diese Proteinfamilie gesammelt werden konnten, sind die 
vorhandenen Strukturinformationen immer noch sehr ungenügend. Die einzige für diese 
Proteinsuperfamilie bisher verfügbare dreidimensionale Struktur hoher Auflösung ist die 
des bovinen Rhodopsins. Einer der Hauptgründe für die Schwierigkeit der 
Stukturaufklärung bei GPCRs ist die mangelnde Verfügbarkeit des Zielproteins selbst: In 
ihren nativen Geweben werden GPCRs üblicherweise nur in verschwindend geringen 
Mengen exprimiert. Daher ist die Reinigung der für Strukturuntersuchungen benötigten 
Mengen aus nativen Geweben stets sehr zeitaufwendig und in vielen Fällen gar nicht 
möglich. Um diese erste Hürde auf dem Weg der Strukturaufklärung zu überwinden, wurde 
eine Vielzahl heterologer Expressionssysteme etabliert. Eine weitere Schwierigkeit bei der 
Strukturbestimmung von GPCRs liegt in der Tatsache begründet, dass es sich bei dieser 
Proteinfamilie um integrale Membranproteine handelt, und bei diesen eine 
Strukturbestimmung generell eine große Herausforderung darstellt. Während zurzeit bei 
den löslichen Proteinen bereits mehr als 13000 hochauflösende Strukturen zur Verfügung stehen, sind es bei den Membranproteinen gerade einmal etwa 120. Einer der Gründe für 
dieses dramatische Ungleichgewicht dürften die nur recht kleinen hydrophilen 
Oberflächenbereiche der Membranproteine sein, da hierdurch die Möglichkeiten für 
Kristallkontakte zwischen den einzelnen Proteinmolekülen einschränkt wird. Bei GPCRs 
letztlich werden die einzigen hydrophilen Bereiche von den die Transmembranhelices 
verbindenden intra- und extrazellulären Schleifen sowie den N- und C-Termini gebildet. 
Die genannten Bereiche sind sowohl relativ klein als auch strukturell eher flexibel, was eine 
Kristallisation weiter erschwert.  
 
Die vorliegende Arbeit ist ein Versuch, Wege zur Lösung der oben genannten 
Probleme aufzuzeigen. Ziel des Projektes war die Verwendung von G-Proteinen, um 
zusammen mit einem GPCR einen Komplex zu schaffen, dessen hydrophiele Beireiche 
stark vergrößert sind. Es handelt sich hierbei um einen der Protein-Kokristallisation mit Fv-
Antikörperfragmenten entsprechenden Ansatz. Da es sich bei G-Proteinen zudem um den 
physiologischen Bindungs- und Interaktionspartner der GPCRs handelt, wäre die Struktur 
eines solchen Komplexes zudem von besonderem Interesse. Bei G-Proteinen handelt es sich 
um heterotrimere Proteine, mit je einer α-, β- und γ-Untereinheit, wobei der α-Untereinheit 
(Gα) bei der Wechselwirkung mit dem GPCR die größte Bedeutung zukommt. Im humanen 
Genom wurden 21 verschiedenartige α-Untereinheiten identifiziert, wobei es sich jedoch 
bei einigen von ihnen um Splice-Varianten handelt. In der vorliegenden Arbeit wurden 
insgesamt 16 verschiedene Gα-Untereinheiten unter Verwendung des GATEWAY
®-
Systems in den Vektor pDEST14 kloniert und in Escherichia coli expremiert. Zur 
Bestimmung der optimalen Induktionsbedingungen und -zeiten kam ein Hochdurchsatz-
Screen auf Dotblot-Basis zum Einsatz. Bei fünf der in E. coli exprimierten Gα-
Untereinheiten war es möglich, diese mittels einer Kombination aus Immobilisierter 
Metallchelat-Affinitätschromatographie (IMAC) und Ionenaustausch-Chromatographie rein 
darzustellen. Die Bemühungen, auch die Gβ- und Gγ-Untereinheiten in E. coli herzustellen, 
waren hingegen nicht erfolgreich. Gαq, das zu jenen Gα-Untereinheiten zählt, die sich nicht 
in  E. coli expremieren ließen, wurde erfolgreich in der methylotrophen Hefe Pichia 
Pastoris produziert. Das aus P. pastoris gereinigte Gαq-Protein konnte für 
Kristallisationsansätze genutzt werden. Unter einer Bedingung wurden Kristalle erhalten, 
die eine Röntgenbeugung bis 6,5 Å zeigten. Zurzeit besteht ein Problem bei der Produktion 
dieser Untereinheit, das noch der Klärung bedarf. Die Gα-Untereinheiten, die rein dargestellt werden konnten, wurden hinsichtlich ihrer Aktivität in Detergenz analysiert. 
Hierbei zeigte sich, dass die Mitglieder der Gαs-Subklasse (stimulieren die Adenylat-
Cyclase) in Detergenz keinerlei Aktivität aufwiesen. Die Mitglieder der Gαi-Subklasse 
(inhibieren die Adenylat-Cyclase) behielten hingegen in den meisten der getesteten 
Detergenzien ihre Fähigkeit der Guanosintriphosphat(GTP)-Bindung bei. Aus diesen 
Ergebnissen folgt, dass die Kokristallisation eines GPCRs mit Gαs wohl nicht sinnvoll ist, 
da bei solchen Ansätzen aufgrund des Rezeptors stets Detergenz anwesend sein muss. Zu 
diesem Zeitpunkt des Projektes standen in unserem Institut nur wenige an Gαi koppelnde 
GPCRs zur Verfügung, die in ausreichenden Mengen rein dargestellt werden konnten um 
die Gαi-Bindung zu studieren. Des Weiteren legten andere Veröffentlichungen nahe, dass in 
E. coli produzierte Gα-Untereinheiten alleine nicht in der Lage sind, an GPCRs zu binden. 
Aus diesen Gründen wurde das Projekt dahingehend erweitert, einen jener GPCRs zu 
gewinnen, von denen berichtet wurde, sie lägen in der Zelle bereits ohne gebundenen 
Liganden in einem Komplex mit ihrem G-Protein vor. Von der Reinigung eines solchen 
physiologischen Komplexes wurden sich erhebliche Vorteile für die Kristallisation 
versprochen. 
 
Für die heterologe Produktion und anschließende Reinigung unter oben genanntem 
Aspekt wurden die Cannabinoid-Rezeptoren ausgewählt. Zurzeit unterscheidet man zwei 
Subtypen von Cannabinoid-Rezeptoren. Zum einen den Cannabinoid-Rezeptor 1, der 
vornehmlich im zentralen und peripheren Nervensystem vorkommt und zum anderen den 
Cannabinoid-Rezeptor 2, welcher in Immunzellen gefunden wird. Beide Subtypen koppeln 
an Gαi/o. Aus ihrer histologischen Verteilung wurde gefolgert, dass der Cannabinoid-
Rezeptor 1 vermutlich eine neuroprotektive Funktion hat, während der Cannabinoid-
Rezeptor 2 immunosuppressiv wirkt. Die Cannabinoid-Rezeptoren sind zudem der 
Angriffspunkt der Inhaltsstoffe von Cannabis (Marihuana, Haschisch), der am weitesten 
verbreiteten Rauschmittel. Die Verwendung von Marihuana geht jedoch über die eines 
bloßen Rauschmittels hinaus, da es bereits seit 2000 vor Christus zur Behandlung einer 
Reihe von Krankheiten eingesetzt wird. Der Pflanzenextrakt aus Cannabis sativa war z.B. 
dafür bekannt, Schmerzen zu lindern, Übelkeit zu unterdrücken und den Appetit zu fördern. 
Nach wissenschaftlicher Analyse des Cannabis sativa-Extraktes konnte ∆9-Tetrahydro-
cannabinol als hauptsächlicher aktiver Bestandteil identifiziert werden. Der Pflanzenextrakt 
enthält jedoch etwa 50 weitere, diesem verwandte Verbindungen, die mit unterschiedlichen Affinitäten an die Cannabinoid-Rezeptoren binden und eventuell eigene pharmakologische 
Wirkungen entfalten. Weitreichende Forschungen während der letzten Jahrzehnte haben 
demonstriert, dass es sich bei den Cannabinoid-Rezeptoren um viel versprechende Ziel-
proteine bei der Bekämpfung einer Vielzahl von Krankheitssymptomen handelt. 
 
Die Produktion des Cannabinoid-Rezeptors 2 wurde zunächst im Pichia pastoris 
Expressionssystem untersucht. Das Expressionskonstrukt beinhaltete ein N-terminales 
Dekahistidin-Anhängsel sowie C-terminal die Biotinylierungsdomäne der Transcarboxylase 
aus Propionibacterium shermanii (Biotag). Leider stellte sich das produzierte Protein als 
ausgesprochen heterogen heraus, in den Zellmembranen waren mehrere oligomere Formen 
vorhanden, sowie verschiedene Degradationsprodukte. Versuche zur Reinigung des 
Proteins erwiesen sich sowohl hinsichtlich der erreichten Reinheit als auch der Ausbeute als 
ungenügend. Zudem zeigte die analytische Gelfiltrations-Chromatographie, dass der 
Großteil des Proteins aggregiert war.  
 
Als alternatives Expressionssystem wurde daher die Bakulovirus-vermittelte 
Expression in Insektenzellen untersucht. Hierbei lag der Fokus mehr auf der heterologen 
Produktion des Cannabinoid-Rezeptors 1, da bei diesem zum einen detaillierteres 
Verständnis der biochemischen Vorgänge vorliegt und er zum anderen die größere 
pharmakologische Wichtigkeit besitzt. Für die heterologe Produktion wurde sowohl eine 
Vollängenversion  des Rezeptors als auch eine Version mit deletiertem C-Terminus 
verwendet. Zur Reinigung mittels Affinitätschromatographie wurden von beiden Versionen 
Konstrukte erstellt, die mit einem N-terminalen Polyhistidin-Anhängsel versehen waren 
und C-terminal entweder das Strep II-Anhängsel oder das Biotag trugen. Bei sämtlichen 
getesteten Konstrukten war eine Überproduktion in Spodoptera frugiperda (Sf9) Zellen zu 
beobachten.  
 
Mit N-terminalem Decahistidin-Anhängsel und C-terminalem Strep II-Anhängsel 
betrug das Produktionsniveau (Bmax) für das Vollängenkonstrukt 40 pmol/mg und 53 
pmol/mg für die verkürzte Version. Diese Mengen sind gut doppelt so hoch wie die besten 
bis jetzt veröffentlichten Angaben und bilden eine gute Grundlage für eine nachfolgende 
Reinigung des Rezeptors. Die Charakterisierung des Rezeptors mittels 
Radioligandenbindung zeigte, dass die Agonistenbindung des Cannabinoid-Rezeptors 1 von der Anwesenheit von Magnesiumionen abhängig war, während die Antagonistenbinung 
Mg
2+-unabhängig erfolgte. Ferner führten hohe Natriumchlorid-Konzentrationen im 
Reaktionspuffer zu einer verminderten Agonisten-Bindung, während sie die Antagonisten-
Bindung nicht beeinflussten. Im Gegensatz zu anderen GPCRs konnte für den Cannabinoid-
Rezeptors 1 auch dann noch Ligandenbindung gemessen werden, wenn 1,4-Dithiothreit 
(DTT) in höheren Konzentrationen (10 mM) anwesend war. Andererseits führte die 
Mehrzahl der getesteten Detergenzien zu einer Verringerung der Ligandenbindung. 
Aufgrund hoher unspezifischer Bindung des Radioliganden war ein Nachweis der 
Ligandenbindung für den solubilisierten sowie für den gereinigten Rezeptor bisher nicht 
erfolgreich. 
 
Wie den bereits vorliegenden Publikationen anderer Gruppen zu entnehmen war, 
stellte die reine Darstellung dieses Rezeptors eine erhebliche Herausforderung dar. Die 
nach Reinigung mittels IMAC vorliegende Präparation wies dann auch eine Reinheit von 
bestenfalls 50% auf. Eine nachfolgende zweite Affinitätschromatographie unter 
Verwendung von monomerer Avidin-Matrix (Biotag) oder Strep-Tactin-Agarose (Strep II-
Anhängsel) führte zu einer drastischen Verringerung der Ausbeute. Im Falle der Strep-
Tactin-Agarose erfolgte die Bindung des rekombinanten Rezeptors mit nur geringer 
Effizienz, während die Bindung an die monomere Avidin-Matrix überwiegend irreversibel 
war. Auch nach der zweiten Affinitätschromatographie wies die Präparation noch 
verschiedene Verunreinigungen auf und Variationen der Waschbedingungen konnten keine 
Verbesserung herbeiführen. Daraufhin wurde die Reinigung des Rezeptors mittels 
verschiedener IMAC-Matrices erprobt. Unter Verwendung einer von der Firma Sigma 
vertriebenen Ni-NTA-Matrix mit der Bezeichnung His-Select konnte ein deutlich 
verbessertes Reinigungsprofil erhalten werden. Unter optimierten Bedingungen wurde zwar 
eine Reinheit von etwa 80% erreicht, die Ausbeute lag hierbei allerdings lediglich bei 20% 
und war damit für den Beginn von Strukturuntersuchungen nicht genügend. Das 
Gelfiltrationsprofil des gereinigten Rezeptors war zudem inhomogen und deutete auf 
verschiedene oligomere Formen in der Präparation hin. Hier sind noch weitere 
Bemühungen erforderlich, um sowohl die Ausbeute als auch die Reinheit/Homogenität der 
Rezeptor-Präparationen so weit zu steigern, dass Kristallisationsversuche unternommen 
werden können.  
 Von den Cannabinoid-Rezeptoren ist bekannt, dass sie in der Zelle auch ohne 
gebundenen Liganden bereits in einem Komplex mit dem G-Protein vorliegen (GPCR/G-
Protein-Komplex). Diese Eigenschaft könnte für die Kristallisation durchaus von großem 
Nutzen sein. Der GPCR/G-Protein-Komplex existiert sowohl in einer aktiven als auch einer 
inaktiven Form. Während der aktive GPCR/G-Protein-Komplex die konstitutiv aktive Form 
des Rezeptors darstellt, sind beide Formen an der G-Protein Sequestrierung in der Zelle 
beteiligt. Die Existenz beider genanter GPCR/G-Protein-Komplex wurde in dieser Arbeit 
mittels Fluoreszenztechniken untersucht. Durch Fluoreszenz-Resonanz-Energietransfer 
(FRET)-Messungen konnte gezeigt werden, dass der Cannabinoid-Rezeptor 1 in dem 
beschriebenen Komplex mit Gi1 vorliegt. Für den C-terminal verkürzten Cannabinoid-
Rezeptor 1 in Fusion mit dem gelb fluoreszierenden Protein (CB1-417-YFP) und Gi1 in 
Fusion mit dem cyan fluoreszierenden Protein (Gil-CFP) konnte die Kolokalisation 
innerhalb der Zelle auch bei Abwesenheit eines Liganden nachgewiesen werden. Mit einem 
Guanosintriphosphat-Bindungsassay an Zellmembranen konnte ferner nachgewiesen 
werden, dass der aktive GPCR/G-Protein-Komplex auch in der Abwesenheit eines 
Agonisten vorliegt. In einem weiteren Experiment wurden die Membranen von Zellen, die 
das verkürzte Rezeptorkonstrukt mit N-terminalem Flag-Anhängsel und das heterotrimere 
G-Protein koexprimierten solubilisiert und erfolgreich eine Koimmunopräzipitation des 
Rezeptor/G-Protein-Komplexes mittels Anti-Flag M2-Agarose durchgeführt.  
 
Die in der vorliegenden Arbeit erhaltenen Ergebnisse zeigen, dass die C-terminal 
verkürzte Form des Cannabinoid-Rezeptors 1 in Insektenzellen funktionell produziert 
werden konnte, wobei die erreichten Produktionsniveaus weit über denen in bisherigen 
Veröffentlichungen liegen. Ferner konnte durch FRET-Experimente gezeigt werden, dass 
dieser Rezeptor auch in Abwesenheit eines Liganden in einem Komplex mit dem G-Protein 
vorliegt. Diese Ergebnisse wurden durch die erfolgreiche Koimmunopräzipitaion des 
Rezeptor/G-Protein-Komplexes bestätigt. Weiterführende Untersuchungen sind 
erforderlich, um zu überprüfen, in wie weit dieser Rezeptor/G-Protein-Komplexe gereinigt 
und eventuell für die Kokristallisation eingesetzt werden kann.  
 
 
 
 
Summary: 
 
G protein coupled receptors form the largest group of transmembrane proteins, 
which are involved in signal transduction and are targeted directly or indirectly by 40-50% 
of the drugs in the market. Even though a lot of biochemical and pharmacological 
information was acquired for these receptors in the past decades, structural information is 
still insufficient. G protein coupled receptors are expressed in a very minute scale in the 
tissues. Purification of G protein coupled receptors, in amounts needed for structural 
studies, from  native tissue is tedious and almost impossible. To overcome this first hurdle 
of insufficient protein, several heterologous protein expression systems are being used. 
Another difficulty in structural determination of a G protein coupled receptor is that it is a 
membrane protein. Membrane proteins are difficult targets for structural studies. One of the 
possible reasons is the little hydrophilic surface area on the membrane protein, reducing the 
chances of crystal contact between the molecules.  
 
The present work is an attempt to investigate possible ways to overcome these 
problems. Aim of the project was to use G proteins to increase the hydrophilic area of the G 
protein coupled receptor. G protein is a physiological partner to the G protein coupled 
receptor which makes the complex functionally relevant. In the present work five Gα 
proteins were purified to homogeneity by a two step purification using metal affinity and 
ion-exchange chromatography. The Gα subunits purified were tested for their detergent 
susceptibility. It was found that only some G proteins were active in the presence of 
detergent. Observation from contemporary reports also suggest that the Gα proteins 
expressed in Escherichia coli, alone may not be sufficient to bind to the G protein coupled 
receptors in solution. So the project was extended towards expressing a G protein coupled 
receptor which was reported to exist in a complex with the  G proteins, in the cells. 
Purifying such a functional complex could be more beneficial to use for crystallization. 
Cannabinoid receptors were chosen for heterologous expression and purification. 
Production of recombinant cannabinoid receptor 2 was investigated in Pichia pastoris. The 
protein obtained was highly heterogenous. There were several oligomeric forms as well as degradation products in the cell membranes. Most of the protein was lost in the purification 
steps leading to a poor yield. Several oligomeric forms and other impurities were still 
present in the protein sample after purification. Alternatively, a baculovirus mediated insect 
cell expression system was investigated, to produce the receptors. Cannabinoid receptor 1 
was investigated in insect cell expression system because of its better biochemical 
understanding and pharmacological importance than cannabinoid receptor 2. Cannabinoid 
receptor 1 was produced in two forms, a full length and a distal carboxy terminal truncated 
version. All the several gene constructs made could be expressed in the Spodoptera 
frugiperda (Sf9) insect cells. Expression levels (Bmax) for the constructs with a  deca-
histidine tag at the amino terminus and Strep-tagII at the  carboxy terminus were 40 
pmol/mg and 53 pmol/mg respectively, for full length and truncated versions. These 
expression levels are 2 fold higher than the levels reported till now in the literature. As was 
quite evident from  previous experiences of other research groups, purification of this 
receptor was a challenge. Protein purified from immobilized metal affinity chromatography  
(Ni-nitrilo tri acetate)(Ni-NTA) was not even 50% pure. A second purification by 
immobilized monomeric avidin or Streptactin agarose, making use of Biotag and Strep-
tagII respectively, drastically reduced the protein recovery. Later on, purification of 
receptor was investigated on different metal chelating resins. His-Select, a Ni-NTA based 
matrix from Sigma, with much lesser density than Ni-NTA from Qiagen, showed a better 
purification profile. Purification was optimized to get  80% homogeneity but with low yield 
(20%). Further efforts are needed to improve the yield and purity of the receptor, to use it 
for crystallization.  
 
Cannabinoid receptors are known to exist in a precoupled form to G proteins in the 
cells. The existence of such precoupled forms of the receptor was investigated using the 
fluorescence techniques. Guanosine-5-triphosphate binding assay on the cell membranes, in 
the absence of agonists confirmed the active precoupled form of the receptor. It was found 
that it is possible to co-immunoprecipitate the complex. These results show that the 
truncated cannabinoid receptor can be produced in functional form in insect cells in much 
higher yields than reported. This receptor exists as a complex with G proteins even in the 
absence of ligands. It was also shown that the receptor/G protein complex can be co-
immunoprecipitated. Further work is required to investigate the possibility of purifying this 
complex to use it for co-crystallization.  
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1 INTRODUCTION 
_________________________________________________ 
 
1.1 Membrane  proteins 
 
  Cells are the smallest functional units of all living organisms. These cells exist alone 
or as a unit of a multi-cellular organism. Cells, co-ordinate the functions of all basic 
reactions within itself, as well as they respond in time to the external environment. A 
continuous plasma membrane separates the inside and outside of the cell. Eukaryotic cells 
have organelles, which perform specific functions and need specific environments within 
them. These organelles are also surrounded by the lipid membranes. These lipid membranes 
are impermeable for hydrophilic molecules. But the cell has to take up many hydrophilic 
components, e.g. nutrients, to survive. To allow transport across the membrane, many 
proteins are embedded in the cell membranes. These proteins possess the function of 
transporting the essential chemical components into or out of the cell. Cells need to pass on 
a lot of information from the outside to the inside to co-ordinate the functions and they also 
have to communicate with the surrounding cells. How do they communicate? Again,   
proteins embedded in the membrane carry on the function.  
 
  The plasma membrane is a bilayer of phospholipids. The outer and inner surfaces of 
the lipid bilayer are hydrophilic, which are in contact with the universal solvent, water and 
its solutes. The inside of the double layer made from the fatty acyl tails, is hydrophobic or 
lipophilic which renders the bilayer impermeable for the hydrophilic molecules. Proteins 
embedded in the membranes render them permeable and connect  the exterior and interior 
of the cell. Proteins in the membrane are thus called membrane proteins. The 
transmembrane parts of the membrane proteins are generally hydrophobic in nature, so that 
they can stay within the lipophobic bilayer.  ___________________________________________________Introduction.. 
  2
  
Proteins which are lying on the surface of the lipid bilayer are called peripheral 
membrane proteins or extrinsic membrane proteins. Proteins which span the bilayer or 
deeply incorporated in the lipid bilayer are called intrinsic membrane proteins. 
 
 
 
 
 
 
 
Fig 1.1: Representation of a few types of membrane proteins.  
 
As represented in Fig 1.1, there are several functions associated with the membrane 
proteins. Transport of ions and other biomolecules, linkers (integrin) forming a part of 
cytoskeleton, signal transduction by receptors (e.g. GPCRs), synthesis or degradation of 
certain biomolecules by enzymes (cAMP synthase, ATP synthase) are few of many 
functions. Proteins involved in transporting the chemical components are generalized as 
membrane transporters. These proteins are named pumps or channels according to their 
mechanism of action.  Passive transport is a mode where no energy is utilized to permeate 
the ions or chemical components across the channels. Diffusion is a simple way of passive 
transport. Selective transport of molecules across the membrane through the channels either 
non-gated or gated also does not utilize any energy. In active transport of molecules energy 
is needed in one form or another. Primary active transporters like P-type ATPases utilize 
the energy stored in ATP molecules to transport the ions across the membrane. These are 
generally termed as pumps. Secondary active transporters utilize energy differences   
because of the coupled transport to other molecules. It can be a symport where both   
molecules move in the same direction or antiport where the molecules move in opposite 
directions. 
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1.2 Cell  surface  receptors 
The concept of receptors to describe the interaction of drugs with cells is believed to 
be put forward by Paul Ehrlich(1854-1915) and John Newport Langley(1854-1936), which 
was later mathematically modeled by Alfred J. Clarke (1885-1941), considered as father of 
modern receptor theory (Kenakin et al., 2004). Ehrlich used the term receptors originally 
called “Seitenketten” or side chains on the cell surface which binds antigens. We know now 
that these side chains are all proteins. A receptor is a protein which binds to a certain 
chemical molecule or ligand and initiates a cellular response. There are several protein 
molecules in the plasma membrane which help to transfer the information across the 
membrane. There are primarily four kinds of membrane receptors.  
1.  Ligand gated ion channels, bind a specific ligand and opens a channel to allow 
the transport of chemical components, e.g.: acetylcholine, GABA-A, glutamate 
receptors 
2.  Tyrosine kinase receptors, phosphorylate effector molecules upon ligand 
binding and initiate signaling, e.g.: insulin, growth factor, interferon receptors 
3.  Guanylate cyclase receptors, couples to guanylate cyclase to initiate the 
signaling cascade,  e.g.: the atrial natriuretic factor receptor 
4.  G protein-coupled receptors 
1.3  G protein-coupled receptors 
  G protein-coupled receptors (GPCRs) are seven transmembrane receptors coupled 
to the guanine nucleotide binding proteins. GPCRs constitute the largest class of membrane 
proteins encoded by about 3% of the human genome (~850). GPCRs have been discovered 
in phylogenetically diverse organisms ranging from yeast to mammals (Fredriksson et al., 
2005). G protein-coupled receptors get activated by a variety of stimuli such as photons, 
ions, lipids, peptides, nucleosides, nucleotides, hormones and neurotransmitters. The signal 
is transduced across the membranes to guanine nucleotide binding proteins or    G proteins. 
Around 50% of the identified GPCRs respond to smell (olfactory receptors) (Glusman et 
al., 2001). Only a small percentage of the non-olfactory receptors have been 
pharmacologically targeted till now. Still recent estimates say that about 40-50% of the 
marketed drugs target these GPCRs (Flower, 1999 et al.; Kroeze et al., 2003). So the ___________________________________________________Introduction.. 
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diversity in the GPCR family and the potential as pharmacological targets necessitates an 
extensive investigation of these proteins. 
  The knowledge of GPCRs that we had till 1986, when the first reports of primary 
structure of β-adrenergic receptors from hamster (Dixon et al., 1986) and turkey (Yarden et 
al., 1986) appeared was mainly based on  pharmacological studies, radioligand binding 
studies of these low abundance proteins from natural sources. The identification of the 
seven transmembrane architecture of bovine rhodopsin similar to bacteriorhodopsin, by 
electron cryomicroscopy, led to identification and modeling of several GPCRs (Unger et 
al., 1997). More than 1000 GPCRs and putative GPCRs, were submitted to GenBank, to 
date and the list is increasing, thanks to molecular cloning techniques.   
 
Fig 1.2 shows the key events in the signal transduction cascade through GPCRs. 
Ligands activate the GPCR, which in turn activates the G proteins on the cytoplamic side of 
the membrane. Heterotrimeric G proteins after GTP exchange get seperated into α and βγ 
subunits and activate the downstream effector molecules, which gives rise to a biological 
response. 
 
Fig 1.2: Important steps in receptor-G protein mediated signal transduction (Marinissen, 2001). ___________________________________________________Introduction.. 
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1.3.1  Classification of GPCRs 
Based on the amino acid sequence similarity and nature of ligand,  GPCRs are 
classified into 6 classes in GPCR Data Base (GPCRDB). Around 850 GPCRs are reported 
to date from the human genome, which are found in the first 3 major classes. 
1.  Class A or Rhodopsin-like  
2.  Class B or Secretin-like 
3.  Class C or metabotropic glutamate / pheromone 
4.  Class D or Fungal pheromone 
5.  Class E or cAMP receptors 
6.  Frizzled / Smoothened family 
Rhodopsin-like receptors form the largest receptor class. The overall sequence 
identity of the receptors in this class is very low. The identity of Class I receptors is 
determined by a set of 20 amino acids highly conserved in this class and located in the 
cytoplasmic half of the transmembrane receptor core. These residues are required for 
protein stability and receptor activation ( Wess et al., 1993; Baldwin et al., 1994; Wess et 
al., 1997). The only residue that is conserved among all Class A receptors (Fig 1.3) is the 
arginine in the Asp-Arg-Tyr (DRY) motif at the cytoplasmic side of the transmembrane 
segment, TM3 (Probst et al., 1992). Ligands binding to Class A receptors include light,   
odorants,   biogenic amines,  protein 
hormones,   peptides,  opioids, lipid-like 
molecules, nucleosides or nucleotides, 
etc,. In most Class A receptors, a 
disulphide bridge is connecting the second 
and third extra cellular loops. In addition, 
a majority of the receptors have a 
palmitoylated cysteine in the C-terminal 
tail forming a putative fourth intracellular 
loop. 
Fig 1.3: Topological model of a prototypical member of Class A GPCRs.  The conserved residues are 
represented by black letters in white circles. The disulphide bridge is represented by crosslinked white C in 
black circles. N is the N-terminus and C is the  C-terminus of the protein. A unique DRY motif is present. ___________________________________________________Introduction.. 
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Class B receptors (Fig 1.4) include approximately 20 different receptors for a 
variety of intestinal peptide hormones and neuropeptides.  These  receptors contain a 
relatively large N-terminal extracellular domain with six conserved cysteine residues 
presumably forming disulphide bridges. Only the disulphide bridge between 2
nd and 3
rd 
extracellular loops is the common feature between Class A and Class B receptors. Notable 
difference is that there is no DRY motif in the Class B receptors (Ulrich et al., 1998). 
 
 
 
 
Fig 1.4: Topological model of a prototypical 
member of Class B GPCRs.  Class B receptors 
have a long N terminus with 6 conserved cysteine 
residues probably forming disulphide bonds. (Fig 
1.3, 1.4 and 1.5 are redrawn from Gether, 2000) 
 
 
 
  
 
 
 
Class C receptors (Fig 1.5) have an exceptionally long amino terminus. The 
receptors include the metabotropic  glutamate receptors, GABA-B receptors (Kaupmann et 
al.,1997), calcium receptors (Brown et al., 1993), vomeronasal receptors and mammalian 
pheromone receptors.  Class C receptors  like Class A and B receptors, have two putative 
disulphide forming cysteines in 2
nd and 3
rd extracellular loops. The N-termini of the 
metamorphic receptors have certain homology with bacterial periplasmic binding proteins, 
especially with leucine, isoleucine,  and valine binding proteins (O’Hara et al., 1993). So it 
is believed that the amino terminus of Class C receptors contains the ligand binding site 
(Conn et al., 1997; Brown et al., 1996).  
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Fig 1.5: Topological model of a 
prototypical member of Class C GPCRs.   
Class C receptors have extremely large N 
termini ranging from 500-600 amino acids. 
The disulphide bridge is represented by 
crosslinked white C in black circles. N is the 
N-terminus and C is the  C- terminus of the 
protein. 
 
  Class D receptors are expressed in organisms like yeast, and  are functional during 
mating. Class E receptors are cAMP receptors with higher similarity to the secretin family 
receptors, discovered in amoeba Dictyostelium discoideum and slime mold Polyspondylium 
pallidum (Oyama et al., 1986; Kawabe et al., 2002). Frizzled/Smoothed class receptors 
were discovered in Drosophila melanogaster and named after the Frizzled locus 
contributing to  cytoskeletons of the epidermal cells. These receptors are found to regulate 
cell development, proliferation, differentiation and apoptosis (Wang et al., 2006). 
1.3.2  Structural features of GPCRs 
Not much high resolution structural information is available about GPCRs. 
Several models were constructed for the GPCRs. Most of these models are based on the x-
ray or electron cryomicroscopic structures of bacteriorhodopsin (Henderson et al., 2000) 
and bovine rhodopsin (Unger et al., 1997). Bovine rhodopsin is the only GPCR whose 
structure has been studied by x-ray crystallography till now (Palczewski et al., 2000) (Fig 
1.6). The initial crystals were of the inactive protein. The active metarhodopsin II form of 
the receptor was obtained in crystalline form later (Choi et al., 2002; Salom et al., 2006). In 
the rhodopsin structure, the arrangement of  7 transmembrane helices relative to each other, 
is clear now. The 7 transmembrane helices are arranged in a clockwise manner 
(intracellular view) forming a tightly packed helical bundle (Baldwin et al., 1994). The 
earlier cryo electron microscopic studies showed that helices 1, 2, 3 and 5 are tilted by ___________________________________________________Introduction.. 
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about 25 degrees. Helices 4 and 7 are perpendicular to the plane of the membrane. Helix 6 
appears almost perpendicular to the plane of the membrane in the cytoplasmic side and 
tilted towards helix 5 on the extracellular side (Unger et al., 1997). The high resolution x-
ray structure of bovine rhodopsin showed a so called 8
th helix at the cytoplasmic membrane 
side. The other important finding is that the helices are not straight, but are kinked and bent. 
Kinks in the helices 1, 4, 5, 6 and 7 were associated with  proline residues (Stenkamp et al., 
2002).  Further structural information is needed to understand the mechanism of activation. 
More and more GPCRs are gaining pharmacological interest and need more structural 
information to develop potent drugs and to understand the mechanism of action. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.6: 3D Structure of bovine rhodopsin.  7 transmembrane helices are shown as ribbons and numbered in 
roman letters.  N and C are the amino and carboxy termini of the protein (Palczewski et al., 2000). 
 
1.4 Heterotrimeric  G  proteins 
 
  Heterotrimeric G proteins are members of a super family of GTPases which are 
conserved from bacteria to mammals (Gilman et al., 1995). Heterotrimeric G proteins are 
reported in  yeast,  plants (Oki et al., 2005), invertebrates (insects by Knight et al., 2004),  
and  vertebrates.  They were initially called N-proteins after their function as nucleotide ___________________________________________________Introduction.. 
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binding proteins. Heterotrimeric G proteins transduce the receptor generated signals into 
the cell (Gilman et al., 1987). GPCR signal transduction is mainly carried out by these G 
proteins though G protein independent pathways are also known. There are three partners in 
the heterotrimer  (Fig 1.7) of G proteins. One subunit each of α, β and γ form a trimer with 
one Mg
2+ and one GDP molecule embedded in a pocket of the α subunit.  
 
In humans there are 21 different α-subunits (encoded by 17 genes), some of which 
are splice variants of the same gene. The molecular weights of these proteins range from 39 
to 46 KDa. α-subunits have two distinct domains; a Ras-like GTPase domain and a unique 
α-helical domain. Based on the amino acid similarity and function, the G proteins can be 
divided into four main families: Gαs, Gαi/o, Gαq/11 and Gα12/13 (Helper et al., 1992) (Table 
1.1). The Gαs class contains Gαs (several splice variants) and Gαolf (specifically expressed 
in olfactory tissue, Jones et al., 1989). This class of proteins activates adenylyl cyclase and 
increase the production of cAMP. These proteins are substrates for ADP-ribosylation of  an 
argininyl residue catalysed by the A1 subunit of a cholera toxin, which inhibits the intrinsic 
GTPase activity of these proteins (Gilman et al., 1989).  
 
The Gαi/o class contains three subtypes of Gαi : i1, i2, i3, two forms of transducin  
Gαt : GαtRod (Rod cell specific) and GαtCone (Cone cell specific), two forms of Gαo : GαoA 
and GαoB (exclusively expressed in brain), Gαgust (gustatory epithelium) and Gαz. Except  
for Gαz, all  members of  this family have a conserved C-terminal cysteine, which is the site 
of ADP-ribosylation by pertussis toxin. This modification uncouples the G proteins from 
the corresponding receptors (Ui et al., 1990). Gαi family members inhibit the adenylyl 
cyclase and decrease the cAMP production (Taussig et al., 1994). Gαt activates the cGMP 
phosphodiesterase in the retina. These proteins activate the potassium channels and 
decrease the calcium channels and chloride channels. Phospholipase A2 is another effector 
for this family members. Gαq/11 family contains Gαq , Gα11 ,Gα14  and Gα16. These proteins 
activate  phospholipase C (Helper et al., 1993), protein kinase C and calcium channels. 
Gα12 and Gα13 constitute the last family. These proteins interact with mitogen activated 
protein kinases (MAPK) through Rho proteins. They are important in the cytoskeleton 
formation and other functions during the cell differentiation (Jho et al., 1997).  
 ___________________________________________________Introduction.. 
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Table 1.1 Effectors for different G protein subunits. Red arrows indicate an increased 
activity and green arrows indicate a decreased activity (Morris et al., 1999; Wettschureck et 
al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Six different G protein β and 12 different γ subunits have been reported in humans 
till now (Clapham et al., 1997). The Gβ subunits have a molecular mass of approximately 
35 KDa. The amino acid sequences of these proteins contain 7 or 8 tandem repeats with a 
central conserved Trp-Asp (WD) sequence that is termed  a WD-40 motif (Garcia-Higuera 
et al., 1998). The γ subunits are small ranging from 7-8.5 KDa. The C-termini of all γ 
subunits contain the sequence CAAX, where A can be any aliphatic amino acid. The 
protein undergoes a post-translational prenylation at the Cys in this sequence followed by 
proteolytic cleavage of the last three amino acids (Backlund et al., 1990). γ1 subunit is 
unique in two ways, that it is specific for the transducin heterotrimer and that the prenyl 
group attached to the C-terminus is  a farnesyl group. All other γ subunits are modified by 
geranyl geranyl groups (Mumby et al., 1990). β and γ form a stable tight dimer complex.  
The βγ dimer also interacts with a wide range of effector molecules (Clapham et al., 1997). 
A domain on β subunit  interacting with several effector molecules was identified earlier 
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+ channels 
 Ca
2+ channels 
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+ channels 
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cGMP phosphodiesterase (Gαt) 
Gαq/11 Phospholipase  C
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(Yan et al., 1996). γ subunits were reported to be playing an important role in the G protein 
interaction with the receptors (Azpiazu et al., 2001; Kisselev et al., 2006). There is also 
increasing number of reports available which confirm that γ subunit is involved in the βγ 
interaction with effector molecules like phospholipase C (Akgoz et al., 2002). There is 
evidence  that the prenyl modification of the γ subunit is a requirement for the βγ complex 
action on effectors (Katz et al., 1992). Proper processing of G protein  γ has been reported 
to be dependent on complex formation with a β subunit (Pronin et al., 1993). 
 
1.4.1 Structural  features of G proteins 
  
  X-ray crystallographic structures of Gαt (Noel et al., 1993), Gαi1 (Coleman et al., 
1994), chimeric proteins i.e. Gαi/12 and Gαi/13 (Kreutz et al., 2006) and Gαi1/q (Tesmer et al., 
2005) have been reported till now with different nucleotides bound to them and with 
effector molecules. Gαi1  was crystallized together with β1γ2 (Wall et al., 1995, Fig 1.7). 
Chimeric Gαt/i  and Gαt together with β1γ2  were also crystallized (Sondek et al. , 1996). 
There are distinct conformational changes in the α subunit but not in βγ subunit. There are 
three conformational changes with the so-called switch regions in the α subunit. The N-
terminus is of α-helical secondary structure and protrudes away from the two domains. The 
α-helical domain consists of one bigger α-helix in the centre surrounded by five shorter 
helices. In the Ras like GTPase domain a 6-stranded β sheet is surrounded by six helices of 
this domain and one helix from the helical 
domain. In the βγ dimer the γ subunit 
entwines with the N-terminal  helix of β 
subunit and touches 6 of 7 propeller blades. 
This dimer forms a tight complex. 
 
Fig 1.7: Structure of the G protein heterotrimer. 
Subunit in green is Gα, golden yellow is Gβ and 
purple is Gγ. N stands for the N-terminus of the 
protein. http://www.fli-leibniz.de/IMAGE.html 
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1.5  Mechanism of signal transduction 
 
  Our present knowledge of what happens when the ligand binds to the receptor is 
very limited and based on the rhodopsin crystal structures, in active and inactive forms. 
Models have been constructed based on the TM conformational changes observed in 
rhodopsin (Fig 1.8). When a ligand binds to the receptor the transmembrane helices 
undergo a relative orientation change to each other. In rhodopsin TM3 and TM7 are 
constrained by a salt bridge in the inactive form (Govardhan et al., 1994). When the ligand 
activates the receptor the salt bridge is broken and  TM3 rotates  and  moves apart relatively 
more on the cytoplasmic side (Fahmy et al., 1995). Considerable evidence indicates that 
TM3 and TM6 move together leaving a cavity on the cytoplasmic side which might be the 
activation site for the G proteins (Farrens et al., 1996).  
 
 
Fig 1.8: Arrangement of 7 transmembranes and conformational changes.  The arrangement is based on 
the projection map of 2D crystals of rhodopsin. R is the inactive form of the receptor and R* is the active 
form. The double line between TM3 and TM7 represents the predicted salt bridge (based on Unger, 1997). 
 
  The invariably conserved arginine in the DRY motif is constrained in a hydrophilic 
pocket  in the inactive form. In the active form this arginine shifts out of the polar pocket 
because of the protonation of preceeding aspartic acid (Arnis et al., 1994) residue leading to 
cytoplasmic exposure of the buried residues in the crevice formed because of the movement 
of TM3 helix (Scheer et al., 1997). The arginine is a crucial residue here, mutation of which 
allows coupling to G proteins but no activation (Acharya and Karnik., 1996).   
Extracellular view 
Cytoplasmic side 
R 
R* ___________________________________________________Introduction.. 
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The C-terminal helix of the G protein is supposed to be interacting with the amino 
acids in the crevice formed in the receptor. The message is passed onto the helical domain 
and then to the GTPase domain, which activates the G proteins attached to the receptor. As 
shown in fig 1.9, activation of G proteins, leads to changes in the three switch regions in the 
GTPase domain. GDP is held at the interface of the two domains of the α subunit. Activated 
switches loosen the GDP binding. All these switches are in the interface between the α and 
βγ subunits. GDP is then exchanged for GTP. Guanine nucleotide exchange factors assist in 
this exchange. The three switches are held in place by contacts to the terminal γ phosphate 
(Coleman, 1994). The altered switch regions decrease the interactions with the βγ subunits 
thereby dissociating the whole trimer complex into two functional units, the α subunit and 
the βγ dimer. 
 
 
  
  
  
 
 
 
 
 
 
 
Fig 1.9: Active and inactive conformations of Gα subunits overlapped on each other. The helical domain 
is shown in green colour ( light colour for GDP bound form and dark for GTP bound form) and the GTPase 
domain in pink colour. The three numbered switch regions are represented in yellow when bound to GDP and 
in violet when bound to GTP.  http://www.bmb.psu.edu/faculty/tan/lab/gallery/galpha_ribbon3.jpg  
 
  Both  functional units activate the respective effector molecules to pass on the signal 
downstream. The Gα subunit has an intrinsic GTPase activity and so the bound GTP is 
hydrolysed to GDP, which converts the G protein again to the inactive form. The hydrolysis 
is assisted by GTPase activation proteins (GAPs). The trimer complex forms again. 
 
1
2
3___________________________________________________Introduction.. 
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1.6 Cannabinoid  receptors 
 
  Two types of cannabinoid receptors have been identified so far. Cannabinoid 
receptors were identified in the rat brain in the year 1988 (Devane et al., 1988). 
Cannabinoid receptor 1 (CB1) was cloned in the year 1990 (Matsuda et al., 1990) and 
cannabinoid receptor 2 in 1993 (Munro et al., 1993). A splice variant of CB1, CB1a has 
also been isolated (Rinaldi-Carmona et al., 1996). CB1 receptors show a high level of 
sequence identity between the different mammalian species: human to mouse 90% and 
human to rat 96% (Chakrabarti et al., 1995).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.10: Secondary structure model of CB1 receptor showing the conserved residues with CB2.  Blue 
circles indicate the conserved residues between CB1 and CB2 residues. Green circles indicate the amino acids 
unique to the CB1 receptor. Linked hexagons represent the N-linked glycosylation sites. CB1 and CB2 share 
only 44% overall identity but around 68% identity in the transmembrane region. ( image based on snake like 
plots from GPCRDB) ___________________________________________________Introduction.. 
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CB2 receptors show more interspecies differences. CB1 receptors are expressed in 
central nervous system and also in peripheral tissues including pituitary gland, immune 
cells, and reproductive tissues and in sperm cells,  lung, adrenal gland, etc, (Pertwee et al., 
1997). CB2 receptors are expressed  mainly in immune cells like B cells and NK cells 
(Galiegue et al.,1995). Human  CB1 and CB2 receptors share a overall  identity  of  44%  
but the transmembrane regions have around 68% identity (Fig 1.10). Transmembrane 
segments 4 and 5 show a high degree of dissimilarity which might be the important site for 
the ligand selectivity.  
 
1.6.1  Structural features of cannabinoid receptors 
 
  Cannabinoid receptor 1 consists of 472 amino acids and cannabinoid receptor 2 is a 
polypeptide of 360 amino acids. These receptors have 7 transmembrane helices and a juxta 
membrane  8
th helix (Qun Xie et al., 2005). These proteins don’t have a specific N-terminal 
signal peptide. There are three potential N-glycosylation sites (NIT, NKS, NPS) on the N-
terminus of CB1 receptor, but they are not important for ligand binding  (Howlett, 1991) 
and one site on CB2 receptor (NGS).   
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.11: A. Homology model  CB1 receptor.   α helices are shown as Green ribbons. The conserved 
residues are represented as ball and stick models (Montero, 2004). B. ic3 loop of CB1 receptor, D
338-V
346. 
NMR structure of third intracellular loop bound to Gi1 protein (Ulfers et al., 2002). C. 8
th helix of CB1 
receptor, I
397-G
418.  The 8
th helix or the 4
th intracellular loop of CB1 receptor was determined by NMR (Choi 
et al., 2004). ___________________________________________________Introduction.. 
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The structure of these receptors is not understood in detail. Synthetic CB2 receptor 
fragments are studied by NMR technique. Recent work by Zheng et  al, 2006  reported the 
structure of the first and second transmembrane helices of the CB2 receptor (27-101 amino 
acids). Zhao et al. (2006) reported the structure of TM5 and the third intracellular loop 
(180-233 amino acids) also by NMR technique. Qun Xie et al. (2005) solved the structure 
of 8
th membrane parallel helix of the CB1 (I
397-G
418) and CB2 (I
298-K
319) receptors. They 
also reported that Cys
416 in CB1 and Cys
313 in CB2 point towards the membrane suggesting 
a possible palmitoylation at these conserved residues. The structure of the third intracellular 
loop (ic3) of CB1 (D
338-V
346), was determined bound to Gαi1. This report confirms that the 
ic3 forms an  α helix (Ulfers et al., 2002).  
 
1.6.2   Cannabinoid ligands and ligand binding site 
 
Cannabinoid receptors are now known to be the site of action for the active 
compounds of marihuana like Δ
9–tetra-hydrocannabinol (Δ
9-THC). Cannabidiol (CBD) and 
cannabinol are other abundant natural cannabinoids active at these receptors (Fig 1.12). 
These are the active compounds in the prevalent, ancient street drug Marijuana (Cannabis 
sativa). Δ
9 –THC has an almost equal affinity for both CB1 and CB2 receptors (Huffmann 
et al., 2000). In 1992 a ligand for cannabinoid receptors was isolated from pig brain. This 
endogenous cannabinoid ligand was arachidonoyl ethanolamide, a derivative of arachidonic 
acid and named as anandamide after the Sanskrit word ananda meaning bliss (Devane et 
al., 1992). Another endocannabinoid is 2-arachidonoyl glycerol or 2-AG, which is more 
abundant but less potent than  Δ
9 –THC (Sugiura et al., 2000). Most of the endogenous 
cannabinoids discovered so far are high or low efficacy agonists. But there is one recently 
reported inverse agonist called virodhamine after the Sanskrit word virodh meaning oppose 
(Pertwee et al., 2005). There is an extensive list of pharmacological benefits of cannabis 
dating from 2000 BC.  
 
High affinity non-eicosanoid, non classical cannabinoids were first developed by the 
pharmaceutical company, Pfizer. Most important and potent among them is CP 55940. 
Another important and extensively used ligand is WIN 55,212-2, developed by a Sterling 
Winthrop research team. The break through selective ligands for CB1 and CB2 receptors 
were developed by Sanofi. Both these ligands are antagonists or inverse agonists. ___________________________________________________Introduction.. 
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SR141716A is a selective antagonist for the CB1 receptor and SR144528 is selective for 
the CB2 receptor (Shire et al., 1999). Most of the cannabinoid ligands are highly lipophilic 
and nearly insoluble in water. One exception and worth mentioning is the ligand O-1057 
which is highly water soluble and almost as potent as CP55940 (Pertwee et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.12: Some commonly used ligands of cannabinoid receptors.  Δ
9 –THC is the active constituent of 
Cannabis. CP55940 is the first non-classical ligand synthesized. Anandamide and 2-AG are 
endocannabinoids. SR141716A and SR144528 are CB1 and CB2 selective antagonists developed by Sanofi-
Aventis. 
 
  Different amino acid residues from transmembranes 3, 4, 5 and 6 were identified to 
be important for the binding of different cannabinoid ligands. Lysine K
192 of CB1 receptor 
(K
109 of CB2 residue) was found to alter the binding of several agonists but not for 
WIN55,212-2 (Chin et al., 1998). This result proved that the binding site is different for 
this ligand. An aromatic microdomain modeled  from the residues F
190 (TM3), F
201 (TM3), 
W
256 (TM4), W
280 (TM5) and W
357 (TM6) was shown to form a binding site for many 
ligands. Mutation of these residues showed a profound effect on ligand binding. Mutation 
of F190A reduced the affinity for the agonist anandamide, whereas the mutations F
201A, 
W
280A and W
357A reduced the affinity for ligands like WIN55,212-2 and SR141716A 
(McAllister et al., 2003).   
 
 ___________________________________________________Introduction.. 
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1.6.3  Signal transduction by cannabinoid receptors 
 
1.6.3.1 Receptor-G protein  interactions 
 
  Cannabinoid receptors interact with Gαi/o proteins. A reconstituted system having 
Sf9 cell membranes expressing CB1 and CB2 receptors and Gi/o trimers from bovine cortex 
shows that CB1 and CB2 receptors interact equally with Gi protein  and less effective at Go 
protein. CB2 was less efficient than CB1 to bind to Go proteins (Glass et al., 1999), in a 
ligand dependent manner.  Mukhopadhyay et al. (2001) demonstrated that distinct 
intracellular domains determine G protein subtype selectivity of CB1 receptor. The so 
called 8
th helix (CB1
401-417) peptide reduced the CB1 receptor association with Gαi3 but not 
Gαi1 and Gαi2. Peptide from the third intracellular loop reduced the association of CB1 
receptor with Gαi1  and Gαi2  but not Gαi3.   So these intracellular receptor regions are 
important for G protein interaction.  CB1 receptor is a constitutively active receptor (R*G)  
and  is also able to sequester Gi/o proteins in a inactive conformation (IARºG) making other 
receptors, which share these proteins, inactive  (Vasquez et al., 1999). The receptor-G 
protein  complexes  involved  in  these phenomenon are explained by a cubic ternary model 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.13: Cubic ternary complex model of Ligand-Receptor-G protein.  R represents the inactive form of 
receptor and R* the active form.  G is the G protein. A is the agonist and IA is the antagonist. The R*G form 
is responsible for the constitutive activity of the receptor which is shifted towards the AR*G in the presence 
of agonist. In the presence of inverse agonist the inactive ternary complex ARG is stabilized and G proteins 
are sequestered from the pool. (Howlett et al., 2004). 
R 
AR 
RG  R*G 
R* 
AR* 
AR*G  ARG 
IAR
oG 
(Constitutive activity) 
(Ligand dependent activity) 
(G protein Sequestration) ___________________________________________________Introduction.. 
  19
as in Fig 1.13. Truncation of the distal C-terminal tail of the    receptor   (CB1-417)   
enhanced both   the constitutive and sequestration ability. Nie et al. (2001) reported that 
mutation of aspartate (D164N) in the second transmembrane segment of CB1 abolished 
both these abilities of the receptor without disrupting agonist stimulated activity.  Receptors 
interact with G proteins in a ligand dependent manner. Inverse agonists like SR141716A 
seem to  stabilize the inactive IAR
oG state of the complex which leads to sequestration 
(Howlett et al., 2004). 
 
1.6.3.2 Adenylyl cyclase mediated signaling 
 
 Agonist  activated  receptor  induces the activation of Gi/o proteins. The Gi subunits 
inhibit a few isotypes of adenylyl cyclases AC V and AC VI (Dessauer et al., 2002). Go 
subunits inhibit isotypes AC I, and Gz subunits inhibit AC I and AC V (Taussig et al., 
1995). Inhibition by Gi proteins is characteristic of  cannabinoid agonists in the brain tissue 
(Childers et al., 1994). The decreased cAMP concentration reduces the cAMP dependent 
protein kinase (PKA) activity which in turn causes a decreased dephosphorylation level of 
potassium channels and increased potassium currents (Childers et al., 1996) leading to 
hyperpolarization of the membranes. The CB2 receptor also shows this kind of inhibitory 
effect on cAMP production in immune cells (Felder et al., 1995). Cannabinoid receptors 
not only inhibit  cAMP production but also show the contrary effect in certain cases. This 
effect depends on the cell type and the available AC subtype population. In cells having 
high levels of AC II, AC IV and AC VII, cannabinoid receptor activation leads to an 
increase in the cAMP levels but not because of the Gi interaction but because of βγ 
interaction with these subtypes (Rhee et al., 1998). A recently studied mechanism is the 
direct interaction of cannabinoid receptors in the presence of dopamine receptors with the 
Gs protein to increase the cAMP production (Jarrahian et al., 2004). 
 
1.6.3.3 Regulation of ion channels 
 
Cannabinoid agonists  modulate several ion channel activities. N-type voltage gated 
Ca
2+ channels are inhibited through the Gi/o  proteins (Fig 1.14, Guo et al., 2004). Q type 
calcium currents were also inhibited as a result of cannabinoid receptor activation (Mackie 
et al., 1995). Inwardly rectifying potassium channels were activated by cannabinoid ___________________________________________________Introduction.. 
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receptor activation (Fig 1.14, Guo et al., 2004). This mediation was G protein dependent 
but not dependent on cAMP levels. This indicates that βγ subunits are involved which alter 
the IK.ACh type of  potassium channels. These physiological mechanisms in the neurons 
attribute to the neuroprotective function of cannabinoid receptors by a mechanism called 
depolarization-induced suppression of inhibiton (DSI) or excitation (DSE). According to 
this mechanism the depolarization opens the N-type Ca
2+ channels, which leads to 
endocannabinoid production. Diffusion of endocannabinoids from the postsynaptic neuron 
stimulates the CB1 receptors on presynaptic terminals leading to decreased release of 
neurotransmitters like GABA (Wilson et al., 2002). Several other mechanisms of signaling 
by cannabinoid receptors like MAPKinase pathway, Jun-N-terminal kinases, Nitric Oxide, 
etc were reviewed in Howlett (2005). 
 
CB2 receptors are known to modulate the ion channel activity, but less is known 
about the physiology of CB2 receptors. There are reports that CB1 receptors sometimes 
don’t utilize G proteins as transducers. Sanchez et al. (2001) showed that spingomyelinase 
activation by the CB1 receptor was mediated by the adaptor protein Fan but not by G 
proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.14: Signaling pathway of CB1 receptor by agonists. Activated receptor stimulates the Gi/o proteins 
which inhibit the adenylate cyclase activity and subsequent inactivation of protein kinase A (PKA) or to 
stimulation of mitogen activated protein kinase (MAPK). CB1 activation is inversely coupled to voltage 
activated Ca
2+ channels and stimulation of inwardly rectifying K
+ channels, which subsequently inhibit 
neurotransmitter release at the neuronal ends.   (redrawn from Di Marzo, 2004) 
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1.6.4  Cannabinoid receptor interactions with other proteins 
 
1.6.4.1 Receptor dimerization 
 
  GPCR dimerization is an accepted phenomenon now-a-days with more and more 
reports confirming this once not accepted fact. GPCRs form homo and heterodimers. 
Heterodimerization leads to binding sites that bind ligands not recognized by either 
components.  The heterodimerization also could change the signaling process of the 
component proteins (Mackie et al., 2005). CB1 receptors do form homo and heterodimers. 
The existence of homodimers has been confirmed by a “dimer antibody” which only 
recognizes a dimer but not a monomer and also by  classical immuno-precipitation (Wager-
Miller et al., 2002). CB1 and D2 dopamine receptors together form heterodimers (Kearn et 
al., 2004). The functional significance of this heterodimer formation was demonstrated by 
Glass and Felder (1997). In general both these proteins decrease the cAMP production. But 
when both proteins are expressed together, high concentrations of CB1 agonists increase  
cAMP production making D2 agonists inefficient.  CB1 and opioid receptors also were 
reported to form heterodimers with each other. A recent report demonstrates that all the 
three opioid receptor subtypes (μ, κ and δ)  directly interact with the CB1 receptors. CB1 
receptor agonists attenuated the opioid receptor mediated signaling reciprocally. 
 
1.6.4.2 Cannabinoid receptor desensitization and internalization 
 
  GRK3 and β-arrestin 2 mediate agonist dependent CB1 receptor desensitization.          
The C-terminal residues 418- 439 were found to be important for this desensitization (Jin et 
al., 1999). The residues S
426 and S
430  seem to be the most likely sites of phosphorylation by 
GRK3. It is reported that β-arrestin does not interact with these two Ser residues, since the 
mutant receptors also internalized normally. The exact site of interaction with  arrestin is 
not clear yet. 
 
1.6.5  Functions of cannabinoid receptors 
 
  Cannabinoid receptor distribution symbolizes their functions in the body. CB1 
receptors are mainly distributed in the central and peripheral nervous system. The coupling ___________________________________________________Introduction.. 
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of these receptors to the ion channels makes the endocannabinoid system ideal for 
modulating neurotransmitter release. Inhibition of glutamatergic, GABAergic, glycinergic, 
cholinergic, noradrenergic and serotonergic neurotransmission has been observed in the 
central nervous system. In the peripheral nervous system, the CB1 receptor mediates the 
inhibition of adrenergic, cholinergic, and sensory neuroeffector transmission (Szabo et al., 
2005). The suppression mechanism observed in the nociceptive neurons correlates with the 
nociceptive effects of cannabinoids (Walker et al., 2005). CB1 receptors are generally 
credited as neuroprotective, because of this neurotransmitter inhibitory mechanism. 
Activation of CB1 receptors expressed in basal ganglia and cerebellum modulate the 
locomotor activity. The cannabinoid receptors in the hippocampus control the short-term 
memory. The cannabinoid receptor in the neocortex is involved in drowsiness after 
intoxication. One of the most important effects of cannabis consumption is the increase of 
appetite, which is controlled by receptors in the hypothalamus (reviewed by Iversen et al., 
2003). CB2 is predominantly expressed in the immune cells and controls humoral and cell 
mediated immunity. Cytokine release is modulated by the CB2 receptors. A recent finding 
is that CB2 receptor maintains the bone mass and protects from osteoporosis (Ofek et al., 
2006).  
 
1.6.6  Cannabinoid receptors as therapeutic targets 
 
  Cannabinoid receptors were targeted for pain relief mainly because of their 
antinociceptive action.  Sativex
®, a cannabis based drug containing Δ
9-THC and CBD was 
approved in Canada for the treatment of neuropathic pain in multiple sclerosis. Marinol
® 
and Cesamet
®, containing Δ
9-THC and the analogue nabilone are marketed as medicines 
for suppressing nausea and vomiting caused in chemotherapy and also to stimulate appetite 
in AIDS patients. CB1 receptor agonists have many other potential uses in Parkinson’s 
disease, Alzheimer’s disease, inflammation (CB2 agonists), fertility, epilepsy and alcohol 
withdrawal (Robson et al., 2005; Pertwee et al., 2006).  Since the discovery of receptor 
selective antagonists like SR141716A for CB1 receptor by Sanofi, their use as medicines is 
also under extensive study. SR141716A (Rimonabant) is approved under the tradename 
Acomplia
® in the European Union, as an anti-obesity drug because of its reversal of the 
munchis effect of cannabis consumption. Munchis effect arouses the desire to eat sweet 
foodstuffs. ___________________________________________________Introduction.. 
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1.6.7  Purification of cannabinoid receptors 
 
  Determination of protein structure in detail is possible by 2D or 3D crystallography 
and NMR spectroscopy for smaller proteins. All these techniques need milligram quantities 
of protein. The structure of the cannabinoid receptor has not been determined, as is the case 
with any other GPCR, except bovine rhodopsin. Cannabinoid receptors or GPCRs are 
produced in a very low quantity in natural tissues. Purification of these proteins in the 
quantities required for structural identification is highly tedious or nearly impossible. 
Several groups have tried to produce these receptors using heterologous expression 
systems. A few early reports are : Cannabinoid receptor 1, was  expressed in insect cells 
(3.7 pmol/mg, Pettit et al., 1994) and COS-3 cells (18.7 pmol/mg, Shire et al., 1996).  Glass 
et al. (1999) reported expression levels of CB1 and CB2 receptors as 15 and 33 pmol/mg 
respectively, in insect cells. 
 
The Grisshammer group was one of the first to attempt to produce the cannabinoid 
receptors in a prokaryotic expression system.  The E. coli expression system was chosen 
because of its simplicity, ease of handling and the high productivity obtained. Production  
of both CB1 and CB2 receptors, was tried as a fusion protein with the maltose binding 
protein (MBP). The CB2 receptor could be expressed in higher yields (38 pmol/mg) in a 
functional form and the CB1 receptor could not be expressed even in the detectable limits. 
The CB1 receptor was highly degraded (Calandra et al., 1997). Recently the CB2 receptor 
was produced and purified in a functional form from E. coli (Yeliseev et al., 2005). A 
mixture of 0.5% CHAPS+1% DM+ 0.1% CHS was used to solubilise the protein. The 
authors reported that they could purify CB2 receptor upto 80-90% purity in small scales (as 
judged by SDS-PAGE), but large scale purifications  yielded only 50-60% pure protein. 
Additional purification steps improved purity to a small extent (85-90%), but loss of protein 
was observed because of increased number of purification steps.  This purity is not 
sufficient for crystallization attempts. The CB2 receptor fragments ( residues 27-101, 
residues 180-233) were expressed in E. coli for NMR spectroscopic structural 
determination.  
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CB1 and CB2 receptors were expressed in functional form in the P. pastoris 
membranes. Purification attempts of polyhistidine tagged receptors were made for both  
proteins solubilised by 1% DM. The CB2 receptor was bound very tightly to the matrix, 
which needed upto 500 mM imidazole to elute the protein from the IMAC column, on the 
other hand CB1 was so loosely bound that the receptor was washed away even with 30 mM 
imidazole. It has been concluded that the purification of  CB1 (Kim et al., 2004) and CB2 
(Feng et al., 2002) was successful in scales suitable for mass spectroscopic analysis. This is 
quite far from the amount needed for crystallization. They also report that they couldn’t 
detect any ligand binding of the purified proteins. In the literature there are several reports 
regarding the production of cannabinoid receptors in insect cells using the baculovirus 
expression system. Purification attempts were made by Makriyannis group, to use the 
protein again in mass spectroscopic analysis. The CB2 receptor was expressed at a level of 
upto  9.3 pmol/mg of membrane protein (Filppula et al., 2004). CB1 expression levels were 
much higher with upto 24.5 pmol/mg for SR141716A but only 1.7 pmol/mg for agonist 
CP55940, which could mean that most of the protein is present in an inactive form not 
recognized by agonists (Xu et al., 2005). Harsh washing steps (with 8M Urea) were used 
for the purification of the receptors. In these studies they observed several bands in SDS-
PAGE after purification which correspond to cannabinoid receptors. Some of them were 
oligomeric forms and some were N-terminally degraded forms. 
 
1.7  Expression systems for the production of recombinant protein 
 
  The ability to clone a gene into a plasmid made it possible to produce a protein of 
interest in a different organism. If the gene can be expressed in higher yields compared to 
the natural tissue or cell, it is called overexpression. There are several expression systems 
being used now-a-days to overproduce proteins. A gene is cloned downstream of an 
inducible promoter. The expression host can be a prokaryote or an eukaryote. Prokaryotic 
expression systems are the cheapest and fastest of all expression systems. Another 
advantage of these systems is the success rate and high yield. Eukaryotic expression 
systems are relatively expensive and time consuming. Cell-free expression is another novel 
method to produce recombinant proteins. 
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1.7.1 Prokaryotic  expression  system 
 
  E. coli is the most frequently used organism for laboratory use, since the first report 
that it is possible to express foreign genes in E. coli. Several promoters are in use like the  
lac promoter (lactose promoter), the tac promoter (a hybrid of trp and lac promoter), the ara 
promoter (arabinose promoter)    or  the bacteriophage   T5  or  T7 promoters. The T7   
promoter  system  is  most successful and most used now-a-days. In this system the gene of 
interest is under the control of T7 promoter which is recognized by T7 RNA polymerase. 
The production of T7 RNA polymerase is under the control of lac promoter with a lac 
operator in between. Under normal conditions the lac repressor, product of the lacI gene 
suppresses the production of T7 RNA polymerase thereby inhibiting transcription of the 
gene of interest. Upon addition of IPTG which is a derepressor, T7 RNA polymerase is 
produced and transcribes the gene of interest using T7 promoter leading to protein 
production. For the production of recombinant GPCRs in E. coli, the tac promoter was used 
extensively. GPCRs like the β2 and β1 adrenergic receptors, the serotonin receptor 5HT1A, 
the endothelin receptor-B, the neutotensin receptor, the adenosine receptor A1 and A2a, the 
neurokinin receptor-2, opioid receptors (Sarramegna et al., 2003) etc. and recently the 
cannabinoid receptor-2 were expressed in E. coli. 
 
1.7.2  Eukaryotic expression systems 
 
There are several drawbacks in prokaryotic expression systems despite their 
extensive use for protein production. E. coli is a simple organism with a simple machinery 
for protein production and modifications. The post-translational modifications observed in 
eukaryotic proteins are not seen in prokaryotic proteins and  so E. coli lack this machinery. 
Such eukaryotic proteins, produced in E. coli might be non-functional or don’t express at 
all. These problems occur mostly with mammalian proteins which have complicated post-
translational modifications like glycosylation, acylation and phosphorylation. To overcome 
these problems several eukaryotic expression systems were developed. 
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1.7.2.1 Yeasts as expression hosts 
 
Yeasts are the simplest among eukaryotes used for protein production. Yeasts have 
short generation times (2h), grow on simple media and like bacteria are easy to manipulate. 
Unlike bacteria they have a complex machinery for most of the post-translational 
modifications. Several yeast species have been developed as expression hosts. 
Saccharomyces cerevisiae is the first yeast used for heterologous protein production. The 
inducible GAL1 (galactose inducible) promoter is commonly used. Another most 
extensively used yeast is the methylotrophic yeast Pichia pastoris. P. pastoris possesses a 
strong inducible alcohol oxidase promoter (AOX1) which can be used to induce protein 
production. The gene of interest is stably integrated into the genome. Multicopy gene 
integration enhances protein production. Membrane protein production could be increased 
by using the S. cerevisiae α-factor mating signal peptide. It is estimated that alcohol oxidase  
can constitute  upto 80% of the total cell protein (Tschopp et al., 1987; Cregg et al., 2000; 
Reilander  et al., 1998). Though this system has been successful in producing several 
proteins in milligram quantities, it too has some drawbacks, when it is used for production 
of mammalian proteins like GPCRs. The N-glycans added by yeasts are different from 
those of the mammalian cells, which might affect the glycosylation status and there by the 
activity of the protein produced (Eckart et al., 1996). The lipid composition of the yeast 
membranes is also different from that of the mammalian cells. Yeasts do not produce 
cholesterol which is one of the important lipids of the mammalian cell membrane. Other 
commonly used yeast species are Schizosaccharomyces pombe, Hansenula polymorpha and 
Candida boidinii (Gellissen et al., 2000). GPCRs like the β2 adrenergic receptor (115 
pmol/mg), the µ-opioid receptor (100 pmol/mg), the bovine rhodopsin (2 mg/10
10 cells), the 
endothelin receptor-B (30-60 pmol/mg), were produced in high levels (Sarramegna et al., 
2003). 
 
1.7.2.2 Expression systems based on insect cells 
 
Insect cell expression systems can be used as alternate systems for mammalian 
expression system to overproduce mammalian proteins, because of the ability of post-
translational modifications. The most used insect cell expression system is based on the 
baculovirus.  Autographa californica nuclear polyhedrosis virus (AcMNPV) is a double ___________________________________________________Introduction.. 
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stranded DNA virus surrounded by a lipid membrane which infects a very narrow range of 
insect hosts (Fraser et al., 1992). This virus is known to infect only members of the 
Lepidoptera and Hymenoptera class of insects and to be safe for other insects and humans. 
Baculovirus production occurs in a biphasic lifecycle. In first phase virus is produced as 
nucleocapsids in the nucleus and buds out of the plasma membrane. In the second phase the 
virus particles are occluded in the polyhedrin protein to form a crystal polyhedra, rendering 
them an environmentally stable structure to be carried on to other insects in the field. The  
non-occluded form is the one used in cell culture. The polyhedrin gene is replaced by the 
gene of interest to be expressed. So this gene is under the control of a strong polyhedrin 
promoter which gives rise to production of  polyhedrin protein, upto 30% of the cell protein 
during the second phase of life cycle.  
 
In the baculovirus expression system, two vectors are used, a non-modifiable viral 
genome and a transfer vector with the foreign gene and being capable of homologous 
recombination with the viral genome. These two components recombine in the cell to form 
a functional baculovirus genome. A relatively easier technique of recombination was 
developed as Bac-to-Bac
® by Invitrogen. A plasmid pFastBac
TM having the expression 
cassette is transformed into the E. coli strain DH10Bac
TM containing parent baculovirus 
bacmid  [bMON14272 (136Kb)]. Recombination occurs in  E. coli and this bacmid is 
isolated and transfected into the insect cells (Bac-to-Bac, Invitrogen). Since the foreign 
gene is under the control of the polyhedrin promoter the recombinant protein will be 
produced when the polyhedrin promoter is switched on. The polyhedrin promoter is a late 
phase promoter which normally starts after 48 hr of infection. Alternately the p10 promoter 
is used which is an early phase promoter. Commonly used cell lines for the insect cells are 
Sf9, Sf21 from Spodoptera frugiperda ovary and High Five from Tricoplusia ni ovary. 
Another way of protein production using insect cells is based on the stable integration of 
the foreign gene into the insect cell genome. Drosophila melanogaster cell expression uses 
this kind of stable expression without any virus mediation. Stable expression is possible in 
cell lines from the moth as well. In this system the early phase promoter, OpIE2 from 
Orgyia pseudotsugata is used.  The production levels are lower than the baculovirus 
expression system. 
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Fig 1.15: Baculovirus mediated protein production insect cells.  The linear baculovirus genome and the 
transfer vector having recombination sites and a foreign gene under the control of polyhedrin promoter 
recombine in the cell. This recombined genome produces the recombinant virus and drives protein production 
under the control of virus promoter. 
 
      Though insect cell based expression systems are invaluable in recombinant 
eukaryotic protein production, they do have a set of drawbacks. The doubling rate of the 
cells commonly used in this system is about 18-24 hr, which makes it a slower system. 
Another practical problem is that the protein production is not good when the infection is 
done at a high cell density. Scaling up is not as easy as in E. coli or yeasts. Further the 
media used is complex and expensive compared to the earlier discussed expression systems. 
Several GPCRs were successfully expressed in higher yields in insect cells. Though some 
of them do not show high affinity binding. Cholesterol is less abundant in the insect cell 
membranes which might alter the function of the GPCRs produced. One advantage of the 
insect cell expression system is that some human GPCRs have been shown to couple to the 
endogenous G proteins, which increases the high affinity binding state of the receptor. 
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1.7.2.3 Expression systems based on mammalian cells 
 
The mammalian expression system is the most natural way of producing a 
functional recombinant mammalian protein. The advantage of the mammalian expression 
system is that all the post-translational modifications are provided by the cell line. The 
functional analysis of the recombinant protein in vivo is possible to a greater extent than in 
the insect cells because of the presence of the effector molecules. There are two major 
approaches for heterologous expression of recombinant proteins in mammalian cells: 
transient  and stable expression. Several virus types like vaccinia virus (Moss et al., 1991), 
Semliki Forest virus (Liljestrom et al., 1991) are used for transient expression. Stable 
expression can be achieved by stable integration of the foreign gene into the genome or by 
vectors capable of episomal replication. The biggest disadvantage of the system is the high 
costs of the media components and longer time scales. The β2-adrenergic receptor was 
expressed to 200 pmol/mg in CHO cells and bovine rhodopsin upto 10 mg/l in HEK293S 
cells. Scaling up is difficult with mammalian cultures. 
 
1.8 GATEWAY
® cloning technology 
 
The “Gateway” cloning technology is a novel system for cloning DNA. This system 
uses phage λ based site (att) specific recombination instead of restriction endonucleases and 
ligase, as in the classical way of cloning. This recombination system is used by phage λ  
during the switch between the lytic and lysogenic pathways. Two reactions constitute the 
Gateway cloning technology. The BP reaction is a recombination reaction between an 
expression clone (or an attB-flanked PCR product) and a donor vector to create an entry 
clone. The LR reaction is a recombination reaction between an entry clone and a destination 
vector to create an expression clone and a by-product. 
 
Table 1.3: Reactions in Gateway cloning technology 
Reaction Sites  involved  Enzyme  mix  Product 
BP reaction  attB x attP BP  Clonase 
Enzyme Mix 
EntryClone 
(Plasmid) 
LR reaction  attL x attR BP  Clonase 
Enzyme Mix 
Expression 
Clone (Plasmid) ___________________________________________________Introduction.. 
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Figure 1.16: Important reactions and the products of the Gateway Cloning Technology. attB, attP, attL, 
attR represent different recombination sites. BP reaction is recombination of attB and attP, LR reaction is 
recombination of attL and attR. ccdB is the gene for E. coli cytotoxin. 
 
The expression clone can be transformed into E. coli and more than 90% of the colonies 
obtained are positive. This high efficiency is because of the ccdB gene in the destination 
vector. Any original destination vector left in the LR reaction would cause the transformed 
cells to die because of the ccdB gene product interference with DNA gyrase. Only colonies 
containing expression plasmid would grow on the plate. 
 
1.9     Fluorescent techniques 
 
1.9.1  Fluorescence resonance energy transfer 
 
Fluorescence resonance energy transfer (FRET) or Förster resonance energy transfer 
is a energy transfer between two potentially fluorescent molecules, when they are within a 
distance called Förster radius. The Förster radius (Ro) is half of distance where maximum 
energy transfer can be seen. The energy transferred is actually nonradiative energy not the 
fluorescence energy. The excited molecule transfers the energy to the second molecule 
because of the dipole-dipole coupling. The maxium distance where FRET can be observed 
in the biomolecules is 100 Å. The  efficiency  of FRET  defined  as E = 1-F’D / FD   
attB1  attB2 
attP1  attP2  attP2  attP1  attB1  attB2 
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Donor Vector 
ccdB 
ccdB 
ccdB 
ccdB 
GENE 
GENE 
GENE 
Expression Clone 
By-product 
By-product 
Entry Clone  Destination Vector 
BP reaction  LR reaction ___________________________________________________Introduction.. 
  31
Ro 
CFP YFP YFP 
FRET 
458 nm  514 nm 
475-525  >530 nm 
458 nm 
CFP
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.17: Fluorescence Resonance Energy Transfer (FRET). When both  fluorescent molecules are more 
than 10 nm apart energy transfer doesn’t occur. But below 10 nm the energy from the donor excites the 
acceptor molecule and results in FRET. CFP is normally excited at 458 nm and YFP at 514. The numbers 
below are the emission wavelengths recorded by the detector. 
 
where F’D and FD are the donor fluorescence intensities with and without the presence of 
the acceptor.  FRET occurs between two partners only when the emission spectrum of 
donor and the absorption spectrum of acceptor molecules overlap with other. Several 
GPCRs are also being studied now-a-days using  the FRET technique to investigate the 
dimerisation behaviour and also the coupling to the G proteins or effector molecules 
(Nobles et al., 2005). Several different kinds of fluorescent molecules can be used as FRET 
couples. When studying protein-protein interactions in vivo, Green Fluorescent Protein 
(GFP) and its variants are commonly used. There are a series of variants which emit blue 
(BFP), cyan (CFP), yellow (YFP), red (DsRed) fluorescnece. These proteins can be fused 
by molecular biology techniques very easily.  
 
1.9.2  Bodipy coupled GTP analogs as alternatives to GTPγS
35 
 
  Radioactive ligand binding assays are potentially dangerous because of the 
radioactive isotopes involved, even though more sensitive. But fluorescence gives a safer 
alternative for doing assays. Further they provide the possibility of monitoring the reactions 
at real time. They don’t need any scintillation mixtures or special counter, not even UV 
optics. A normal spectrophotometer can be used to study the biological reactions. The 
“Bodipy” dye coupled to guanine nucleotides provide an efficient way of monitoring   ___________________________________________________Introduction.. 
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GTPase activities (McEwen et al., 2001). The fluorescence of the Bodipy molecule is 
quenched by the rapid collisions between the fluorophore and guanine ring in the free form. 
But when the guanine nucleotide binds to the protein, the guanine ring moves away from 
the bodipy dye, resulting in an increase in the fluorescence. So this is a kind of dequenching 
mechanism. Korlach et al. (2004) found out that,  the greater the  length of the linker 
between the dye and nucleotide the lesser is the quenching. 
 
  Bodipy 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.18: BODIPY-FL coupled to GTPγS molecule. In this molecule the guanine ring overlaps on the 
BODIPY fluorophore and results in quenching of the fluorescence. Once the molecule is bound to the G 
protein guanine ring moves away from the BODIPY resulting in increase in the fluorescence. 
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2  MATERIALS AND METHODS 
_________________________________________________ 
 
2.1 Materials 
 
2.1.1    Chemicals 
 
The chemicals used were of analytical grade and of the highest purity available. The 
common laboratory chemicals were purchased from Roth (Carl Roth & Co. KG, Karlsruhe, 
Germany), Merck (Merck KGaA, Darmstadt, Germany), Fluka/Sigma (Sigma-Aldrich 
Chemie GmbH, Deisenhofen, Germany) (DE and Germany used alternately for Germany). 
 
Agarose    Bethesda Research Laboratories GmbH,   
Neu-Isenburg, Germany 
Agarose (Low melting)      FMC Bioproducts, Rockland, USA 
AM251     Tocris,  Ellisville,  USA 
AM630     Alexis  Biochemicals,  USA 
Ammonium  persulphate    Koch-Light  Ltd.,  Haverhill,  England 
Ampicillin, sodium salt      Carl Roth GmbH & Co. KG, Karlsruhe 
Bacto  Agar      Difco  Laboratories,  Detroit,  USA 
Bacto Tryptone        Difco Laboratories, Detroit, USA 
Bacto  Yeast  Extract     Difco Laboratories, Detroit, USA 
BCIP       Biomol  Feinchemikalien  GmbH,  Hamburg,DE 
Biotin       Calbiochem,  Merck  KGaA,  Darmstadt 
Bodipy FL GTPγS     Molecular  Probes,  USA 
BSA       Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
Bromophenol  blue     Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
CHS       Sigma-Aldrich  Chemie  GmbH,  Deisenhofen __________________________________________Materials and methods.. 
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Coomassie Brilliant Blue R-250    Serva Elektrophoresis GmbH, Heidelberg, DE 
Deoxynucleotide -5’-triphosphates   Pharmacia  Biotech,USA 
DMSO       Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
DTT       Serva  Elektrophoresis  GmbH,  Heidelberg,  DE 
EDTA       GERBU  Biotechnik  GmbH,  Gaiberg,  DE 
Ethidium bromide        Bio-Rad Laboratories GmbH, Munich, DE 
GDP       Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
Geniticin sufate G418       Novabiochem, Merck KGaA, Darmstadt 
Glass  beads  (0,5mm)     Biomatik GmbH, Frankfurt, DE 
GppNp       Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
GTPγS       Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
HU210       Tocris,  Ellisville,  USA 
Kanamycin          Carl Roth GmbH & Co. KG, Karlsruhe 
Lorglumide      Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
Milk  powder      Nestlé,  Munich,  Germany 
NBT       Biomol  Feinchemikalien  GmbH,  Hamburg 
Peptone      Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
PEI       Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
Rotisol 30          Carl Roth GmbH & Co. KG, Karlsruhe 
Rotiscint  eco  plus     Carl  Roth GmbH & Co. KG, Karlsruhe 
Silver  nitrate      Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
TEMED      Koch-Light,  Haverhill,  England 
Tunicamycin      Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
WIN  55,212-2      Tocris,  Ellisville,  USA 
Yeast Nitrogen Base        Difco Laboratories, Detroit, USA 
 
2.1.2    Radiolabeled chemicals 
 
[
3H]  CCK-8      Amersham  Biosciences,  UK 
[
3H] CP-55,940        Perkin Elmer life sciences, Boston, USA 
[
3H]  SR141716A     Amersham  Biosciences,  UK 
[
35H] GTPγS      Perkin  Elmer  life  sciences 
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2.1.3    Detergents 
 
CHAPS      Calbiochem,  Merck  KGaA,  Darmstadt 
Deoxycholate, Sodium salt      Sigma-Aldrich Chemie GmbH, Deisenhofen 
Digitonin      Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
n-Decyl-β-D-maltoside(DM)     Glycon Biochemicals, Luckenwalde, DE 
n-Dodecyl-β-D-maltoside(LM)    Glycon Biochemicals, Luckenwalde, DE 
N-Dodecylphoscholine(Fos12)   Anatrace,  Maumee,  USA 
N-Tetradecylphoscholine(Fos14)   Anatrace,  Maumee,  USA 
N-Hexadecylphoscholine(Fos16)   Anatrace,  Maumee,  USA 
LDAO          Anatrace,  Maumee,  USA 
n-Octyl-β-D-glucopyranoside (OG)    Glycon Biochemicals, Luckenwalde, DE 
n-Octyl-β-D-maltoside(OM)      Glycon Biochemicals, Luckenwalde, DE 
SDS       Carl  Roth  GmbH  &  Co.  KG,  Karlsruhe 
   
2.1.4    Protease inhibitors 
 
Aprotinin      Biomol  Feinchemikalien  GmbH,  Hamburg,DE 
E-64       Biomol  Feinchemikalien  GmbH,  Hamburg 
Leupeptin      Biomol  Feinchemikalien  GmbH,  Hamburg 
Pepstatin      Biomol  Feinchemikalien  GmbH,  Hamburg 
PMSF       Carl  Roth  GmbH  &  Co.  KG,  Karlsruhe 
 
2.1.5    Antibodies  
 
Anti-flag M1 antibody      Sigma-Aldrich Chemie GmbH, Deisenhofen 
Anti-flag M2 antibody      Sigma-Aldrich Chemie GmbH, Deisenhofen 
Anti-flag M2-AP conjugate      Sigma-Aldrich Chemie GmbH, Deisenhofen 
Anti-polyhistidine  antibody    Sigma-Aldrich Chemie GmbH, Deisenhofen 
Anti-polyhistidine-AP conjugate    Sigma-Aldrich Chemie GmbH, Deisenhofen 
Streptavidin-AP     Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
Anti Gαi antibody        Calbiochem, Merck KGaA, Darmstadt 
Anti Gβ antibody        Calbiochem, Merck KGaA, Darmstadt __________________________________________Materials and methods.. 
  36
Anti-Mouse IgG, AP conjugated    Sigma-Aldrich Chemie GmbH, Deisenhofen 
Anti-Rabbit IgG, AP conjugated    Sigma-Aldrich Chemie GmbH, Deisenhofen 
 
2.1.6    Chromatographic resins and columns 
 
Anti-Flag
TM M2 Affinity Gel     Sigma-Aldrich Chemie GmbH, Deisenhofen  
ImmunoPure
®  Immobilized  
Monomeric Avidin Gel      Pierce, Rockford, USA 
Ni-NTA
® Agarose        Qiagen GmbH, Hilden, Germany 
His-Select  Agarose     Sigma-Aldrich Chemie GmbH, Deisenhofen 
Profinity IMAC
®     Biorad,  Munich,  Germany 
Hi-Trap
® Ni-IMAC column      Amersham Pharmacia Biotech, Freiburg, DE 
Strep-Tactin
®-Agarose   IBA  BioTAGnology,  USA 
Superdex 200 PC 3.2/30      Amersham Pharmacia Biotech, Freiburg 
Q-Sepharose      Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
 
2.1.7    Enzymes 
      
KOD Hot start polymerase      TOYOBO, Japan 
Restriction  endonucleases    MBI  Fermentas GmbH, St.Leon-Rot, DE 
      New  England  Biolabs  GmbH,  Schwalbach 
T4 DNA ligase        New England Biolabs GmbH, Schwalbach 
Benzonase      Merck  KGaA,  Darmstadt,  DE 
EndoH       New  England  Biolabs  GmbH,  Schwalbach 
PNGaseF      New  England  Biolabs  GmbH,  Schwalbach 
 
2.1.8    Sf9 culture media and components 
 
TNMFH medium w/o Glutamine    CC Pro GmbH, Germany   
SF 900 II medium with Glutamine    GIBCO®, Invitrogen Corporation, USA 
Express  Five  medium     GIBCO®, Invitrogen Corporation, USA 
Foetal kalf serum        PAA Laboratories GmbH, Pasching   
L-Glutamine      PAA  Laboratories  GmbH,  Pasching 
Gentamycin  Sulphate     Biowest,  Nuaille __________________________________________Materials and methods.. 
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Vitamin B12      Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
Pluronic  F  68      Sigma-Aldrich  Chemie  GmbH,  Deisenhofen 
 
2.1.9    Kits  
 
Qiagen Plasmid miniprep kit      Qiagen GmbH, Hilden 
QIA quick Gel Extraction kit     Qiagen GmbH, Hilden 
QIA quick PCR Purification Kit    Qiagen GmbH, Hilden 
BCA Protein Assay Kit      Pierce, Rockford, USA 
E.coli Expression Systems with  
Gateway Cloning Technology Kit   Invitrogen  Corporation,  USA 
 
2.1.10    Buffers and Solutions 
 
Agarose gel (1%)        1 g agarose in 100 ml 1X TAE buffer 
Ampicillin Stock solution (1000x)    150 mg/ml in sterile water (-20ºC) 
Alkaline Phosphatase Buffer      100 mM Tris/HCl, pH 9.5 
      100  mM  NaCl 
      5   m M   M g C l 2 
Aprotinin  (1000x)     10  mg/ml  in  water  (-20ºC) 
APS       10%  w/v  in  water 
BCIP  solution      50  mg/ml  in  DMF  (-20ºC) 
Blotting  buffer  5x     190  mM  glycine 
      5 0   m M   T r i s  
Blotting  buffer  1x     38  mM  glycine 
      1 0   m M   T r i s  
      20%  (v/v)  methanol 
Conditioner  (Silver  staining)    100  µl  Sodium thiosulphate in 60 ml water 
Coomassie solution        0.25 g Coomassie Brilliant Blue R250 in 
      100  ml  (45  water+45  methanol+10  acetic  acid) 
Destaining solution (Coomassie gels)    1 L methanol   
      1   L   w a t e r    
      200  ml  acetic  acid 
Developer  (Silver  staining)    1.2  g  sodium carbonate, 25 µl formaldehyde __________________________________________Materials and methods.. 
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            25 µl sodium thiosulphate in 60 ml water 
dNTP  mix  (10x)     8  mM  (2 mM each dATP,dCTP,dGTP,dTTP) 
E64  (10000x)      3.5  mg/ml  50%  ethanol  (-20ºC) 
Gel fixer (Silver staining)      60 ml 50%(v/v) acetone 
      1.5  ml  50%  (w/v)  trichloro  acetic  acid 
      25  µl  formaldehyde 
Kanamycin stock        40 mg/ml in water (-20ºC) 
Leupeptin(2000x)     10  mg/ml  in  water  (-20ºC) 
Loading buffer 4x (SDS PAGE)    25 mM Tris/HCl, pH 6.8 
      4 0 %   ( w / v )   g l y c e r o l  
      2 0 %   ( v / v )   β-Me 
      8 %   ( w / v )   S D S  
      0.004%  (w/v)  bromophenol  blue 
Loading buffer 20x (Agarose gels)    50 mM Tris/HCl, pH 7.4   
      5   m M   E D T A  
      50%  (v/v)  glycerol 
      0.5%  (w/v)  bromophenol  blue 
      0.5%  (w/v)  xylene  cyanol 
NBT  solution      50  mg  NBT/ml in 70% DMF in water (-20ºC) 
PepstatinA  5000x     10  mg/ml  in  methanol  (-20ºC) 
PMSF       200  mM  in  isopropanol 
Radioligand binding buffer      20 mM Tris/HCl pH 7.4 
      100  mM  NaCl 
      5   m M   M g C l 2      
      1 mM EDTA 
      1 %   B S A  
Staining solution (Silver staining)    0.8 ml 20% (w/v) silver nitrate 
      0.6  ml  formaldehyde  (37%)  in  60  ml  water 
SDS gel running buffer (10x)     500 mM Tris 
      1.92  M  glycine 
      1 %   ( w / v )   S D S  
TAE buffer (50x) pH 7.4      2 M Tris 
      1  M  acetic  acid 
      5 0   m M   E D T A    __________________________________________Materials and methods.. 
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TBS  buffer      50  mM  Tris/HCl,  pH  7.4   
      150  mM  NaCl 
 
2.1.11    E. coli media recipes 
 
LB medium for E. coli   1%  (w/v)  tryptone 
      0.5%  (w/v)  yeast  extract 
      0.5%  (w/v)  NaCl 
LB-Agar for Plates        LB-medium with 1.5% agar 
 
2.1.12   P. pastoris media recipes 
 
The stock solutions of YNB, biotin, phosphate buffer were prepared according to 
the recipes given in the manual (Multi-copy Pichia Expression Kit) from Invitrogen life 
technologies. The procedure to make the media is also from the manual. 
 
BMGY/BMMY  medium    1%  yeast  extract    
(Buffered Glycerol/Methanol complex)  2% peptone   
      100  mM  potassium  phosphate,  pH6.0 
      1.34%  YNB 
      4 x   1 0
-5 % biotin 
      1%  glycerol  /  0.5%  methanol   
MD  plates      1.34%  yeast  nitrogen  base   
(Minimal Dextrose)     4x  10
-5 biotin 
      2%  dextrose 
      1.5%  agar 
YPD  medium      1%  yeast  extract 
(Yeast extract Peptone Dextrose)   2%  peptone   
      2%  dextrose 
      1.5%  agar  (  for  YPD  plates) 
YPD  Geneticin  Plates     0.25-1.0  mg/ml  YPD-agar 
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2.1.13   Sf9 media recipe 
            
TNMFH  medium       4  mM  L-glutamine 
      5 %   ( v / v )   F C S  
      50  µg/ml  gentamycin 
      10  µg/L  Vit  B12 
Plaque assay plates        TNMFH complete medium 
      2%  (w/v)  low  melting  agarose 
      X-gal  200  µg/ml   
       
2.1.14   Instruments   
   
Confocal microscope  LSM 510    Carl Zeiss AG, Germany 
Electroporation device    Biorad,  Munich 
Fluorescence microscope      Carl Zeiss AG, Germany 
Gel documentation system      Biorad, Munich 
Light  Microscope     Olympus  Inc.,  Japan 
Luminescence photometer LS50B    PerkinElmer LAS (Germany) GmbH, Rodgau 
Optima LE-80K UC        Beckman-Coulter, Fullerton, CA, USA 
Radioactivity  counter     PerkinElmer LAS (Germany) GmbH, Rodgau 
Shakers     Infors  AG,  Switzerland 
Sigma 3K 12 tabletop centrifuge    Sigma Laborzentrifugen GmbH, Osterode 
Sorvall  RC-5B      Sorvall,  Bad  Homburg 
Spectrophotometer     Thermo  Spectronic,  UK 
Tabletop Eppendorf 5415D      Eppendorf GmbH, Hamburg 
Tabletop Ultracentrifuge TL 100    Beckman Instruments Inc., Palo Alto, USA 
Thermomixer  5436     Eppendorf  GmbH,  Hamburg 
Vortexer          Bender & Hobein AG, Zurich, Switzerland 
 
2.1.15   Consumables 
 
15ml/50 ml culture tubes      Greiner bio-one 
Disposable  pipets     Sarstedt,  Nümbrecht,  Germany 
Glass  bottles      Schott  AG,  UK __________________________________________Materials and methods.. 
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Microfuge tubes         Eppendorf GmbH, Hamburg, Germany 
Pipette  tips      Sarstedt,  Nümbrecht,  Germany 
Syringe  filters      Sarstedt,  Nümbrecht,  Germany 
Tissue  culture  flasks     Nunc  GmbH & Co. KG, Wiesbaden, DE 
 
   
2.2  Methods 
 
2.2.1  Working with Escherichia coli 
 
2.2.1.1  Culturing E. coli  
 
A single colony on the freshly transformed or streaked LB-agar plate was used to 
inoculate 5 ml LB medium with appropriate antibiotic. The culture was grown overnight at 
37ºC and 220 rpm. This culture was used for further experiments like plasmid DNA 
isolation or as seed culture for expression of the transformed gene. 
 
2.2.1.2  E. coli competent cell preparation and transformation  
 
Tranformation Buffer (TB): 
15 mM CaCl2 
55 mM MnCl2 
250 mM KCl 
10 mM PIPES-Na, pH 6.7 
 
For the high efficiency competent cells preparation, a single colony of E. coli was 
grown overnight in 2 ml LB medium. This was used to seed 100 ml LB medium containing 
10 mM MgCl2 and grown at 18ºC, shaking at 100 rpm. When the OD600 was 0.1, the culture 
was cooled on ice for 10 min. Cells were pelleted using a centrifuge and resuspended in 1/3 
culture volume (33 ml) of TB. The suspension was pelleted again and resuspended in 8 ml 
of TB. 600 µL of DMSO was added. The suspension was aliquoted and flash frozen in 
liquid nitrogen before storing at -80ºC. 
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To transform plasmid DNA, an aliquot of the competent cells was thawed on ice. 
Plasmid DNA (100-1,000 ng) was added and incubated on ice for 20 min. The cells were 
given a heat shock at 42ºC for 2 min. The transformed mixture was spread evenly on a LB-
agar plate with an appropriate antibiotic. The plate was incubated over night at 37ºC. A 
single colony was used for any further experiments done. 
 
2.2.1.3  Gene amplification by PCR 
 
To amplify the genes from cDNA, Hot start KOD or Pfu polymerase was used. The 
amplification conditions were according to the supplier’s manual. To incorporate a foreign 
gene inside another gene (Gi-CFP), a typical overlap PCR was done (see Appendix). 
 
2.2.1.4  Cloning of E. coli expression vectors 
 
Introducing a foreign gene into a vector was done in one of two ways for the E. coli 
expression system. In the classical method, the vector and the PCR product were digested 
with the compatible restriction endonucleases according to the supplier’s instructions. The 
vector and the PCR product were purified using the gel extraction kit/ PCR purification kit. 
The ligation was done using T4 DNA ligase  for 2 hr at 24ºC or overnight at 15ºC. Ligation 
reaction was stopped by heat inactivation of the enzyme at 65ºC for 15 min. 6 µL of the 
ligation mix was used to transform the competent E. coli cells. The cells were plated on 
LB-agar plate and incubated overnight. Positive colonies were identified by isolation of 
plasmid DNA (Plasmid isolation kit) and restriction digestion. Alternatively the   
GATEWAY cloning technology from Invitrogen was used. The reactions of this cloning 
technology were performed according to the protocols given in the manual. The entry 
vector pENTR11 and destination vector pDEST14 were used for this work. pDEST uses the 
T7 promoter.  Tags were introduced into the genes by PCR. Oligonucleotides used for the 
PCR amplification of the G protein subunits contained the following sequences: 
 
Forward(attB1): 5' GGGG ACA AGT TTG TAC AAA AAA GCA GGC TTC GAA GGA 
GAT AGA ACC ATG GTG CAT CAT CAT CAT CAT CAT XXX XXX XXX  3’ 
 
Reverse(attB2): 5' GGGG AC CAC TTT GTA CAA GAA AGC TGG GTC TCA XXX 
XXX XXX 3’ __________________________________________Materials and methods.. 
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2.2.1.5  Expression screening in E. coli 
 
For the screening of protein expression in E. coli, expression hosts like BL21(DE3), 
BL21-CodonPlus RP/RIL, Rosetta(DE3), Rosettagami(DE3), C43(DE3) were used. The 
plasmid with the gene of interest was transformed into the competent cells of  expression 
the strain. A single colony was picked from the LB-amp plate for a 2 ml overnight seed 
culture. 5 ml cultures were inoculated with 1% of the overnight culture and incubated at 
37ºC. At an OD600 of 0.5-0.6, expression was induced by addition of  IPTG at 
concentrations of 50 and 200 µM. The cultures were incubated at 30ºC for different 
intervals of time. 1 ml culture was aspired at regular intervals from all the culture tubes. 
This aliquot was pelleted and stored at -20ºC until use. The pellets were resuspended in 200 
µl of buffer (20 mM Tris/HCl, 100 mM NaCl). The suspension was heated on a thermo 
block at 95ºC for 10 min, to lyse the cells. The debris was pelleted by centrifugation and the 
supernatant was used either for SDS-PAGE or for 96 well dot blot. 
 
2.2.2  Working with Pichia pastoris 
 
2.2.2.1  Maintaining yeast culture 
 
Pichia pastoris was maintained in YPD medium. A single colony from a freshly 
streaked YPD plate was inoculated into YPD medium and incubated overnight at 30°C. 
 
2.2.2.2  P. pastoris transformation 
 
The transformation in P. pastoris was done by electroporation. A single colony of 
the strain SMD1163/SMD1168 was inoculated in 2 ml YPD medium and grown overnight. 
A 100ml culture was inoculated from the overnight culture at an OD600 equal to 0.1. The 
cells were grown to a OD600 of 1.5. The culture was cooled on ice for 30 min. The cells 
were pelleted by centrifugation and resuspened in 100 ml of autoclaved water. This 
washing step was to remove excess medium and buffer components. The suspension was 
pelleted again and resuspened in 50 ml water. One more washing was done using 2 ml of 1 
M sorbitol. Finally the pellet was resuspended in 200 µl of 1M sorbitol. This suspension 
was used for electroporation. 
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The supercoiled plasmid was linearised using one of the suitable enzymes (mostly 
PmeI) and purified using the Qia-quick PCR purification kit. 80 µl of cell suspension was 
mixed with 10-20 µl (10 µg) of linearised DNA and incubated on ice for 5 min.  The 
suspension was added to a 2 mm electroporation cuvette. Electroporation was done using a 
Bio-rad electroporation device with 600 mA current and 1.5 kV voltage at 25 µF 
capacitance. A short pulse was given and the time constant was monitored (11-12.5) to 
assess the successful transformation. 1 ml of 1 M Sorbitol was added to the transformed 
cells and 200 µl of this solution was plated onto an MD plate. The plates were wrapped 
with parafilm and incubated at 30°C till prominent colonies appeared. 
 
2.2.2.3   96 colony screening for selecting high expression clone    
 
The colonies obtained on the MD plate after transformation are His
+, which means 
that they  are right recombinants with a stable integration of the gene of interest. Since in P. 
pastoris the expression levels depend very much on the number of integrated genes, there is 
a need to screen maximum possible number of colonies. In this work a rapid expression 
screening technique was used alternately for screening based on antibiotic resistance. 
 
Figure 2.1: Steps  in the rapid  expression screening.   Colonies  were  grown for about 2 days on BMGY 
plates and 1-2 days on BMMY plates. Lysis was done at 65°C for 3 hr. Immunoblot was done using the 
epitopes on the protein of interest. 
96 well YPD culture
BMGY-agar plate  BMMY-agar plate Lysis over paper towels 
Immunoblot __________________________________________Materials and methods.. 
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96 colonies were picked from a fresh MD plate and inoculated in a 96 well plate 
containing 200 µl of YPD per well. The plate was incubated overnight. This culture was 
replica copied onto a nitrocellulose paper, placed over BMGY-agar in a 1 well rectangular 
dish. The plate was incubated in a humid chamber in a 30°C incubator. When the colony 
grew to about 3 mm in diameter on the nitrocellulose membrane (NC), the paper was 
removed from the BMGY plate and placed on a BMMY plate. The plate was incubated 
again for 24-48 hr.  
 
After the incubation, colonies   on   the NC paper were lysed   using   the   lysis   
buffer (50 mM Tris/HCl, 100 mM NaCl, 10 mM MgCl2, 50 mM β-Me, 6 M urea, 2% SDS). 
The NC membrane with colonies was placed over paper towels presoaked with the lysis 
buffer and incubated at 65°C for 3 hr. The dried colony debris was washed with water 
properly using a wash bottle. This washed paper was used for immunostaining. The colony 
which gave the brightest dot was selected and stored as glycerol stocks (Fig 2.1). 
 
2.2.2.4  Preparation of P. pastoris cell membranes 
 
For the large scale purification of a soluble protein or to prepare the membranes of   
P. pastoris the cells were broken using glass beads. The cells were pelleted and the pellet 
was resuspended in breaking buffer, pH 7.4 (25 mM Tris/HCl, 100 mM NaCl, 5 mM 
MgCl2, PMSF). Typical 1 L shaking flask culture pellet was re-suspended in 50 ml buffer 
and chilled on ice. An equal volume of 0.5 mm glass beads was added to the suspension in 
a beaker. The suspension was stirred at 1000 rpm for 15 min using a homogenizer fitted 
with a metal rod with spikes at the bottom. The suspension was filtered through a sieve 
funnel, to remove the glass beads. The cell suspension was centrifuged at 3000 rpm for 10 
min to remove the unbroken cells and cell debris. The supernatant was centrifuged at 
150,000 g in a ultracentrifuge (UC), to pellet the cell membrane. For soluble proteins, the 
supernatant after UC was used for further steps of purification. For membrane proteins, the 
pellet from UC was homogenized using a potter, in a resuspension buffer (breaking buffer 
+10% (v/v) glycerol). The homogenized membrane  was flash frozen and stored at -80°C, 
until further usage. 
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2.2.2.5  Storage of positive clones of P.pastoris 
 
Since the transformants of P. pastoris possess stable integration of the gene, it is 
very important to store the clones properly. The positive clones were grown  to an OD600 of  
0.5 in YPD medium. Glycerol was added to 30% (v/v) of culture volume. The culture was 
divided into 1 ml aliquots,  flash frozen in liquid nitrogen and stored in -80°C refrigerator. 
 
2.2.3  Working with insect cells 
 
2.2.3.1  Maintaining insect cell cultures 
 
The Spodoptera frugiperda pupal ovarian cell line Sf9 was maintained in complete 
TNMFH medium. The cell line was maintained in tissue culture flasks as well as in   
suspension. For  shaking suspension cultures 0.1% (w/v) Pluronic F-68 was included in the 
medium to reduce the shearing of cells. The cells were grown in 27°C incubators. The 
suspension culture was grown  in a shaker at 150 rpm, in a square bottle or a conical flask.  
 
2.2.3.2  Baculovirus DNA transfection of insect cells 
 
Transfection of the virus DNA (Baculo Gold) and the pVL expression plasmid 
DNA into the Sf9 cells was done using Cellfectin reagent. A transfection mix was made 
with the following components. 
0.4 µg  pVL plasmid DNA  
0.1 µg Baculo Gold  (4µl) 
30  µl  transfection reagent  
were mixed and the volume was adjusted to 50 µl with sterile water. The transfection mix 
was incubated for 15 min at room temperature. Meanwhile 1.28 x 10
6 cells were added to 
each well of a 6 well culture plate. The cells were washed 3 times with medium without 
FCS. 1 ml medium without FCS was added to the transfection mix and then added to the 
cells. The plates were incubated at room temperature for 1 hr. The solution was removed 
from the well and 2 ml fresh medium with FCS was added to the cells. The plates were then 
incubated at 27ºC for one week, to produce mother stock virus. After one week the medium 
was centrifuged in a 2 ml Eppendorf tube. The clear supernatant was stored at 4ºC. 
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2.2.3.3  Plaque assay 
 
Plaque assay was done to select the clones producing the protein of interest. 2x10
6  
cells  were  added  to  each  5 cm  round  Petri-dish.  Cells  were allowed to attach to the 
bottom. They were washed thrice with medium without FCS. The mother stock virus was 
diluted in the order of 10
-1 to 10
-5. These diluted virus samples were added to the cells in the 
Petri-dish. The cells were infected for 1 hr. The supernatant was removed and  4ml of 
medium with agarose (1:1 mixture of 3% (w/v) LM agarose and TNMFH medium with 
10% (v/v) FCS) warmed to 37ºC was added over the cells. The medium was allowed to 
solidify and then incubated at 27ºC for 4-6 days.  
 
After 6 days when the plaques could be seen, 2 ml of medium with agarose 
containing 200 µg/ml X-gal was added. The plates were incubated for 24 hr. The white 
plaques were picked using a pipette and added to the cells freshly added to a 6 well plate. 5 
plaques were picked for each construct. The plates infected with the plaque virus were 
incubated for 1 week to produce the virus for the clone. The virus containing medium was 
collected after one week and stored at 4ºC. 
 
2.2.3.4  Determining the virus titre by endpoint dilution assay 
 
The endpoint dilution assay (Summers & Smith, 1987) was done in a 96 well 
microtitre plate. 1x10
5 cells were added to each well in the plate. Virus was diluted 
typically starting from 10
-2 to 10
-10. 10 µl of each dilution was added to each well of a row 
(of 12 wells) in the plate. 8 dilutions were typically used, one for a row. The plates were 
incubated for 1 week. Then each well was scored for infection. When at least a single cell 
was infected in the well, it was scored positive and negative otherwise. Using this score the 
percentage of infection was determined for each dilution. This percentage was used to 
determine proportionate distance (PD) between the infection dilutions. 
PD= (a-50)/(a-b)     
a= nearest percentage of infection above 50% 
b=nearest percentage of infection below 50% 
Using the PD  a factor  called Tissue  culture  infection  density  at  50%  infection  
(TCID50)   was calculated.  
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 logTCID50=(dilution of a - PD) 
 1/log  TCID50 gives the titre of the virus per 10 µl virus used. 
Plaque forming units (Pfu) were determined from the titre. 
  Pfu/ml=titre/ml x 0.69 
Pfu was used as a standard unit to infect the cells at different MOI (multiplicity of 
infection).  
 
2.2.3.5  Expression screening 
 
  Small suspension cultures were grown, to screen the conditions for a good 
expression of the protein. 1 MOI corresponds to an infection with virus which has equal Pfu 
as there are cells in the well. 1, 5, 10 MOI were used to determine the best expression levels 
of the protein. Different infection times were also investigated to get the best expression 
level. The cells from the small suspension cultures were used to check the expression of the 
protein.  
 
1x10
5 cells were collected in a centrifuge tube and  lysed  using 1% SDS in a buffer 
(50 mM Tris/HCl) containing Benzonase and a cocktail of protease inhibitors. The tubes 
were incubated for 30 min on ice to allow proper lysis and digestion of DNA by Benzonase. 
A high speed spin was given to remove any cell debris. The supernatant was used to run a 
SDS-PAGE followed by immunoblotting. For large scale expressions, cells were grown 
first to a density of 2x10
6 cells/ml. Cells were pelleted at 2,000 rpm in sterile centrifuge 
tubes. The pellet was resuspended in fresh medium to the same density and then infected 
with virus. 
 
2.2.3.6  Preparation of cell membranes 
 
Insect cells were lysed using a Parr-bomb. The cells were resuspended in a buffer 
containing 10% (w/v) saccharose and a cocktail of protease inhibitors (pepstatin, aprotinin, 
leupeptin, E64, PMSF). The cell suspension was stirred slowly under a pressure of 500 psi 
in the Parr-bomb for 1 hour. The pressure was released slowly and the collected suspension 
was spun at 3,000 rpm for 10 min to separate unbroken cells. The supernatant was 
ultracentrifuged at 150,000 g for 1 hour. The pellet was homogenized in resuspension 
buffer  containing 10% glycerol. The membrane was flash frozen and stored at -80ºC. __________________________________________Materials and methods.. 
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2.2.4  Protein detection and staining 
 
2.2.4.1  SDS-polyacrylamide gel electrophoresis 
 
SDS-PAGE was routinely used for identifying the protein from crude samples and 
to assess the purity of the protein preparation. 12% separating gels were prepared 
(according to the protocols by Maniatis) in ready to use cassettes from Invitrogen. Samples 
were prepared using a 2X sample buffer. But when the samples were membrane proteins 
heating at 95ºC was omitted, to avoid aggregation of the membrane protein. Electrophoresis 
was done in a vertical unit (X Cell Sure lock) from Invitrogen. The gels were run in gel 
running buffer at a constant current of 25 mA for each gel. These gels were stained by 
Coomassie or  silver or used for immunoblotting. 
 
Separating gel:   Water    13.2 ml    Stacking gel:       10.2 ml   
(for 40 ml)        Rotisol   16.0 ml    (for 15 ml)         2.5 ml 
      Buffer, pH8.8 10.0 ml    Buffer pH 6.8        1.8 ml   
   APS       0.4  ml              0.15  ml 
      SDS (10%)    0.4 ml             0.15 ml 
      TEMED        0.016 ml                               0.015 ml 
 
2.2.4.2  Coomassie staining of SDS-PAGE gel 
 
The gel after electrophoresis was stained using Coomassie staining solution with 
slow shaking for 1 hr-overnight. The staining solution was removed and the gel was 
destained using a destaining solution, in a closed container. The container was closed to 
avoid excess evaporation of acetic acid and methanol. Destaining was done till the 
background was clear. The gel was dried in a gel drier at 80ºC and documented. 
 
2.2.4.3  Silver staining 
 
Silver staining of a SDS-PAGE gel was done in a glass Petri-dish. The gel was fixed 
in 60 ml fixer solution for 5 min and washed afterwards with Millipore water for 5 min. 
The gel was rinsed with water again  5 times for 3 sec to remove any fixer solution and 60 
ml 50% acetone was added. After 5 min  the acetone was removed and 60 ml of conditioner __________________________________________Materials and methods.. 
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was added and incubated for 1 min. The gel was washed properly with water for 5 times. 
Then the gel was kept in the staining solution for 8 min. Staining solution was removed and 
washed with excess water to remove silver ions. The developer was added to the gel and 
once the protein bands were visualized, acetic acid was added to stop the reaction. The gel 
was rinsed in water and dried for documentation. 
 
2.2.4.4  Immunoblotting 
 
Electric currrent was  used to transfer the proteins from the gel onto a PVDF 
membrane, in a semi-dry method. A PVDF membrane similar in size to the gel was 
activated with methanol for 5sec and then transferred to transfer buffer. Filter paper was cut 
in dimensions similar to the gel and soaked in transfer buffer. Three soaked papers were 
kept on the horizontal blotting apparatus. The gel was placed on paper towels. PVDF 
membrane was kept on top of the gel. Three more paper towels were placed on top to make 
a sandwich of gel and PVDF membrane. This sandwich was slowly rolled over using a 
glass pipette, to remove air bubbles between the layers. The upper graphite electrode plate 
was placed and electroblotting was done at a constant current of 50 mA for 2 hr. 
 
After the gel was electroblotted, the PVDF membrane was placed in a 5% solution 
of fatty acid free milk powder for blocking. After 20 min the membrane was washed using 
TBS and it was incubated for 1 hr with the antibody specific (primary) to the epitope on the 
protein of interest. If the antibody is not conjugated to an enzyme(AP), membrane was 
washed with TBS and then incubated with the secondary antibody conjugated to AP. After 
the antibody treatment the gel was washed thoroughly with TBS and developed using the 
substrate solution    (66 µl NBT+ 33 µl BCIP in 10 ml AP buffer). Once the bands were 
visualized the membrane was washed with excess water to stop the reaction. For   
immunoblotting  done  in  a dot-blot  technique the  membrane onto which the protein 
samples are blotted was directly blocked with milk powder and treated with antibody 
solutions in the same way as done for the electroblotting. 
 
2.2.5  Radiolabeled ligand binding assay 
 
For radiolabeled ligand binding assay of a GPCR, the cell membrane was incubated 
with different concentrations of  the radiolabeled ligand ([
3H] SR141716A, [
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55,940) . For each concentration the assay with the radio ligand was done in triplicate and 
duplets for the controls containing cold ligand (3 mM WIN 55-212,2 for CB1 and CB2 
receptors) in the binding buffer to a final volume of 250 µl. The reactions were incubated at 
30ºC in a water bath for 1 hr. They were then filtered through glass fiber filtermats (GF/B 
Whatmann) in a 12 slot or 24 slot filtering apparatus using a vacuum pump. The glass fiber 
filters were washed with the same binding buffer at 30ºC, three times 4 ml each. Glass fiber 
filters were removed from the filtering apparatus and put into a scintillation vial. 4.5 ml of 
scintillation fluid was added to each vial. The vials were vortexed briefly and the 
radioactive counts were measured in a β-counter. 
 
The GTPγS
35 binding assay was done in a similar filter based binding assay.   The 
membranes containing the G proteins were incubated with 50 µM GDP prior to the 
activation of the receptors. The CB1 receptor was activated using 1 µM WIN 55-212,2 and 
inactivated using AM251. The membranes were incubated with ligands at 30°C for 1 hr and 
the reaction mixture was filtered over GF/C filters. The filters were washed with buffer and 
radioactivity was measured as mentioned above. 
 
2.2.6  Fluorescent GTPγS binding assay 
 
Bodipy FL GTPγS  was used as an alternate to the radioactive GTPγS
35. Bodipy FL 
GTPγS binding was done in a buffer containing 20 mM Tris/HCl, 100 mM NaCl, 10 mM 
MgCl2 and 50 µM GDP. The fluorescent ligand was used at a concentration of 500 nM. The 
binding was monitored in a time scale program in a luminescence spectrophotometer. In the 
measurements of GPCR and G proteins interactions, concentrations of 20 nM and 100 nM 
were used respectively. 
 
2.2.7  Protein purification 
 
2.2.7.1  Immobilized metal affinity chromatography 
 
Ni-NTA agarose and His-Select were used for IMAC. For purification of G protein 
α subunits, a large scale culture (1 L) was centrifuged and the cell pellet was resuspended in 
20 ml of buffer A (20 mM Tris/HCl, 100 mM NaCl, 5 mM MgCl2, PMSF). The cells were 
lysed using lysozyme at 0.5 mg/ml of suspension. The suspension was incubated for 30 min __________________________________________Materials and methods.. 
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on ice and then flash frozen in liquid nitrogen. The frozen suspension was thawed slowly. 
After thawing, the suspension was sonicated with 3 pulses of one minute each to shear the 
DNA. The suspension was centrifuged at 135,000 g and the supernatant was loaded to the 
Ni-NTA agarose column fixed to a peristaltic pump. The cell lysate was loaded at 0.5 
ml/min flow rate.  
 
The column was first washed with 10 column volumes of buffer A containing 50 
µM GDP.  Second washing was done with 10 column volumes of buffer B (buffer A 
containing 500 mM NaCl and GDP). Third wash was with 20 column volumes buffer C 
(buffer A containing 30 mM imidazole and GDP). Protein was eluted with elution buffer 
(buffer A containing 250 mM imidazole and GDP). After elution, the eluate was 
concentrated and diluted several times with buffer A in a Centricon (Viva-spin), to remove 
imidazole.  
 
Membrane proteins were first solubilized using a suitable detergent and centrifuged 
at 150,000 g for 1 hr. The supernatant or the solubilizate was loaded onto the column. To 
facilitate efficient binding of membrane protein, the matrix and the solubilizate were 
incubated under slow rocking in a cold room for 1 hr and then  loaded into the column. The 
washing steps were similar except that a detergent was always present in all the buffers at 2 
times CMC. (The buffers didn’t contain GDP). 
 
2.2.7.2  Ion-exchange chromatography 
 
For G protein purification IMAC was followed by ion-exchange chromatography. 
The eluate from the Ni column was concentrated using a Centricon and diluted with a 
buffer containing no NaCl. This protein solution was loaded to the Q-Sepharose matrix in 
the column at a flow rate of 1ml/min. After loading, the column was washed with 5 column 
volumes of 50 mM NaCl to remove any unbound proteins. Then a gradient of 50 to 300 
mM NaCl in 60 ml was applied using the High-Flow automated purification system. 
Fractions of 2 ml were collected and analysed by SDS-PAGE for the presence of protein. 
The fractions containing protein were pooled, concentrated and strored in a -80ºC 
refrigerator. The column was washed with 500 mM NaCl and then with water and stored in 
20% ethanol. 
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2.2.7.3  Streptavidin affinity chromatography 
 
  Proteins fused to the biotinylation domains  from P. shermanii were purified using a 
monomeric avidin based matrix. Irreversible binding sites of the monomeric avidin matrix 
were blocked by biotin prior to loading the protein sample. The matrix was blocked with 5 
column volumes of 2 mM biotin containing buffer. Then it was washed with 5 column 
volumes of 0.1 M glycine (pH 2.8), to remove reversibly bound  biotin. The  column  was  
equilibrated  with  purification buffer (20 mM Tris/HCl, 100 mM NaCl, 5 mM MgCl2, 1 
mM EDTA). Protein sample was incubated with the matrix for 2 hr at 4ºC. The suspension 
was loaded onto the column and washed with 10 column volumes of equilibration buffer. 
The protein was eluted using 10 mM biotin in buffer. The column was washed with glycine 
to remove biotin then with equilibration buffer to reuse the matrix. 
 
  To purify proteins fused to Strep-tag II, a modified streptavidin, Strep-Tactin was 
used. Blocking of irreversible binding sites was done with biotin. To remove reversibly 
bound biotin the column was washed with a 10 mM solution of HABA (4-
hydroxyazobenzene 2-carboxylic Acid). The column was then equilibrated with 
purification buffer. The protein sample was incubated with the matrix at  4ºC for 2 hr to 
facilitate better binding. The column matrix was washed with 10 column volumes of 
purification buffer to remove any unbound proteins. The protein was eluted using a 5 mM 
solution of desthiobiotin in purification buffer. Column regeneration was done using 
HABA solution. 
 
2.2.7.4  Analytical gel filtration 
 
  Analytical gel filtration had been used to assess the homogeneity of the protein. A 
Superdex 200 column was used frequently in the SMART system (analytical purification 
system from Amersham). The column was equilibrated with 1.5 column volumes of 
purification buffer. The protein sample (50 µl), a minimum of 10 µg, was loaded onto the 
column. The column was run with the purification buffer and fractions of 50 µl were 
collected. The fractions were analysed by SDS-PAGE.  
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2.2.8  Co-immunoprecipitation 
 
Co-immunoprecipitation was done to check the complexes of cannabinoid receptor 
and the G proteins. Membranes containing both CB1 receptor and G proteins were 
solubilized in different detergents. The solubilizate was centrifuged at 100,000xg for 1 hr 
and the supernatant was incubated with anti-flag M2 antibody-agarose. The matrix was 
washed with purification buffer to remove any unbound proteins. Bound proteins were 
eluted using SDS loading buffer. This eluate was analysed by immunoblotting for the 
presence of both proteins.  
 
2.2.9  Fluorescence resonance energy transfer (FRET) 
 
A confocal microscope (LSM 510, Zeiss) was used to observe the co-localization of 
the CB1 receptor and G proteins. The receptor and the Giα1-protein were fused to modified 
Green fluorescent proteins. The CB1 receptor was fused to YFP (Yellow Fluorescent 
Protein) at the C-terminus. CFP (Cyan Fluorescent Protein) was introduced into a loop 
between the α-helical domain and the GTPase domain, by overlap PCR (Yu and Rasenick, 
2001). Cells containing both proteins were used to monitor  FRET resulting from the co-
localization of  proteins. Fluorescence was recorded in channel mode using two channels, 
one for the acceptor (YFP) fluorescence and one for the donor (CFP) fluorescence. CFP 
was excited using a 458 nm laser and the fluorescence through a band pass filter of 475-525 
nm was recorded. YFP was   excited using  a 514 nm  laser and emission was recorded 
from a long pass filter of 530 nm. Bleaching of the receptor was done using 514 nm laser at 
80% laser strength for 30 sec. The pre-bleach and post-bleach fluorescence of the donor 
protein was recorded from the first channel. The differences in the fluorescence intensities 
of the pre and post-bleach images were calculated and there by the % FRET signal was 
calculated using the formula 
      %FRET = Dpost-Dpre x 100/ Dpost  
      Dpost = Donor emission intensity in the post-bleach image 
      Dpre  = Donor emission intensity in the pre-bleach image 
 __________________________________________Materials and methods.. 
  55
2.2.10  3-Dimensional protein crystallization 
 
To crystallize the proteins, crystallization kits from Hampton Research, Jena 
Biosciences and Nextal crystal screens were used. Crystallization of Gαq protein was done 
using Hampton Research screens. The buffer conditions of the positive hits were broadened 
to make a sparse matrix screen. One component of the buffer was varied keeping the other 
components constant. Crystallization was done in hanging drop setups. The protein sample 
at a concentration of 10 mg/ml was mixed (1:1) with buffer on a silanized cover slip and 
placed over the well with buffer. The plates were incubated at 18ºC. The crystals, after 
repeated washes were checked on SDS-PAGE. The diffraction pattern was checked at 
ID14, ESRF, Grenoble. An automated robotic system to setup nl sitting drops was also 
used, while screening a large number of conditions. 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 __________________________________________Materials and methods.. 
  56
                                                                                                                                                                              
 
 
 
 
 
 
 
 
 
3. Results.. 
 
 
 
 
 
 
 
 
 
 
 
 
  _______________________________________________________Results.. 
  57
 
 
 
3   RESULTS 
_________________________________________________ 
 
Chapter I: G protein production, purification and functional 
analysis 
 
3.1  Cloning of G protein subunit genes 
 
Cloning of a total of 35 genes coding for human G proteins was done in a high 
through put scale, using the GATEWAY cloning technology (see Introduction 1.8). The 35 
genes included 17 Gα, 6 Gβ, and 12 Gγ subunits.  
 
Figure 3.1: An over view on the human G protein subunits. 35 G protein subunits from human were 
cloned using the Gateway cloning technology into the pDEST14 vector (Appendix A1), to produce in E. coli. 
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3.2  Expression of the G protein subunit genes 
 
  Expression of G protein subunit genes was carried out in various E. coli expression 
strains. Since there were several rare amino acid codons (not used by E. coli) found in 
human G protein genes, the E. coli strains (materials and methods 2.2.15) used for the 
expression contained the tRNAs for these rare amino acid codons.  The gene construct 
coding for an N-terminal hexahistidine tag and for the G protein gene is represented in Fig 
3.2 
 
 
 
 
Fig 3.2: Expression construct of G protein gene in the pDEST14 vector. T7 is the T7 promoter, attB1 and 
attB2 are the recombination sites, and His stands for a hexahistidine tag. 
 
3.2.1  Production of  recombinant Gα subunits 
 
The G protein α subunits were produced best among all the subunits screened (Fig: 
3.3). Out of the 16 Gα   subunits tried, 11   proteins   could be produced in high yields (3-10 
mg/liter culture).  
 
Incubation time and the IPTG concentration had varying effects on the production 
of different G protein subunits. Gαi3 subunit production reached a maximum after an 
incubation time of 6 hr, whereas other proteins were produced better with longer incubation 
times. For most of the produced proteins, production reached a saturation point at about 12 
hr post induction, where as Gαi1 showed an increase even till 20 hr. Interestingly, GαoB and 
GαtC (transducin cone type) protein production was seen at lower IPTG concentrations and 
absolutely no recombinant protein production at higher induction levels. 
 
 Among the Gα subunits tested, Gα15 protein production was the least and Gαi3 was 
the highest. Gα11, Gα13, Gα14, Gαq and Gαolf subunits could not be produced in the BL21-
CodonPlus strain of E. coli. Different expression strains were tested to produce these 
proteins. Rosettagami (DE3) pLysS strain gave better results for Gα11, Gα13, Gα14, Gα15 
(Fig: 3.4-A) than the BL21 CodonPlus strain (assessed by dot intensity). The production 
level of Gα14 subunit was better than others. But there was a considerable amount of protein 
in the insoluble fraction (may be in the form of inclusion bodies) (Fig: 3.4-B). 
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Fig 3.3: Anti-his immuno dotblot screen showing production of Gα proteins in E. coli. 16  G proteins  
were checked  for production  in  BL21-CodonPlus (DE3) strain of E. coli. 100 µl  of the supernatant after cell 
lysis was used for each well of the dotblot apparatus (see materials and methods 2.2.1.5). 11 proteins could be 
expressed in higher yields. Cells were harvested after 6, 12, 20 hr post induction. Two concentrations of IPTG 
were used, 0.03 mM and 0.2 mM. Neg stands for the E. coli strain without any insert. 
 
 The production level of Gα proteins, as assessed from the 20 hr dot intensities shows that 
Gαi3> GαsL> GαsS> GαoA> Gαi2> Gαz> GαtC> GαtR> GαoB> Gαi1> Gα15. 
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Fig 3.4: Production of Gα subunits in the Rosettagami(DE3)pLysS strain of E. coli. A. Those G proteins 
which could not be produced in the BL21-CodonPlus strain were obtained in Rosettagami(DE3)pLysS strain. 
Gα11, Gα13, Gα14, Gα15 showed better production.  B. Gα14 was found in insoluble fractions. S represents the 
soluble fraction  of the cell lysate and U represents urea (6M) extract of the pellet fraction. (Anti-his tag 
antibody immuno dotblot was done similarly as mentioned in Fig 3.3). 
 
3.2.1.1 Production of the Gαq subunit in the yeast Pichia  pastoris. 
 
The Gαq subunit could not be obtained in E. coli. The P. pastoris expression system 
was investigated to express this protein. The Gαq gene (Fig 3.5) was introduced into 
pPIC3.5K (Appendix A2) vector and transformed into the SMD1163 strain of  P. pastoris.  
Protein production was checked by immunoblotting (Fig 3.6). All the colonies selected 
from the minimal dextrose agar plate contained a band at the expected size (38 KDa), in the 
immunoblot, indicating the production of G protein. 
 
 
 
 
Fig 3.5: The gene construct used for the  Gαq subunit in pPIK3.5 K vector.  AOX1 is the alcohol oxidase 
promoter. His is the hexahistidine tag on the amino terminus.  
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Fig 3.6: Production of the Gαq protein in P. pastoris.  M is the marker and six lanes of the gel represent the 
6 colonies selected from the minimal dextrose medium. 20 µl of the cell lysate was loaded to each lane. (Anti-
his tag antibody immunoblot). Arrow indicates the Gq protein at the expected size. 
 
3.2.2  Production of Gβ and Gγ subunits 
 
5 Gβ proteins were screened  for  production.  Only the  Gβ1, Gβ5S and Gβ5L proteins 
could be obtained in the Rosettagami(DE3)pLysS strain of E. coli (Fig: 3.7). The Gβ5S 
production was less compared to the other two subunits. Protein production was saturated 
after an incubation time of 8 hr. None  of  the  11 Gγ  subunits  screened  could  be 
produced in any of the  E. coli strains used (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.7:  Dotblot showing production of Gβ subunits in the Rosettagami(DE3)pLysS strain of E. coli. 
Gβ1 , Gβ5S and Gβ5L subunits could be produced in E. coli. 8 hr and 18 hr incubations times were tested. 8 hr 
incubation time was sufficient for protein production. Different IPTG concentrations showed similar 
production levels. Neg is the Negative control (no gene). (Anti-his tag antibody immuno dotblot). 
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3.2.3  Co-expression of  the βγ subunits in P. pastoris 
 
Since the γ subunits could not be expressed separately in E. coli, co-expression of  
the βγ subunits was explored in the yeast P. pastoris . The genes for the β and γ subunits 
were cloned into an in vitro multimerisation vector pAO815. The final construct (Fig 3.8) 
with one gene for β1 subunit and one gene for γ5 subunit was transformed into the yeast 
cells. One copy of each gene was cloned into the vector to maintain the stoichiometry of the 
subunits. 
 
 
 
 
Fig 3.8: The construct for the βγ subunits in pAO815 vector. AOX is the alcohol oxidase promoter, H 
stands for hexahistidine tag, and T stands for transcription termination sequence. BglII and BamHI are 
restriction endonucleases used in cloning. 
 
  An anti-his tag immunoblot showed a prominent band, approximately at 42 KDa 
which is the expected size for the βγ dimer (Fig 3.9). A monomeric form of either subunit 
could not be seen in the immunoblot.  
 
 
 
 
Fig 3.9: Anti-his  immunoblot showing 
production of a βγ dimer in P. pastoris. βγ 
subunits were co-expressed in P. pastoris. 
M denotes the marker. Arrow indicates the 
βγ dimer band at ~42KDa in an immunoblot 
(15% SDS-PAGE gel). 
 
 
3.3  Purification of Gα subunits 
 
GαsL from the Gs family, Gαi1, Gαi3, GαoA and GαoB from the Gi/o family were 
produced in the BL21 CodonPlus strain of E. coli and purified by IMAC and ion-exchange 
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chromatography. After Ni-NTA purification the protein was almost 80% pure, as estimated 
by Coomassie stained SDS-PAGE gel (Fig 3.10). The eluate from Ni-NTA was again 
purified using the Q-sepharose matrix. All the G proteins investigated eluted at 150-200 
mM NaCl. As observed on SDS-PAGE gel of the samples obtained from the Q-sepharose 
matrix, the protein was more than 90% pure (Fig 3.11). When the protein was used for 
crystallization, a third step of purification (gel filtration) was used in order to maintain the 
buffer  composition  constant  from all the batches of purification. The protein eluted at a 
retention volume of 1.35 ml from a Superose 12 column (Fig 3.12). The GαsL, Gαi1 and 
Gαi3 subunits were purified in order to check the coupling with the GPCRs. GαoA and GαoB 
were expressed in large scale culture and the protein purified was used for crystallization.  
 
Fig 3.10: SDS-PAGE of purified Gαi1 using a Ni-NTA agarose matrix. A. Coomassie stained 12% SDS-
PAGE gel showing: M-marker, 1-cell lysate, 2-flow through, 3-wash with equilibration buffer, 4-wash with 
500 mM NaCl buffer, 5-wash with 20 mM imidazole buffer, 6-wash with  40 mM imidazole buffer, 7-9 
different fractions of elution with 250 mM imidazole buffer, 10-Protein purified using the Q-Sepharose 
matrix. B. Immunoblot by anti-his tag antibody. 20 µl of different purification fractions were loaded to each 
well. 
  
 
 
 
Fig 3.11: G protein samples after a two step 
purification . Samples of GαsL, Gαi3, GαoA, 
GαoB were analysed by SDS-PAGE, to assess the 
purity. A 20 µl sample of the peak fraction from 
the Q-Sepharose gradient elution was analyzed 
using a 12% SDS-PAGE gel. 
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Table 3.1: Yield of pure Gα subunits  produced in E. coli, by two step purification: 
  
Protein  Yield of pure protein  E. coli strain 
Gαi3  10 mg/L  (BL21(DE3) CodonPlus RP) 
GαsL  8 mg/L  (BL21(DE3) CodonPlus RP) 
GαoA  5 mg/L  (BL21(DE3) CodonPlus RP) 
Gαi1 3  mg/Liter  culture  (Rosettagami(DE3)pLysS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.12: Gel filtration profile of the GαoA protein on a Superose 12 column. The protein eluted at a 
retention volume of 1.35 ml. 100 µl protein sample (~100 µg), purified by Ni-NTA and Q-Sepharose was 
loaded onto the column. Gel filtration was carried out at 4ºC at a flow rate of 50µl/min. 
 
3.3.1  Purification of G proteins produced in P. pastoris 
 
 The  Gαq subunit was produced in P. pastoris. A two step purification of Gq protein 
yielded approximately 4 mg/L culture. The protein was pure as seen in Fig 3.13. 
 KDa      M       1       2       3       4        5        6       7     
 
Fig 3.13: SDS-PAGE gel showing Gαq protein, 
expressed in P. pastoris. Each lane of the gel 
corresponds to one  fraction of the NaCl gradient 
(50-300 mM) applied to the Q-Sepharose column. 
(Coomassie stained 12% SDS-PAGE gel) 
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 The  Gβγ dimer was produced in P. pastoris. Most of the protein produced was 
found in the cytosol rather than in the membrane. The protein was purified from the cell 
lysate by Ni-NTA chromatography. On SDS-PAGE gels a prominent band was obtained at 
the size of βγ dimer. There were three major visible impurities two above and one below 
the dimer band (Fig 3.14). Gel filtration experiments to investigate whether a heterotrimeric 
complex from GoA and β1γ5 dimer formation, did not prove existence of such complex. 
            KDa         M 
 
 
 
 
 
Fig 3.14: SDS-PAGE gel showing the βγ dimer expressed in P. 
pastoris. The arrow shows the  dimer complex (42 KDa) of the βγ 
subunits purified by Ni-NTA, in the Coomassie stained SDS-
PAGE gel.  
 
 
3.4  Fluorescent GTPγS binding assay 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.15: Time dependent fluorescence changes showing effect of magnesium on GTP binding. 1µg G 
protein (GsL) was used to determine the effect of Mg
2+ on GTPγS binding. Reaction was started with the 
addition of 1µg pure G protein to the buffer containing 100 nM fluorescent GTPγS. 100 nM fluorescent 
GTPγS, without protein was used as a negative control. 
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G protein activity was determined using the fluorescent GTPγS binding assay. 
Bodipy-FL GTPγS was used as a fluorescent analog of GTP. GTPγS was excited at 485 nm 
and the emission was detected at 520 nm. Mg
2+ ion is an important requisite for GTPγS 
binding to the G protein (Fig 3.15). Different Gα subunits require different concentrations 
of Mg
2+ ions. The Gαs protein requires a Mg
2+ ion concentration of more than 20 mM in the 
buffer, where as the Gαo protein showed good binding even at 1 mM (data not shown). 
Increasing concentrations of GDP in the assay reduced the  GTPγS binding to the G protein 
as expected. So GDP was added to  reduce  the background binding when  receptor-G 
protein interactions were measured. 
 
3.4.1  Effect of detergent on GTPγS binding to G protein 
 
An interesting result of the GTPγS binding assays was the effect of detergents on 
the GTPγS binding to the G protein. In general, detergents had a negative effect on GTPγS 
binding. The Gαs protein was more sensitive to detergents among the G proteins tested. 
Gαi/o family members remained active at detergent concentrations which abolished Gαs 
protein activity (Fig: 3.16). Detergents at concentrations below their CMC had very little 
effect. But as soon as the concentration of the detergent was increased to its CMC or above, 
the protein tends to lose its activity. Polar detergents and  non-polar detergents  both 
destroyed the activity. Detergents like laurylmaltoside, octylglucoside, octylmaltoside, 
LDAO, Foscholine12, Tween 20, digitonin were checked, all of them prevented GTPγS 
binding (not shown). 
 
Fig 3.16: Effect of detergent on GTPγS binding to G protein as measured by fluorescence.  Gαs (1µg) 
was added to 500nM Bodipy GTPγS to start the reaction. Presence of 0.1% LM prevented the GTPγS binding.  
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  In order to determine whether the loss of activity was permanent or reversible, the 
Gαs protein was added to buffer (methods 2.2.6) containing 0.1% LM. The protein solution 
was incubated for 1 hour and then the protein was purified by gel filtration to remove the 
detergent from the protein sample (Fig 3.17). The protein from the gel filtration was again 
checked for the activity. It was found that the removal of the detergent from the solution 
restored the activity of the G protein. 
 
Fig 3.17: Effect of LM on GTP binding activity of GαS protein. Gαs (4 µg ) shows the activity with out 
detergent. Neg denotes the negative control which is the fluorescent GTPγS ligand (500nM) in buffer. 
Gαs+LM shows the loss of G protein activity when 0.1% LM was included in the reaction. Gαs–LM 
represents activity after removing the detergent, by gel filtration.  Reactions were started by the addition of 
protein to buffer with GTPγS. 
 
The intrinsic fluorescence of the protein was measured for Gαs protein to determine 
the conformational changes occurring upon the addition of detergent. Fluorescence of the 
protein due to tryptophan was measured for this  purpose. The  protein was  excited at 280 
nm and the emission was monitored at 340 nm (Fig: 3.18). If there are any changes in the 
conformation of the protein there will be a change in the tryptophan fluorescence, because 
of the exposure of hidden tryptophans. As expected in this case with the addition of 
detergent (0.1% LM) the protein (Gαs) has undergone a conformational change which 
resulted in an increase of the intrinsic fluorescence.  This change was observed in those 
proteins which lose their activity upon addition of detergent. Gαs protein showed an 
increase in intrinsic fluorescence where as Gαi protein did not show any change. 
 
40
45
50
55
60
65
70
75
80
85
0235689
Gαs 
Gαs - LM 
Gαs + LM 
Neg 
Time in min 
F
l
u
o
r
e
s
c
e
n
c
e
 
[
A
U
]
 _______________________________________________________Results.. 
  68
 
 
 
 
 
 
 
 
 
Fig 3.18: Intrinsic fluorescence of G protein. G protein, Gs (10 µg) was mixed with a buffer containing 
detergent (0.1% LM) to start the reaction and the intrinsic fluorescence of Tryptophan at 340 nm was 
monitored by exciting the protein sample at 280 nm. 
 
3.5  Crystallization of G proteins 
 
G protein crystallization trials were carried out using the crystal screens from 
Hampton Research, Jena Biosciences and Nextal. The crystallization technique used was 
vapour diffusion. Crystallization drops were set up in a 24 well plate or a 96 well plate 
depending on the number of screening conditions. In a 24 well plate a 3+3 µl drop of 
protein and buffer was setup as a hanging drop. When using large number of crystal 
screens, a 0.5+0.5 µl drop was set up as a sitting drop in a 96 well plate. For setting drops 
in 96 well plate a robotic system (Cartesian tech.) was used. Plates were incubated at 18ºC. 
GαoA, GαoB and Gαq proteins were used in crystallization experiments. GαoA and GαoB 
never gave any promising hits which could be further optimized. But Gαq protein which 
was produced in the P. pastoris expression system gave positive hits from Hampton 
Research (Screen I, buffer 41). Crystals were observed in a 3+3 µl sitting drop, in a buffer 
containing 100 mM HEPES-Na, pH 7.5, 10% (v/v) isopropanol, 20% (w/v) PEG 4000. 
Protein solution was used at a concentration of 10 mg/ml in a buffer containing 20 mM 
Tris/HCl, pH 8.0, 200 mM NaCl, 5 mM MgCl2, 5 mM DTT, 50 µM GDP.  
 
  Crystals were observed after 2 days at 18ºC. Crystals were like needles/tubes. 
Crystals were not separate but seemed to be stacked on each other (Fig 3.19 A). To check 
whether the crystals were of protein or salt, they were washed in reservoir buffer and then 
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analyzed on a SDS-PAGE gel by silver staining (Fig 3.19 B). SDS-PAGE of the crystals 
gave a protein band at the expected size (38 KDa). Crystals were checked for diffraction 
synchrotron radiation (ESRF, Grenoble). Crystals diffracted to about 6.5 Å (Fig 3.19 C). 
The spots obtained were not prominent but diffused or overlapped. The Crystal quality has 
to be optimized to get better diffraction. At present there is a problem of protein production 
in P. pastoris which has to be sorted out. These experiments became obsolete because the 
crystal structure had been published by Tesmer et al., 2005. 
 
Fig 3.19: Characterization of Gαq protein crystals. A. 3D Crystals of G protein obtained in a 6 µl drop. B. 
Silver stained SDS-PAGE gel. Lane 1 represents the G protein  used for crystallization (left in refrigerator 
for 3 months after crystallization). The higher bands might contain aggregated protein. Lane 2 contained 
crystals  (100 microns in length) dissolved in loading buffer. C. Diffraction pattern at 6.5 Å resolution. 
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Chapter II: Production and purification of the cannabinoid 
receptors CB1 and CB2 
 
  Production of the cannabinoid receptor 2 (CB2) was first tried in P. pastoris. To 
find a solution for the problems encountered in receptor production in the Pichia system, 
baculovirus expression system was used later. In the baculovirus expression system both 
CB1 and CB2 receptors were produced. A detailed characterization was carried out for the 
CB1 receptor because of its better biochemical characterization and its importance in the 
pharmaceutical industry. 
 
3.6     Production of the cannabinoid receptor 2 in P.  pastoris. 
 
The gene for the cannabinoid receptor 2 was cloned in pPIC9K vector and initial 
expression screening was performed in the MEPNET program. A 96 well plate containing 
the cultures of 96 colonies from MD plates was obtained from MEPNET team (Andre et 
al., 2006). A colony which gave a high expression signal on immunoblot was chosen for 
further investigations. The gene construct in pPIC9K contained an N-terminal Flag epitope, 
a decahistidine tag followed by the receptor gene and a biotinylation domain of the C-
terminus (Fig 3.20). Receptor cloning into the vector was done using BamHI (frame is nnG 
GAT CCn) next to TEV cleavage site and EcoRI (GAA TTC) restriction sites. 
 
Fig 3.20: Gene construct for CB2 receptor in pPIC9K vector. AOX1 stands for Alcohol oxidase promoter, 
α-Fac stands for α-Factor secretion signal, Flag stands for Flag epitope, His stands for decahistidine tag, Bio-
tag stands for biotinylation domain, Kex2 stands for Kex2 protease signal cleavage site, TEV stands for 
Tobacco etch virus protease cleavage site. 
 
  The cannabinoid receptor 2 was produced in P. pastoris, cultured in 5 liter baffled 
flasks. Membranes were prepared from the cells as discussed in methods section (2.2.2.4).  
Cell membranes showed specific CB2 ligand binding. Because of the high background 
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Kex2  TEV _______________________________________________________Results.. 
  71
binding of the radiolabeled ligand  [H
3] CP-55,940 and non-saturable binding, 
determination of Bmax and Kd was not very precise.  
 
3.6.1  Solubilization and purification of the CB2 receptor.  
 
  To determine the efficiency of solubilization by different detergents, a small scale 
solubilization  screening  was  performed. 200 µl aliquots containing cell membranes at 5 
mg/ml concentration and 1% detergent was incubated under slow rotation, in a cold room 
for 1 hr. The reactions were ultra-centrifuged at 150,000xg for 30 min. The clear 
supernatant was analysed by SDS-PAGE followed by immunoblotting. 
 
 
 
 
 
 
 
 
 
Fig 3.21: Solubilization screening of the cannabinoid receptor 2 (Anti-flag M2 Immunoblot). The gel 
shows: 1. 1 % laurylmaltoside, 2. 1 % octylmaltoside, 3. 1 % laurylsucrose, 4. 1 % octylglucoside, 5. 1 % 
dodecylamine-N-oxide, 6. 1 % LM + 0.2% Fos 12, 7. 1 % Foscholine 12, 8. 1 % Foscholine 14, 9. SDS. 20µl 
of the solubilizate was loaded to each lane of the 12% SDS-PAGE gel. 
 
  The CB2 receptor could be solubilized in most of the detergents screened, except 
octylglucoside (Fig 3.21). An immunoblot of the solubilized samples showed extensive 
aggregation and many oligomeric states. Laurylmaltoside was used for the purification of 
receptor. About 100 mg (10ml) of yeast cell membranes ware solubilized with LM at 4ºC 
for 1 hr. The clear supernatant after ultra-centrifugation was loaded onto Ni-NTA agarose, 
in a batch process. The purification was performed as discussed in the methods section 
(2.2.7). Eluate from the Ni-NTA material was not pure (Fig 3.22 A). There were many 
aggregation bands visible on the immunoblot even after the Ni-NTA purification. 
Monomeric avidin affinity chromatography was used as a second purification step. In the 
second stage of purification using the monomeric avidin agarose, most of the protein was 
found to be bound to the column material and could not be specifically eluted using biotin. 
The yield of protein eluted from the monomeric avidin matrix was less than 10% of the 
total receptor calculated (~30 pmol/mg) in the membrane. The protein which could be 
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eluted from the monomeric avidin column was not pure or homogenous (Fig 3.22 B). 
Several aggregation bands were still prominently visible in SDS- PAGE gels. 
Fig 3.22: SDS-PAGE showing purification of the CB2 receptor from P. pastoris membrane. A. 
Coomassie stained SDS-PAGE gel shows M. High molecular weight marker, 1. cell membrane, 2. 
solubilizate, 3. wash with equilibration buffer, 4. wash with high salt buffer, 5. wash with 20 mM imidazole, 
6. wash with 40 mM imidazole, 7. elution with 350 mM imidazole, 8. Anti-flag M2 immunoblot of Ni-NTA 
eluate, 9. Strep-AP immunoblot of elute from monomeric avidin. B. Streptavidin alkaline phosphatase 
immunoblot of samples from monomeric avidin purification. 1. Ni-NTA eluate loaded onto monomeric avidin 
agarose matrix, 2. flow through from the column, 3. eluate from column, 4. protein eluted during regeneration 
of the matrix with 0.1 M glycine. Arrow indicates the monomeric form of the receptor. 12% gels were used 
unless otherwise mentioned. 
 
   
 
 
 
 
 
 
 
 
 
 
 
Fig 3.23: Elution profile of the CB2 receptor produced in P. pastoris. Gel filtration was done on Superdex 
200 column. Receptor was found in the peak at 1.15 ml. 1.58 ml  retention volume corresponds to detergent. 
 
The CB2 receptor purified from the monomeric avidin column was analysed by gel 
filtration  to assess the homogeneity of the protein. As evident from SDS-PAGE, the gel 
filtration profile indicates that the protein was mostly aggregated (Fig 3.23). Several 
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stabilizing agents like glycerol, sucrose, glycine were added to the buffer starting from the 
solubilization step but the protein obtained was not homogenous. Several detergents were 
used to solubilize the protein from the membrane, but didn’t show any improvement. 
 
 
3.7      Expression of cannabinoid receptors in insect cells. 
 
Since the CB2 receptor produced in P. pastoris showed extensive aggregation, 
another expression system was investigated. Baculovirus mediated insect cell expression 
system was chosen to produce cannabinoid receptors.  
 
3.7.1  Cloning  and expression of cannabinoid receptors 
Fig 3.24: Gene constructs used for cannabinoid receptor expression in insect cells. PPH stands for 
polyhedrin promoter, Melittin (M) stands for honey bee melittin signal sequence, Flag (F) stands for Flag 
epitope, His (H) stands for decahistidine tag, TEV (Tev) stands for tobacco etch virus protease cleavage site, 
number below CB1/CB2 receptor bar represents the number of amino acids of the receptor cloned and Bio tag 
stands for biotinylation domain. StII stands for strep-tagII. 
Strep-tagII  CB2 receptor His Flag  PPH  Melittin 
Tev 
           1  to  360 aa 
Bio tag CB1 receptor His Flag  PPH  Melittin 
Tev 
                   1   to   472 aa 
Strep-tagII CB1 receptor His Flag  PPH  Melittin 
Tev 
                    1   to   472 aa 
Bio tag  CB1 receptor His Flag  PPH  Melittin 
Tev 
               1 to 417 aa 
Strep-tagII  CB1 receptor His Flag  PPH  Melittin 
Tev 
               1 to 417 aa   
pVLMFHTevCB2StII 
pVLMFHTevCB1Bio 
pVLMFHTevCB1StII 
pVLMFHTevCB1(417)StII 
pVLMFHTevCB1(417)Bio _______________________________________________________Results.. 
  74
The CB1 and CB2 receptor genes were cloned into a modified version of the 
pVL1393 transfer vector, which uses the polyhedron promoter. Different constructs were 
made to use the receptors for purification and for functional investigations (Fig 3.24). For 
purification  of  the   receptors  decahistidine tags at N-terminus and strep-tagII or a 
biotinylation domain at the C-terminus were used. A tobacco etch virus protease cleavage 
site was included after the decahistidine tag, in order to remove the N-terminal tags. Such a 
cleavage was also used in one of the purification strategies, Ni-Tev-Ni. The DNA sequence 
of tags and the cloning sites are shown in the appendix (A.9). The molecular weight of the 
full length CB1 receptor is 52 KDa (without tags) and that of the truncated receptor is 46 
KDa. The CB2 receptor has a molecular weight of 40 KDa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.25: Screening of the CB1 receptor (FlagHisTevCB1StrepII) production in Insect cells. 1, 5, 10 
MOI virus was tested. Cells were incubated for 48 hr (purple), 72 hr (green) or 96 hr (red) post infection. The 
Y-axis shows the binding in dpm (disintegrations per minute) of the radioligand (SR141716A) using 100,000 
cells per assay.  
 
The amount of virus needed  for  good  expression  and  the  incubation time were 
also standardized for small scale (10ml) cultures. The CB1 receptor levels ware maximal at 
10 MOI, after an incubation time of 96 hr (Fig 3.25). But more cells were lysed after 96 hr, 
which lead to proteolysis of recombinant protein. So, incubation for 72 hr was generally 
used to get better protein levels. Different cell lines were verified for expression. Sf21 and 
H5 cells didn’t give any better yields (as detected by radioligand binding assay on the same 
number of cells of each cell-line) compared to Sf9 cells. All constructs of the receptors 
could be expressed in the insect cells (Fig 3.26 A). Membranes were first analysed by SDS-
PAGE to detect the recombinant protein produced. A radiolabeled ligand binding assay was 
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used to estimate the amount of functional receptor present in the membranes.  Addition of  
tunicamycin (10 µg/ml culture) to the cell culture produced receptor with of smaller 
molecular mass (Fig 3.26 B). This shift indicates that the receptor was glycosylated in 
insect cells.  
A.                                                                            B. Glycosylation 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.26: Immunoblots showing receptors produced in insect cells.   A.  Anti-flag immunoblot of the 
membrane (25µg) of  Sf9 cells. 1. C-terminal truncated CB1 receptor (CB1-417) with N-terminal Flag 
epitope, His tag, TEV cleavage site and C-terminal Strep tag II (FHTCB1-417 St II), 2. FHTCB1-417 Bio tag,   
3. FHTCB1 St II,   4. FHTCB1 Bio tag,  5. FHTCB2 St II.  B. Glycosylation of the receptor. 1. Normal 
receptor. 2. Receptor from  tunicamycin (10µg/ml culture) treated cells  showing deglycosylation. The two 
arrows indicate the shift in receptor band because of deglycosylation. A band around 175 Kda (A. Lane 1) is a 
cannabinoid receptor specific oligomeric band. 
 
3.7.2  Radioligand binding assay of the CB1 receptor 
 
Functionality of the expressed protein was assessed by the ligand binding assay. The 
ligands used were either radiolabeled agonists or antagonists. Ligand binding on the 
membranes was performed in a glass fiber filter assay. Cell membranes were incubated 
with the radiolabeled ligand in binding assay buffer (20 mM Tris/HCl pH 8.0, 1 mM 
EDTA, 1% BSA). Since cannabinoids are very hydrophobic and bind non-specifically to 
the plastic or glass, bovine serum albumin was an important component of the ligand 
binding reaction, to reduce the background binding of the ligand. Washing of the glass fibre 
filters was done with the same binding assay buffer warmed to 30˚C. Saturation binding 
assay was performed to determine the amount of receptor expressed and to estimate the 
binding constant (Kd) of the receptor. 8 different concentrations of the radioactive ligand 
were used for the saturation binding assay. Assay reactions contained 1 µg of membrane 
suspension in the binding assay buffer. 200 µl reactions were setup for each condition. 
Triplets of positive reactions and duplets of negative reactions with cold ligand were 
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measured. The mean of the dpm values measured for the samples was used to calculate the 
amount of receptor present in the membrane in pmol/mg.  The data was fitted to a non-
linear regression curve, using Kaleida graph software. Specific binding Y=(Bmax * X )/ 
(Kd+X), where X is the concentration of radioactive ligand, Bmax is the maximum specific 
binding observed on the membrane, Kd is the dissociation constant of the ligand. 
A.       B. 
 
Fig 3.27: Saturation binding curves of CB1 receptor. 1 µg of membrane with FHTevCB1StrepII (A) and 
FHTevCB1(417)StrepII (B) receptor was used. The X-axis represents the pM concentrations of radioactive 
antagonist SR141716A and Y-axis represents receptor concentration in terms of pmol/mg total protein. Bmax 
value of 40 pmol/mg and a Kd of 2.5 nM were obtained for the full length CB1 receptor. For the truncated 
receptor FHTevCB1(417)StrepII, Bmax was 52pmol/mg and Kd was 3.6 nM. 
 
Fig 3.27 shows the Bmax and Kd values of FHTevCB1StrepII receptor and the truncated 
FHTevCB1(417)StrepII receptor. The levels of the truncated receptor ware found to be 
~20% higher than that of the full length receptor. The Kd values of both receptor constructs 
were in the range given in the literature from 0.5 to 7.0 nM for different tissues. The Kd for 
the full length receptor was 2.5 ± 0.3 nM and for the truncated receptor it was  3.6 ± 0.6 
nM. Bmax values of FHCB1StrepII receptor (produced in a bio-reactor at Aventis by Ingo 
Focken) for agonist was 5 times less than antagonist binding. Table 3.2 shows the Bmax 
and Kd values of the receptor constructs produced in insect cells. 
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Table 3.2: Bmax and Kd values for different constructs of the CB1 receptor 
 
Construct  Agonist 
(H
3 CP-55,940) 
Bmax (pmol/mg)
Agonist 
 
Kd (nM) 
Antagonist  
(H
3 SR141716A) 
Bmax (pmol/mg) 
Antagonist 
 
Kd (nM) 
FHCB1StII  7.6 ± 0.95  2.4 ± 0.89  38 ± 1.14   2.0 ± 0.14 
FHTevCB1StII  ND  ND  39.7 ± 1.3   2.5 ± 0.3 
FHTevCB1Bio  ND  ND  20 ± 1.8   4.0 ± 0.8 
FHTevCB1 (417)StII  ND  ND  52 ± 3.09   3.6 ± 0.6 
FHTevCB1 (417)Bio  ND  ND  17 ± 1.68   2.2 ± 0.58 
 
Ligand binding to the receptor was dependent on the NaCl concentration in the 
binding assay reaction. The agonist binding was reduced with increasing NaCl 
concentration, leaving the antagonist binding unaffected (Fig: 3.28). The saturation binding 
on membranes containing FHTevCB1StrepII receptor, with the agonist (H
3 CP-55940) in 
the presence of 1M NaCl showed a decrease in the Bmax and a slight increase in the Kd as 
shown in Table 3.3. Mg
2+ was absolutely necessary for the agonist binding to the CB1 
receptor (Fig 3.28). The antagonist binding was not very much dependent on Mg
2+  
concentration, but increased with high concentrations. DTT had a less detrimental effect on 
cannabinoid receptors, unlike its effect on many other GPCRs. 30% of the agonist binding 
was still observed at a DTT concentration of 10 mM (Fig: 3.29) whereas the antagonist 
binding was decreased only by 10% at 10 mM DTT.  
NaCl               Mg
2+ 
 
Fig 3.28: Effect of NaCl and Mg
2+ on ligand binding to the CB1 receptor.  Blue bar represents the agonist 
binding and maroon colour represents the antagonist binding. Rounded dpm refers to the mean dpm values of 
triplets. 5 µg membrane protein was used in the measurements. 5 nM  radioactive ligand was used. 
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Table 3.3: Effect of NaCl on ligand binding to FHCB1StrepII protein: 
 
FHTevCB1StrepII  100mM NaCl  1M NaCl 
Bmax (pmol/mg)  7.6 ±0.95  5.2 ±0.51 
Kd (nM)  2.4 ±0.89  3.7 ±0.9 
 
    DTT 
 
 
 
 
 
 
 
 
Fig 3.29: Effect of DTT on ligand binding to the CB1 receptor.  Cell membranes were incubated with the 
ligand in a buffer with 10 mM DTT, to observe the effect on ligand binding. 5 µg membrane was used in the 
measurements. 5 nM  radioactive ligand was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.30: Effect of detergent on ligand binding to the CB1 receptor. “No” means no detergent included. 
LM stands for laurylmaltoside, LS stands for laurylsucrose, OG stands for octylglucoside, OM stands for 
octylmaltoside. 0.5 and 1.5 represents the number of times the CMC of the detergent. No specific activity was 
observed when detergents like LDAO, Fos12, Fos14 were used. 
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Different detergents had varying effects on the binding of the ligand to the CB1 
receptor (Fig 3.30). Cell membranes were filtered on glass fiber filters and detergent 
solutions in the binding assay buffer at a concentration of 0.5 or 1.5 times CMC was added 
onto it as a first wash. Filters were washed with buffer without detergent and bound ligand 
was estimated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.31: Effect of the presence of ligands during cell culture on the binding assay.  CB1 and CB2 
receptor agonist WIN55,212-2  or antagonists AM251 (CB1) and AM630 (CB2) were added to the culture 
during protein production. The binding was checked with radioactive agonist CP55,940. + denotes that the hot 
agonist binding was possible and – denotes that hot agonist binding was not seen. 
 
When the receptors were produced in the presence of ligands in the culture (Fig 
3.31), ligand binding was affected. CB1 receptor agonist WIN 55,212-2 or antagonist 
AM251 (1 µM concentration) were added to the culture, 24 hr post infection. After the 
incubation time, the ligand binding was checked on the cells and also on the membranes. 
When agonist  was present in the culture, binding of radioactive agonist (CP 55,940)  was 
unaffected. But when antagonist was present in the culture, radioactive agonist binding was 
dramatically reduced or absent. This effect was seen both on cells and membranes, which 
were prepared after several washes with buffer.  
 
3.7.3  Purification of the cannabinoid receptor 1 
 
Purification of cannabinoid receptors has been a challenge for years. Several 
research groups tried to purify the receptor expressed in different expression  systems 
ranging from E. coli to P. pastoris to insect cells. But the attempts were not successful to 
obtain yields sufficient for protein structure determination using 2D or 3D crystallography. 
Further more, harsh conditions like washing with 8 M Urea were used in some of the 
CB1 
CB1(417) 
Ligand in  Binding by Hot Agonist 
Agonist            +           
 
Antagonist     - 
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purification procedures. Using such conditions could destroy the activity of the protein. So 
in this work several new purification strategies were explored.   
 
3.7.3.1  Ni-Tev-Ni purification 
 
In this purification procedure, the receptors were purified using Ni-NTA agarose. 
Then the N-terminal decahistidine tag was cleaved off using TEV protease. The proteolysed 
protein was again loaded onto the Ni-NTA agarose matrix. Since the receptor now lacks the 
His-tag, it elutes in the flow through. TEV protease binds to the matrix, since it possesses a 
His-tag. Non-specifically bound proteins would still bind to the matrix.  
 
The CB1 receptor could be solubilized in almost all detergents tested (LM, OM, 
DM, OG, LS, LDAO, Fos12, Fos14, Fos16, C12E8, cymal6). Since the receptor didn’t lose 
its binding in the presence of 1.5 times CMC of LM as discussed before, it was chosen for 
further solubilization and purification experiments. Insect cell membranes ware solubilized 
in the presence of 1% LM at 4ºC for 1 hr. The flow through from the Ni-NTA material, in 
the second round of loading was collected and analysed for purity (Fig 3.32). The protein 
obtained after Ni-Tev-Ni purification was impure with many non-specific bands seen in 
SDS-PAGE gel. All the purified proteins showed similar purification profiles. 
 
 
 
 
Fig 3.32: Analysis of the purification of  
cannabinoid receptor by the Ni-Tev-Ni 
strategy.  1. Truncated CB1 receptor 
(CB1-417 Strep-tagII) after Ni-Tev-Ni 
purification analysed on SDS-PAGE 
(12%) and stained by silver. 2. Full length 
CB1 receptor (CB1 Strep-tagII), 3.CB1 
Bio-tag. Approximately 1 µg of protein 
was loaded to each well. 
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3.7.3.2  Ni-NTA and Streptactin purification 
 
In this purification method, protein was first purified by IMAC using Ni-NTA. 
Eluate from IMAC column was loaded onto the Streptactin agarose, washed and the protein 
was eluted with 10 mM desthiobiotin. Different fractions of the eluate were analysed by 
SDS-PAGE, to monitor the purity of protein (Fig 3.33). Most of the protein was found to be 
not binding to the Streptactin matrix. Most of the protein was found in the flow through. So 
the yield of the protein after Streptactin chromatography was very poor. But the purity was 
much better compared to Ni-Tev-Ni purification. Two major impurities were observed 
above the receptor band, in SDS-PAGE gel. 
 
 
 
 
 
 
 
Fig 3.33: SDS-PAGE showing purification of the 
CB1 receptor using His-tag and Strep-tagII.  1. The 
truncated receptor (CB1-417 Strep-tagII) after Ni-NTA 
and Streptactin purification analysed on SDS-PAGE 
and silver stained. 2. Full length receptor (CB1 Strep-
tagII). 
 
 
3.7.3.3  Ni-NTA and monomeric avidin purification 
 
Receptor with the biotinylation domain (Bio-tag) was purified using IMAC as a first 
purification step followed by immobilized monomeric avidin affinity chromatography. The 
eluate from Ni-NTA column was incubated with monomeric avidin material in a cold room 
for 1 hr. The material was packed into the column and washed with 10 column volumes of 
buffer. The bound protein was eluted using 10 mM D-biotin. The eluted fractions were 
analysed on SDS-PAGE to  assess homogeneity (Fig 3.34). Most of the protein was found 
to be irreversibly bound to the monomeric avidin matrix thus decreasing the yield of the 
purification. This protein could only be removed from the material with glycine/HCl buffer 
pH 2.8. 
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Fig 3.34: Purification of cannabinoid receptor using 
His-tag and Bio-tag. 1. Truncated CB1 receptor (CB1-
417 Bio-tag), 2. The full length CB1 receptor (CB1 Bio-
tag) analysed by silver stained SDS-PAGE. 
 
  Purified receptor was analysed by gel filtration to assess the homogeneity of the 
protein. Protein purified by any of the above discussed methods didn’t yield absolutely pure 
protein. So, as expected the gel filtration profile of the receptor didn’t show a symmetric 
peak. A representative gel filtration profile of the CB1 receptor purified by Ni-NTA 
followed by Streptactin is shown below (Fig 3.35). The broad distribution of the peak might 
be a result of the other high molecular weight impurities. 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.35: Gel filtration profile of purified CB1-StrepII protein. The CB1 receptor purified by Ni-NTA and 
Streptactin affinity chromatography was analysed using Superose 12 column. A prominent peak was obtained 
at 1.36 ml which corresponds to the receptor as confirmed by Western blotting.  Approximately 10 µg of 
protein was loaded onto the column. 
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3.7.3.4  Purification of the CB1 receptor using different IMAC resins 
 
Since the protein yield after the second column was very small, metal affinity 
chromatography was optimized to get better purity. Different IMAC resins were tried to 
achieve better purity and yield. Ni-NTA agarose from Qiagen, His-Select from Sigma, 
Profinity-IMAC from Bio-Rad were tested to find out the best matrix for the receptor 
purification. Decylmaltoside was used for these studies instead of laurylmaltoside (DM was 
used by Yeliseev et al., 2005, for the CB2 receptor purification). The protein purified using 
Ni-NTA agarose was impure compared to the protein purified using His-Select or Profinity-
IMAC (Fig 3.36). Most of the protein was lost in the flow through from Profinity-IMAC 
resins. His-Select contains lower density of Ni ions on the matrix. Protein was lost in the 
flow through, as in the case of Profinity-IMAC, but the eluate contained less impurities 
compared to the other two resins. So, His-Select was chosen to further optimize the 
purification. 
 
 
 
 
 
Fig 3.36: comparison of purification of the CB1 Strep-tagII receptor 
on different IMAC resins as analysed by SDS-PAGE.  1. The CB1 
receptor purified from Ni-NTA agarose resin from Qiagen, 2. His-Select 
from Sigma, 3. Profinity-IMAC from Biorad. A 12% SDS-PAGE gel was 
used for analysis and it was silver stained. 
 
  Protein purification was performed on His-Select material, to further optimize the 
washing conditions, to improve the purity of the protein. Solubilizate containing the 
receptor was incubated with His-Select material in a cold room for 1 hr. The material was 
packed into a column and washed with 10 column volumes of buffer containing 500 mM 
NaCl, followed by 10 column volumes of buffer containing 20% glycerol. The column was 
washed with 50 column volumes of buffer containing 30 mM imidazole, to get   
considerably pure protein. The protein was eluted with 200 mM imidazole. The eluate was 
analysed using SDS-PAGE. Protein was identified using the epitopes on the protein (Fig 
3.37- B). Anti-his tag antibody, Anti-flag tag M2 antibody and Streptavidin-alkaline 
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phosphatase were used to detect the full length protein. The Streptavidin-AP blot showed a 
lower band which might be the truncated receptor. Fig 3.37-C shows the N-terminal 
truncated receptor in the cell membrane as well. Almost 50% of the receptor is therefore 
without N-terminus and so most of the protein is lost without binding to IMAC matrix.  The 
protein yield was less, with this procedure of purification as well because most of the 
protein was lost in the flow through and in the excess washing steps (Fig 3.37-A). Never 
the less the protein obtained was much pure compared to the other purification strategies.  
 
Fig 3.37: Analysis of the purification of the CB1-417 Bio-tag receptor using His-Select IMAC resin on 
SDS-PAGE and immunoblots.  A. 1. Flow through from His-Select column, 2. Wash with 30 mM 
imidazole, 3. Elution with 200 mM imidazole. B.  Silver stained SDS-PAGE was shown followed by anti-his 
tag antibody immunoblot, anti-flag M2 antibody blot, and streptavidin alkaline phosphatase blot. The lower 
band (45KDa) in the streptavidin blot might be the N-terminal cleavage product of the receptor. The high 
molecular weight band (175 KDa) is an oligomeric form of the receptor. C. Streptavidin-AP blot of 
CB1(417)Bio tag receptor in membrane. F stands for the full length protein, T stands for truncated protein. 1. 
Sf9 membrane 2. FHTev CB1(417) Bio membrane. 
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Fig 3.38:  Gel filtration of the CB1-417 Bio protein purified from His-Select.  Protein was analysed on 
Superdex 200 column. 30 µg of the purified protein was used. Numbers adjacent to the lines on the 
chromatogram indicate the fractions analysed by immunoblot of SDS-PAGE using the anti-flag M2 antibody. 
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The protein was analyzed by gel filtration on a Superdex 200 column (Fig 3.38). 
There was no clear peak. A major peak was seen at a retention volume of 1.15 ml and a 
minor peak at 1.32 ml. Both peaks contained the protein. There was no protein detected in 
the void volume, which means the protein was not aggregated. The broad peak might be a 
result of impure protein and possible oligomeric forms of the protein. 
 
Table 3.4: Purification yield of the CB1(417) receptor 
 
Purification  Protein recovered            % of total 
Membrane 150  µg receptor   100% 
Ni-NTA NA(Impure)  NA 
His-Select   (417-Bio) 30  µg protein* 20% 
Streptactin 25  µg protein  16% 
Monomeric avidin  30 µg protein  20% 
 
{ A receptor of 50 KDa expressed at a level of 30 pmol/mg of total protein is equal to 1.5 
µg receptor per 1 mg cell membrane} * Calculated yield 60 µg pure protein/L culture. 
 
The purification yields given above in the table are values obtained from BCA 
protein quantification. 150µg receptor was calculated based on the Bmax values of the 
receptor constructs. The protein is not pure enough to determine the exact amount of the 
receptor present in the sample. Radiolabeled binding assay on solubilized or purified 
protein is not successful because of the high non-specific binding of the cannabinoid 
ligands. 
 
3.8      Stable expression of the CB1 receptor in insect cells 
 
  Stable expression of protein in insect cells was explored using the “Invitrogen’s kit 
for selection of stably expressing lepidopteran cells”. This system uses the early phase 
promoters from Orgyia pseudotsugata multicapsid nuclear polyhedrosis virus in vector 
pMIB/V5-His (Appendix A5). The gene coding for the recombinant protein is under   
control of the OpIE2 promoter. Membrane protein expression is enhanced by the honey bee 
melittin secretion signal. Blasticidin S antibiotic is a selection marker which is under   _______________________________________________________Results.. 
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control of the OpIE1 promoter. After transformation the cells were selected by the 
antibiotic resistance. But more than 80% of the cells sustained the antibiotic stress, whereas  
production of recombinant receptor was not confirmed in radioligand binding experiment. 
Later on the protein was fused at the genetic level to YFP for use  as a selection marker. 
Highly expressing cells were selected using FACS machine. Unexpectedly there were two 
populations of Sf9 cells and the cells couldn’t sustain the harshness of the cell sorter. The 
cells didn’t grow after sorting. The cells were selected by the dilution method making use 
of the fluorescent marker itself (Fig 3.39). The presence of the receptor was confirmed by 
immunoblotting and immunogold labeling experiments (Fig 3.40). It was found that the 
number of receptor sites on the cells were only 10% of that obtained using the baculovirus 
expression system. 
                   
 
Fig 3.39: Optical micrographs showing stable insect cells expressing FHTevCB1(417)-YFP. Images were 
taken under oil with a phase contrast microscope. The YFP was excited with a 490-530 nm band pass filter.  
 
Fig 3.40: Electron micrographs showing immuno-gold labeling of the FHTevCB1(417)YFP receptor.  
The stably expressing Sf9 cells were pre-embedded with the mouse anti-flag M2 antibody. Goat anti-mouse 
antibody loaded with gold particles was used to detect the receptor. Sections of cells embedded in resin were 
imaged by electron microscope to detect the gold particles. Arrows indicate the gold labeled receptors. Wild 
type Sf9 cells were used as negative control and didn’t show any spots.  Experiment was done by Dr. Winfried 
Haase. 
Sf9 cells                                                                   Sf9 cells expressing 
Immunogold labeled electron-microscope images _______________________________________________________Results.. 
  87
Chapter III: The CB1 receptor-G protein interaction studies 
 
  The cannabinoid receptor exists in a pre-coupled form to the G proteins. The 
receptor “R” can exist in a “RGGDP”  (GDP bound) form or “RG_” (nucleotide lacking) 
form in addition to the free “R” form (Howlett, 2004). These forms of the receptor are 
considered to be responsible for the sequestration and constitutive activity of the receptor 
(see Introduction 1.6.31).The present experiments have been carried out to investigate and 
prove this pre-coupled form, in the heterologous insect cell expression system. 
 
3.9      FRET to confirm the CB1 receptor-Gi complex 
 
 
 
 
 
 
 
 
Fig 3.41: Gene constructs coding for the CB1 receptor and the Gi protein used for FRET experiments. 
PPH  stands for the polyhedrin promoter in the pVL1393 vector. YFP stands for the Yellow fluorescent protein 
and CFP stands for Cyan fluorescent protein. Other abbreviations are similar as in Fig 3.24. CFP protein was 
inserted in between the α-helical and the GTPase domains of the G protein. 
 
Fluorescence energy transfer occurs when two chromophores are in close proximity.  
The CB1 receptor was obtained as a fusion protein withYFP and the Gi protein as a fusion 
protein with CFP. CFP and YFP form a good donor-receptor couple for the FRET 
experiments.  Recombinant virus was produced using the constructs shown in Fig 3.41. Sf9 
cells co-expressing CB1-YFP, Gi-CFP and β1γ5 were imaged using a confocal microscope. 
Both proteins were found to be colocalized in the cell membrane. The fluorescence energy 
transfer between the proteins was confirmed by acceptor bleaching experiment (Fig 3.43). 
When the acceptor protein was bleached using a high energy laser, there was an increase in 
the donor fluorescence. This result confirms that both proteins are in close vicinity, which 
proves that the receptor and G protein are present in a precoupled form.  The increase in the 
donor fluorescence was calculated for 10 cells, the average 7%. As a negative control CB1-
CFP receptor and H1-YFP receptor were co-expressed and the experiment was repeated the 
PPH  Gαi1  Gαi1 CFP
YFP  CB1 receptor His Flag PPH  Melittin 
Tev _______________________________________________________Results.. 
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same way as above. There was an increase of less than 2%, which could be a result of 
lateral overlap of FRET partners. This value was considered as a background signal. 
 
 
 
 
 
 
 
 
 
Fig 3.42: Fluorescence micrographs showing Sf9 cells producing CB1-YFP receptor (left) and Gαi1-
CFP fusion protein.  G protein produced in Sf9 cells shows a uniform distribution throughout the cytosol. 
The CB1 receptor is located at the periphery and in the membranous region. 
 
 
          Prebleach            Postbleach              Change in fluorescence 
Fig 3.43: Confocal fluorescence micrographs showing FRET between CB1-YFP and Gi-CFP. The cyan 
colour in the confocal image represents the Gi protein. Red colour represents the CB1 receptor coupled to 
YFP. The white box  represents the area bleached by the laser. Images in the first lane are prebleach images 
and the second lane are postbleach images. The graphs represent the increase in donor fluorescence and 
decrease in acceptor fluorescence during the bleaching period. 10 cells were imaged and the values obtained 
were averaged. 
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3.10  Constitutive activity of the CB1 receptor 
 
When a receptor is constitutively active it leads to binding of GTP to G proteins 
even in the absence of agonist. Sf9 cell membranes containing CB1 receptor (20 nM) and 
βγ dimer were mixed with the Gα proteins (100 nM) purified from E. coli and the change in 
the fluorescence due to the Bodipy GTPγS binding was monitored (Fig 3.44). Agonists or 
antagonists were not included in the reaction. Sf9 cell membranes were used in the negative 
control. Addition of Gαi protein to the Sf9 membranes increased already the Bodipy 
fluorescence for reasons unknown. But the increase obtained upon addition of cell 
membranes containing CB1 receptor was higher than that of native Sf9 cell membranes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.44: Fluorescence graphs showing the effect of receptor on GTP binding to the G protein. Above: 
Membranes with CB1 receptor enhance GTP binding to Gi protein but not to Gs. Receptor and G protein 
were used at 1:5 molar ratio. Below: Membrane with CB1 receptor leads to a specific fluorescence 
enhancement.  Doubling of Sf9 membrane in reaction doesn’t change the GTP binding whereas CB1 
membranes double the effect. Reactions were started by adding proteins to buffer containing Bodipy GTPγS. _______________________________________________________Results.. 
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An increase of the cell membrane concentration didn’t increase the Bodipy fluorescence in 
the case of Sf9 membranes but gave a clear additive effect with the membranes containing 
CB1 receptor. There was no significant change in GTP binding when Gαs protein was used 
instead of Gαi protein. The CB1 receptor doesn’t bind to Gs under normal conditions. 
 
3.11  GTPγS
35 binding assay to study CB1 receptor-Gi interactions 
 
   Sf9 cell membranes containing heterotrimeric G proteins alone or together with the 
cannabinoid receptor were used for the radiolabeled GTPγS
35 binding assay. The presence 
of all subunits in the cell membranes was confirmed by immunoblotting against each 
subunit. There was a clear increase in the GTPγS
35 binding when the receptor was co-
expressed along with the G proteins (Fig 3.45). This increase (~ 40% of the control) shows 
the constitutive activity of the receptor. Addition of the agonist WIN 55,212-2 increased the 
GTPγS
35 binding to a lesser extent. Addition of the antagonist AM251 completely inhibited 
the GTP binding to the G proteins. These ligand dependent effects could not be seen in the 
membranes lacking the receptor (control membranes). A similar observation was reported 
by Glass et al. (1999), where cannabinoid receptors present in Sf9 cell membranes and G 
proteins purified from brain were reconstituted. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.45: GTPγS
35 binding to the G proteins. 30 µg of the 
Sf9 cell membrane expressing Gαi1β1γ2 were used to check 
the background binding of GTP. 30 µg of membranes co-
expressing  CB1(417) receptor along with the G proteins were 
used to check the receptor induced increase in the GTP 
binding. 4µM agonist WIN 55,212-2 and antagonist 4 µM 
AM251 were used to see the ligand effect. Membranes were 
incubated at 30ºC for 1 hr.  4 nM radiolabeled GTPγS was 
used in the assay reactions. 10 µM GDP was included in all  
assay conditions. DPM is disintegrations per minute. _______________________________________________________Results.. 
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3.12  Co-immunoprecipitation of CB1 receptor-G protein complex 
 
Sf9 cell membranes containing Gαi1β
1γ
2 protein complex only or together with 
FHTCB1(417)StII were used for co-immunoprecipitation. The membranes containing only 
G proteins or receptor + G proteins together were solubilized using 1% decylmaltoside + 
0.2% cholesterol hemisuccinate mixture for 1 hr. The clarified supernatant was incubated 
with anti-flag antibody agarose at 4˚C for 1 hr. The matrix was washed thrice with buffer 
containing 0.2% DM + 0.04% CHS (5:1). Both samples were incubated in SDS-Gel loading 
buffer for 15 min. The samples were analysed using SDS-PAGE and immunoblotted (Fig 
3.46). The immunoblot with anti-flag antibody showed the CB1 receptor band at 45 Kda. 
An anti-his tag immunoblot showed the receptor band as well as the βγ dimer (γ has his tag 
on N-terminus) at ~34 Kda. The immunoprecipitated sample from the membrane 
containing only G proteins didn’t show any specific band in either immunoblots. The 
immunoprecipitated sample from both membranes containing G proteins alone or receptor 
+ G proteins together showed the Gα protein in the anti-Gi1immunoblot indicating a non-
specific interaction of Gα protein with the matrix.  But the signal obtained in the case of 
receptor + G proteins was higher than that of the G protein alone. 
 
 
 
Fig 3.46 : Immunoblots showing co-
immunoprecipitation of CB1 and Gαi1β
1γ
2 
complex: Sf9 cell membranes containing CB1-417 
receptor and Gαi1β
1γ
2 trimer complex was 
solubilised using mixture of DM and CHS. The 
complex was immunoprecipitated using anti-flag 
M2 antibody agarose matrix. The matrix was 
washed thrice and the bound protein was eluted by 
denaturation with SDS-Gel loading buffer. Lane 1= 
cell membrane solubilized contain only G protein 
trimer, Lane 2= cell membrane contains both 
receptor and G protein trimer. Antibodies used for identifying the different subunits of the complex are 
denoted on the left side of the image. The subunit that was identified is mentioned on the right side of the 
immunoblot image. Anti Gi1/Gi2 antibody immunoblot showed that Gα subunit has non-specific binding, to 
the matrix. But the intensity of Gα subunit was much higher when the receptor was present in the solubilizate. 
 
 _______________________________________________________Results.. 
  92
  
 
 
 
 
 
 
 
 
 
4. Discussion.. 
 
 
 
 
 
 
 
 
 
 
 
 
  _____________________________________________________Discussion.. 
  93
 
 
 
4 DISCUSSION 
_________________________________________________ 
 
4.1  Need to produce GPCR and G proteins 
 
The aim of the project is to find out the possibility of using G proteins to co-
crystallize with G Protein Coupled Receptors (GPCRs). GPCRs are membrane proteins and 
are difficult targets for structural determination by crystallography. The only known 
structure of a GPCR is that of bovine rhodopsin which is abundantly available in the retina 
(Palczewski et al., 2000). The amphipathic nature of the proteins renders them unstable in  
aqueous solutions and they need to be kept in a soluble form using the detergents. Most of 
the protein is covered with the detergent exposing little of its hydrophilic surface to make 
contacts during crystallization.  The hydrophilic portion which is comprised of N and C-
termini and the loop regions are highly flexible and may not be the suitable crystal contact 
regions. How ever this speculation might not be completely true. Most of these regions 
were assigned in the crystal structure of bovine rhodopsin, except a few cytosolic fragments 
which are supposed to be highly dynamic and interact with G proteins (Palczewski et al., 
2000). 
 
One possibility to overcome this problem is to increase the hydrophilic part of the 
protein which is more conformationally stable unlike the loop regions. The use of antibody 
fragments to increase the hydrophilic portion of the membrane proteins is a successful 
practice nowadays (reviewed by Hunte and Michel, 2002). Instead, if we can use   
physiologically interacting proteins like G proteins and arrestins for this purpose, the 
structure of the whole complex gives us valuable information about the functional 
interactions among them. There are several things we need to know before we think of co-
crystallizing these proteins. Does the interaction make these proteins to form a stable 
complex or is this just a transient interaction? If they form a complex, how strong is it? Can _____________________________________________________Discussion.. 
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we have this complex  in vitro, in a stable form for longer times needed for crystallization? 
Is it possible to express these proteins separately and mix them stoichiometrically to get a  
complex? Is it possible to express them together and purify the whole complex? To find an 
answer for these questions we need large amount of pure protein first of all.  
 
4.2  G protein production  
 
G proteins are the cytosolic counterparts of GPCR mediated signal transduction, 
which physically interact with the receptor at the membrane. G proteins are heterotrimers 
formed with one each of α, β and γ subunits. E. coli was used as a successful expression 
system for Gα protein production (Lee et al., 1994). Human Gα proteins (Gi, Gs, Gt) 
produced in E. coli were crystallized successfully (Noel et al., 1993; Coleman et al.,1994; 
Mou et al., 2006), in their ligand bound forms. 
 
 In the present work, 17 Gα subunits were cloned using Gateway cloning technology 
into pDEST14 vector under the T7 promoter. Gene sequences were analyzed by Rare codon 
calculator (RaCC) and found several rare amino acid codons in these human G proteins. So, 
BL21(DE3) Codon plus and Rosettagami(DE3)pLysS strains containing the t-RNAs for 
rare amino acid codons were used for protein production. Gαs family (except Gαolf) and 
Gαi/o family members could be expressed in higher yields (> 5mg/l) compared to the other 
proteins. Gαq and Gα12/13 family proteins could not be produced in E. coli, for reasons not 
clear. Gαq protein could be expressed in the Pichia pastoris expression system. This is a 
first attempt to produce G protein in Pichia. The protein was purified and crystallized. The 
initial crystals diffracted to 6.5 Å. Unexpectedly the protein production level has gone 
down drastically that it can not be purified anymore. This anomalous behaviour was 
observed in the lab for some other proteins as well. But the reasons are not clear yet. But 
recently Gαq (Tesmer et al., 2005) and Gα13 (Chen et al., 2005)  proteins have been 
expressed in insect cells in a chimeric form where the N-terminus of these proteins were 
exchanged with that of Gαi1 protein. Both proteins were crystallized and structures were 
determined. This shows that the N-termini of these proteins are crucial in their production. 
May be the acylation is a requisite for the successful production of these proteins or   
presence of  several positively charged residues present on the N-terminus of the protein 
reduces the protein production in prokaryotic expression system.    _____________________________________________________Discussion.. 
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  The production of the Gβ and Gγ subunits was not very successful in E. coli. Only 
two Gβ subunits could be expressed and none of the Gγ subunits. There are reports 
confirming that the Gβ and Gγ need to be expressed together to make a functional complex. 
It was found that, the Gβ co-expression is needed for the proper processing of the Gγ 
subunit and expression of the subunits individually makes them non-functional (Pronin et 
al., 1993). This might be the reason why they could not be expressed in E. coli.  Another 
explanation would be the small size of Gγ subunit and the simple helical structure that 
makes it highly prone to degradation. The Gβγ dimer produced in P. pastoris could not 
form a trimer complex with Gα subunits tested by gel filtration. It was also observed in the 
present work that most of the Gβγ dimer produced was in the cytosolic portion than in the 
membrane. Several reports confirm that Gα proteins can be produced in any expression 
system but Gβγ should be obtained from higher eukaryotic system in order to make a 
functional trimer complex (Resh, 1999). This shows the significance of isoprenylation on 
the Gγ subunit. It is not yet clear if P. pastoris can make this modification to Gγ subunit.  
 
4.3  Possibility of using G proteins for co-crystallization 
 
GPCR is an integral membrane protein and needs detergent to keep it in solution. If 
G proteins are to be used together with it, we have to confirm their stability in detergent 
solution. The same was done and surprisingly not all Gα subunits retained the capacity to 
bind to  GTP. The Gαs family members were highly susceptible to the detergent. Detergent 
above 1 CMC destroyed the G protein activity. This denaturation is not permanent but was 
reversible upon removal of detergent. This effect was the same with ionic and non-ionic 
detergents. The probable explanation is that the detergent is binding to a hydrophobic patch 
on the protein and thereby changing the conformation of the protein and thereby the 
binding pocket for GTP. On the other hand Gαi/o family proteins seemed to be active even 
at 50 times CMC (LM) of detergent. So the idea of using  Gαs family members for the co-
crystallization experiments might be improbable. Gαi/o family members are likely 
candidates for this purpose.  
 
Is Gα subunit sufficient to bind to the receptor or does it need Gβγ as well. This 
question is still debatable. In a report on solubilized N-formyl peptide receptor / G protein 
interaction studies, it was reported that individual Gα or Gβγ subunits could not alter the _____________________________________________________Discussion.. 
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ligand binding to the receptor (Bennett et al., 2001). The heterotrimer was needed. 
Whereas, in a recent paper on the rhodopsin / transducin interactions, it was reported that a 
native acylated Gα protein alone was capable of interacting with the receptor. But if Gα 
subunit lacks acylation, then it needs acylated Gβγ complex (Hermann et al., 2006). So, 
with the present knowledge we have, Gα proteins produced in E. coli might not be 
sufficient for the purpose of co-crystallization. 
 
What are the other probable alternatives for this purpose of co-crystallization? If it 
is difficult to produce subunits of the complex separately and make a functional complex in 
vitro, it might be possible to isolate the whole complex from the cell membranes. In the 
recent reports more and more GPCRs are found to be present in a complex with G proteins. 
If such a complex is not a mere transient complex, but stable, it can be isolated to use it for 
crystallization. But it is necessary to find out the ways to stabilize such a complex. The 
other potential proteins that can be used to co-crystallize with GPCRs are β-arrestins. β-
arrestins bind to the activated and phosphorylated receptors and terminate the signal of the 
receptors (reviewed by Pierce and Lefkowitz, 2001). These proteins, unlike G proteins are 
few in number and so bind to many receptors. One more class of physiologically interacting 
proteins with GPCRs are the scaffold proteins, which link GPCRs with several effector 
molecules (Hall and Lefkowitz, 2002). 
 
4.4  Why cannabinoid receptor? 
 
The cannabinoid receptors bind to Gi/o family members which are stable in 
detergent solution. An interesting feature of cannabinoid receptors is that they exhibit G 
protein sequestration and constitutive activity. By sequestration, cannabinoid receptors steal 
the Gαi/o proteins from a common pool making other GPCRs which use these G proteins 
non-functional (Vásquez, et al., 1999). This gives us an idea that one of the conformations 
of these receptors do exist in a complex with the G proteins which is not just a transient 
complex that forms upon activation by agonist. The next thing we should know is whether 
this conformation could be stabilized and maintained. The recently proposed mechanism of 
G protein sequestration by cannabinoid receptor 1 gives us a possible clue. According to 
this model, the receptor exists in two conformations: active and inactive. Both   
conformations also exist in a precoupled form to the G proteins. The active form in _____________________________________________________Discussion.. 
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complex with the G proteins is responsible for constitutive activity of the receptor. The 
inactive form precoupled to the G proteins can not be activated by agonists and is also 
responsible for the sequestration. Inverse agonists stabilize this inactive conformation and 
so boosts the equilibrium towards the inactive receptor bound to G proteins (IAR°G) (refer 
to the Fig: 1.15 in Introduction section). A recent report (Mukhopadhyay et al., 2005) gives 
the experimental proof for this hypothesis. It was shown by co-immunoprecipitation that 
CB1 receptor and G proteins exist in a precoupled form even in the absence of ligands. It 
was also shown that different ligands stabilize the different CB1/Gαi subtype complexes. 
These experiments were done using mammalian cells. If this CB1/Gαi complex can also be 
produced at high levels in heterologous expression system, it can be used for isolation and 
structural determination. This is one of the aims in this project, to see if this functional 
CB1/Gαi complex can be produced in the insect cell expression system, at higher levels. 
 
4.5  Production and purification of cannabinoid receptors 
 
Cannabinoid receptors were produced in different expression systems for functional 
and structural analysis. The initial trials of production of cannabinoid receptors for 
purification, was done by Grisshammer’s group in 1997. They reported that the CB2 
receptor could be produced to 38 pmol/mg but the CB1 receptor could not be obtained. The 
reason was the extensive degradation observed for the cannabinoid receptor 1 (Calandra et 
al., 1997). Following this work several groups have produced and purified the functional 
CB2 receptor in E. coli and purified to 85% (Yeliseev et al., 2005).  
 
 
 
 
 
 
 
Fig  4.1: Purified cannabinoid receptors 
analyzed by SDS-PAGE. Images taken from the 
publications of Krepkiy et al.,2006 and Xu et al., 
2005. 
 
Purified CB2  
expressed in E. coli  
Krepkiy et al, 2006 
Purified CB1  
expressed in Sf9 cells 
Xu et al, 2005 _____________________________________________________Discussion.. 
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Song’s group tried to express both the receptors in P. pastoris expression system. 
(Kim  et al., 2005). The results show that the yields of the proteins were sufficient to 
analyze by mass spectroscopy only. The reason for the poor protein yield was extensive 
washing of Ni-NTA matrix. Extensive washing was needed to improve the protein purity. 
The baculovirus mediated insect cell expression system was also explored by 
Makriyannis’s group. They faced the same problem of purification and low yield. Harsh 
washing steps such as washing with 8 M Urea were used in these purification experiments. 
So these results show that not a single successful protein purification system has been 
established yet for cannabinoid receptors. The purification of large amounts of functional 
receptors needed for structural studies is still to be explored, which is one of the aims of the 
present work. 
 
4.5.1  Production of the cannabinoid receptor 2 in P. pastoris  
 
  
 
 
 
 
 
Fig 4.2: Immunoblot and Coomassie 
stained SDS-PAGE gel showing the 
purified CB2 receptor. The band pattern 
on the SDS-PAGE shows high impurity 
levels. 
 
The protein produced was functional with respect to ligand binding. The western 
blotting analysis showed that there were several bands corresponding to the receptor. A 
smear was observed at the higher molecular weight range showing extensive aggregation of 
the recombinant protein produced. The protein obtained from Ni-NTA purification was 
impure. Washing had to be done with high (100 mM) imidazole concentration, generally 
used to elute the protein, to improve the purification. But there were still several high 
molecular weight bands which don’t correspond to the receptor. These results were similar 
to those published by Feng et al. (2002) during the same period.  Purification was not better 
Anti-Flag immunoblot 
of CB2 expressed  
in P. pastoris  
CB2 expressed in P. pastoris,
purified on Ni-NTA  
(100 mM imidazole wash 
and 500 mM elution) _____________________________________________________Discussion.. 
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even after using several other additives like glycerol, sucrose, urea to the buffers during 
washing. The second purification using the bio-tag  also did not improve the purity. Most of 
the protein was found bound to the matrix resulting in extremely low recovery of the 
receptor. This might be because of the presence of irreversible high affinity sites on the 
matrix for biotin. The gel filtration profile showed that the protein was aggregated. This 
means that the receptor was not homogenously produced in Pichia.   
 
4.5.2  Production of cannabinoid receptors in insect cells 
 
Several groups have tried to express cannabinoid receptors in insect cells. 
Purification attempts were also made for both the subtypes of receptors. The results show 
that the purification yields were very low and impure. Special note could be given to CB1 
receptor (Xu, 2005) where the authors report that several receptor bands were observed 
after purification. All these bands were analyzed by mass spectroscopy. All the bands 
correspond to the CB1 receptor. But in the lower band they couldn’t detect the N-terminal 
peptide, which might mean that this is a degradation product. A dimer corresponding to this 
truncated protein was also observed. In the present work I tried to purify the CB1 receptor 
using different tags (Fig 4.1). Several constructs were made to produce recombinant 
receptors fused to poly-histidine tag, Strep-tagII and Biotag at the termini. Worth 
mentioning is the truncated CB1 receptor where the C-terminal 54 amino acids were 
removed, to make a CB1 receptor with 417 amino acids. The importance of this construct is 
that the C-terminal 17 (401-417) amino acids are responsible for G protein activation and 
sequestration.  According to Nie et.al the truncated version enhanced both the constitutive 
activity and the ability of the receptor to sequester G proteins. This will be more useful for 
co-crystallization. All gene constructs produced the recombinant proteins in insect cells. 
The receptor produced, gave two bands on the immunoblots, major monomeric band and a 
higher oligomeric (~ 160-175 KDa) band probably tetrameric. This high molecular weight 
band was also observed by earlier investigators in brain tissue and other heterologous 
expression systems as well (Wager-Miller et al., 2002).  The protein produced was 
glycosylated as determined by the tunicamycin experiment. 
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Fig 4.3: CB1(417) receptor purification. 1. Ni-Tev-Ni 
purification of CB1(417)StII 2. Ni-NTA and Streptactin 
purification 3. Ni-NTA and Monomeric avidin 
purification of CB1(417)Bio 4.His-Select purification of 
CB1(417)Bio 
 
A two step affinity purification was followed for all the recombinant proteins 
produced. Protein purified from Ni-NTA column was highly impure. Ni-Tev-Ni strategy 
didn’t result in any betterment in purification. Digestion with the Tev protease was 
complete but the purity was not better. This might be because the impurities interact with 
the receptor or with the detergent micelle. Use of Strep-tagII improved the purity of the 
receptor. But the protein yield was very poor because of the loss of receptor in the flow 
through and wash. Very little protein specifically bound to the matrix which could be 
eluted. The reason could be an inaccessible strep-tagII or a conformation of the C-terminal 
tail reducing the affinity of the tag to the Streptactin matrix. Experience with the biotag was 
contrary. Monomeric avidin matrix was used to purify the receptor using the biotag. As 
experienced in many cases the receptor seemed to be sticking to the matrix which could not 
be specifically eluted. This in-turn reduced the recovery drastically. So neither Strep-tagII 
nor biotag were helpful for the receptor purification.   
 
Another possibility to improve the purity was optimizing the IMAC purification. 
Different IMAC resins were tested. Out of them His-Select from Sigma gave better purity. 
This matrix has less Ni density compared to Ni-NTA from Qiagen, which might have lead 
to lesser non-specific binding and thence better purity. Another Ni-IDA based matrix from 
Biorad (Profinity IMAC) resulted in loss of protein during loading itself because of week 
binding to the matrix. Protein obtained from His-Select purification and Ni-
NTA/Streptactin was better than other methods of purification, but the yield was not better. 
The gel filtration of these samples did not give a symmetric peak, because the protein is not 
homogenous. From the retention volume of the peaks (Fig 3.38) it can be said that protein _____________________________________________________Discussion.. 
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is present in oligomeric forms. The N-terminal truncated receptor (Fig 3.37-C) lacking N-
terminal tags might be the reason for lower yields in all the purification strategies. All the 
receptor that is present in the membrane is not captured by IMAC matrix. These results 
show that a lot of effort is still needed to improve the yield and purity of the protein. One 
important aspect to be thought of at this point is why there are so many impurities during 
the receptor purification. 
 
4.6  Reasons for the impurity 
 
There are several possible reasons for the high impurity levels for this receptor 
purification. One reason could be the degradation of the receptor itself as was observed by 
Xu et al, 2005. These N-terminal truncated forms could also form dimers or oligomers with 
the full length receptor and co-purify with it. Andersson et al, 2003 reported that compared 
to other class A receptors, CB1 has an exceptionally long N-terminal domain of 116 amino 
acids, which causes problems during protein targeting. They report that there is no clear 
signal sequence at the N-terminus and so it cannot be efficiently translocated across the ER 
membrane, causing the rapid degradation of CB1 receptor.  They propose that receptor 
trafficking might be mediated by chaperones. It might also be possible that these 
chaperones might be some of the impurities observed.  
 
A more probable reason for impurities could be that these are the proteins 
interacting with the receptor. Both, the yeast Saccharomyces and insect cells (Sf9, High 
Five Knight, 2004) possess G proteins which are homologs of mammalian Gq and Gi 
proteins. Cannabinoid receptors are known to exist in a precoupled form with the G 
proteins. These endogenous G proteins from the insect cells or yeast (not known for Pichia) 
might constitute some of the impurities.  Another possible reason is that the impurities are 
other endogenous GPCRs which might form dimers or oligomers with the CB1 receptor. In 
Drosophila melanogaster there are about 200 genes coding for GPCRs. Even though there 
are no cannabinoid receptors in insects (McPartland, 2001), there are sequences which are 
homologous to other mammalian receptors like dopamine receptors (Brody, 2000). 
Dopamine receptors are known to form dimers with cannabinoid receptors. Though it is not 
clear about  Pichia, Sf9 cells might have some GPCRs similar to dopamine receptor. So the 
endogenous GPCRs could also form dimers with the heterologously expressed CB1 _____________________________________________________Discussion.. 
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receptor and co-purify with it. But these reasons don’t sound convincing for the impurities 
obtained during CB2 receptor purification, which was expressed in E. coli (Krepkiy et al, 
2006). Several reports have shown that amino terminus is responsible for the rapid 
degradation of the CB1 receptor (Nordstroem et al, 2006).  
 
What more could be done to solve the problem of purification is a question to be 
thought of at this point. One probable way could be the expression of an amino terminal 
truncated receptor, in yeast or insect cells. This approach can solve the problem associated 
with truncation of the receptor. But how many amino acids can be removed from the N-
terminus, without destroying the function of the receptor has to be investigated. The CB1 
receptor and CB2 receptor share a 70% identity in the transmembrane regions. The CB2 
receptor has been successfully produced and purified where as the purification of CB1 
receptor is still a challenge. So another idea is to try to produce, in Pichia pastoris or insect 
cells, a chimeric protein between the amino terminus of the CB2 and the transmembrane 
regions of the CB1 receptor. Since it is more identical to CB2 receptor, it could be possible 
to purify this chimeric receptor. 
 
4.7  Ligand binding properties of the CB1 receptor 
 
Expression levels: Radioligand binding experiments were performed both with   
agonists and antagonists of cannabinoid receptor 1. Cannabinoid ligands are highly 
lipophilic with high lipid partition coefficient. They are almost insoluble or feebly soluble 
in water. This is why the non-specific binding is too high up to 80%. At least 1% BSA had 
to be included in the binding assay buffer to reduce the non-specific binding. BSA acts as a 
natural carrier for lipophilic molecules in the blood. The saturation binding assays gave Kd 
values comparable to the literature values (0.6 nM-7 nM). The Kd value for the full length 
CB1 receptor and  C-terminal truncated CB1(417) is between 2.0 to 3.6 nM. The Bmax 
values for the CB1StrepII and CB1(417)StrepII were 40 and 53 pmol/mg membrane protein 
respectively. This expression level is almost two fold higher than the levels reported for the 
CB1 receptor (24 pmol/mg in Xu et al., 2005). The agonist saturation binding of 
CB1StrepII gave a Bmax 5 times lower than that of antagonist value. This shows that most 
of the receptor produced was in an inactive R conformation, which has high affinity for the 
antagonist but does not bind agonist. _____________________________________________________Discussion.. 
  103
 
Salt and Mg
2+ effect: High sodium chloride concentrations reduced the agonist 
binding to the receptor. But there was no effect on the antagonist binding. The Kd of the 
agonist CP 55,940 to the receptor was almost double in the presence of 1M NaCl.  The 
Bmax was also reduced to 60%. This is consistent with the earlier discoveries that Na
+ 
reduces the agonist binding to the Gi coupled GPCRs (Swaminathan et al., 2003). Mg
2+ 
was necessary for agonist binding but not for antagonist binding. Mg
2+  might have an 
allosteric effect on agonist binding. Zn
2+ was shown to have a similar effect on the β-
adrenergic receptor (Swaminathan et al., 2003). 
 
Detergent effect: Detergents like OG, LDAO, Foscholines at 1.5 CMC completely 
hindered the ligand binding even though the exposure time of cell membranes and the 
detergents was only a few seconds normally not sufficient for solubilization. This could be 
because the ligand is entrapped in the micelle and not available for receptor binding. 
Laurylmaltoside and decylmaltoside didn’t reduce the ligand binding in this pre-screening 
and hence these detergents were selected to use in protein purification.  
 
Ligand binding could not be detected in the solubilized or purified cannabinoid 
receptor. Several techniques like glass fiber filters, activated charcoal, calcium phosphate, 
gel filtration have been used to investigate the ligand binding. There was no specific 
binding. The high non-specific binding was the reason. Cannabinoid ligands show high 
non-specific binding because of their high lipid partition coefficient. Glass fiber filter assay 
is not a reliable technique because the solubilized receptor can pass through the filter pores. 
Gel filtration on Sephadex columns was also not reproducible because BSA used in the 
binding and wash buffers bind to cannabinoid ligands and elutes at the same void volume 
where the receptor is expected. There by giving high back ground binding.  Water soluble 
ligands  could help to solve this problem of high non-specific binding. But there is no such 
radiolabeled ligand commercially available. 
 
DTT effect: DTT reduced the agonist binding to the receptor but not antagonist 
binding. The receptor retained the agonist binding capacity even till 10 mM DTT 
concentration where a disulphide bond doesn’t exist. This shows that a disulphide bond 
might not be present in the receptor or not be important for ligand binding. This could be _____________________________________________________Discussion.. 
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true because in the predicted secondary structure of the receptor there is no cysteine in the 
first extracellular loop. This cysteine is the one which forms a disulphide bond with the 
cysteine in the second extracellular loop. Shire et al. in their work, to find out the structural 
features that are responsible for the ligand binding, proposed that cysteines in the second 
extracellular loop might directly play a role in ligand binding (Shire et al., 1996).  
 
  Ligands in the culture: Ligands were added to the culture to see if it is possible to 
produce the receptor in one confirmation.  Presence of the agonist WIN 55,212-2 in the cell 
culture media didn’t affect binding of the hot agonist CP55940 to the receptor. But when 
the antagonist AM251 was added to the culture, these cells or membranes didn’t show 
agonist binding anymore.  The possible explanation for this observation could be that the 
antagonist in the culture favours the inactive conformation “R” instead of active “R*” and 
so agonist cannot bind to the receptor anymore. So it might be possible that we can lock 
one particular conformation of the receptor by adding high affinity antagonist to the culture. 
This would be of help to get a conformational homogeneity. 
 
4.8  The CB1 receptor-Gαi precoupled complex in the cells 
 
 
 
 
 
 
 
Fig 4.4: Confocal images showing the colocalized receptor and Gi protein. The blue regions represent the 
Gi-CFP and red regions represent the CB1-YFP. 
 
Several investigations have shown that the CB1 receptor exists in a precoupled form 
with the G proteins. Two different precoupled forms can exist according to the ternary 
complex model. One is the inactive “RGGDP” and other is active “R*GGTP” form. Nie et.al 
proved this by the patch clamp technique showing the constitutive activity of the CB1 
receptor expressed in the nerve cells.  “R*GGTP” form is responsible for the constitutive 
activity of the receptor. Present experiment showed that the existence of a precoupled form 
of recombinant proteins in a heterologous expression system. Cannabinoid receptor fused to 
Real Image  Iso image 
top view 
Iso image 
side view _____________________________________________________Discussion.. 
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YFP, Gi protein fused to CFP and βγ were coexpressed in Sf9 cells.  Confocal microscopy 
was used to see the receptor-G protein precoupled form by FRET. When the acceptor was 
bleached there was an increase in the donor fluorescence upto 7% (average of 10 cells with 
min 4% and  max 15% increase). This happens only when the donor and the acceptor 
molecules are in close contact and involved in FRET.  As a negative control the histamine 
H1 receptor fused to YFP and the CB1 receptor fused to CFP were coexpressed and the 
experiment was conducted in the same way. There was a donor fluorescence increase of 
less than 2%, which might be because of the lateral overlapping of the molecules present in 
the membrane. This value was considered negative. A recent report confirms the existence 
of this kind of precoupled receptor-G protein complexes. Nobles et al., 2005 showed that 
the muscarinic receptor (M4), the α adrenergic receptor (α2A), the adenosine receptor (A1), 
the dopamine receptor (D2) do exist in precoupled form with their corresponding G 
proteins. These investigations were also carried out using the FRET technique. 
 
  Cannabinoid receptor was shown to exhibit constitutive activity in the neuronal cells 
using patch clamp technique (Vasquez et al., 1999). To investigate the constitutive activity 
of the receptor in a reconstituted system fluorescent GTP binding assay was performed. Sf9 
cell membranes expressing the CB1 receptor were mixed with the G proteins expressed in 
E. coli and purified. If the receptor shows the constitutive activity there should be an 
increase in the GTP binding without the addition of any agonist. Gs protein which doesn’t 
couple to the CB1 receptor didn’t show any enhancements in the GTP binding with or 
without the addition of CB1 receptor containing membrane. But Gi protein showed an 
additive increase of BODIPY GTPγS with increasing membrane concentration. No ligand 
was included in the reactions. These results prove that the receptor couples to the Gi protein 
even without the activation of agonist and exhibits basal activity.     
 
A similar experiment was performed with the radioactive GTPγS ligand. It was 
observed that there was a significant increase in the GTP binding when CB1 receptor was 
co-expressed along with the G protein trimer. No ligand was included in this experiment. 
Agonist further increased the GTP binding but to a lesser extent, which could be because of 
the presence of receptor in an inactive conformation not recognized by agonist, as seen in 
saturation binding assay of CB1 receptor with agonist CP-55,940 (Table 3.2). Antagonist 
AM251 inhibited the receptor dependent increase in the GTP binding. These results are _____________________________________________________Discussion.. 
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similar to those observed by Glass et al., 1999. They used a reconstituted system containing 
Sf9 membranes with CB1 receptor and G proteins purified from bovine brain. But from the 
present experiment it is evident that the cannabinoid receptor/Gi protein coexpressed in our 
heterologous expression system exhibits constitutive activity.  
 
Co-immunoprecipitation of detergent (DM) solubilized FHTCB1(417)StII receptor 
and Gi1β
1γ
2 proteins using Anti-Flag M2 antibody agarose matrix proved that the receptor / 
G protein exist together and can be co-precipitated. No ligands were included in these 
experiments. Still both the partners were found to be coupled together. It is necessary to see 
if addition of ligands stabilize this complex as was seen in neuroblastoma cells in 
Mukhopadhyay et al., 2005. Further experiments are needed to see if this complex can be 
purified in a functional and homogenous form to use it for crystallization.  
 
4.9 Conclusion: 
 
  The aim of the project was to investigate the possibility of using Gα proteins to co-
crystallize with G protein-coupled receptors, several recombinant human Gα protein 
subunits had been successfully produced in the E. coli expression system. Some of these 
proteins were purified to homogeneity. Detergent stability of the G proteins was tested and 
found that not all G proteins were stable in detergent solutions. More and more reports are 
stressing on the necessity of a functional G protein trimer to form a GPCR-G protein 
complex, which is not possible in E .coli. It is more probable to produce the whole receptor-
G protein complex in a higher eukaryotic expression system and use it for crystallization. 
For this purpose functional cannabinoid receptor 1 was produced alone and together with G 
proteins in the insect cell expression system. Extensive work on production of the 
cannabinoid receptor 1 resulted in levels almost double than those reported by other groups. 
Despite several difficulties in receptor purification, small scale purification had been 
established for the CB1 receptor. It was also proved that the cannabinoid receptor 1 and 
Gi1β
1γ
2 proteins form a functional complex in the insect cells. It was observed by FRET 
experiments that the receptor and G proteins are precoupled. This precoupled complex was 
confirmed by GTP binding experiments. It was also proved that the complex can be 
solubilized and co-immunoprecipitated. Further efforts are needed to purify the receptor or 
receptor/ G protein complex in higher yields needed for crystallization.
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A1. pDEST14 vector:   Expression vector used in GATEWAY
® cloning technology 
Resistance:    Ampicillin  and  Chloramphenicol  antibiotic  resistance 
Promoter:    T7  promoter 
E. coli Origin of replication:  pBR322 
Recombination:   attR1 and attR2 
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A2. pPIC3.5K vector:  Vector for soluble protein expression in P. pastoris 
Resistance:    Ampicillin  and  Kanamycin 
Selection in Pichia:    His4 (gene) 
Promoter:      Alcohol Oxidase promoter (AOX1) 
E. coli Origin of replication:  pBR322 
 
 
 
 
 
 
 
 
 
 
 
 
 
A3. pPIC9K vector:    Vector for membrane protein expression in P. pastoris 
Resistance:    Ampicillin  and  Kanamycin 
Selection in Pichia:    His4 (gene) 
Promoter:      Alcohol Oxidase promoter (AOX1) 
E. coli Origin of replication:  pBR322 
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A4. pVL1393 transfer vector:     Vector to transfer the foreign gene into baculovirus    
Resistance:     Ampicillin   
Promoter:     Polyhedrin  promoter 
E. coli Origin of replication:    ColE 
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A5. pMIB/V5-His:     Vector for generation of stable (Sf9, Sf21, H5) insect cell line 
expressing membrane proteins. 
Promoter:  pOpIE2  (from  Orgyia pseudotsugata) 
Signal sequence:    Honey bee melittin signal sequence 
E. coli Ori of replication:  pUC   
Antibiotic resistance:  Ampicillin and Blasticidin 
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A6. CB1&CB2 protein sequence alignment 
 
CB1: Human Cannabinoid receptor 1 
CB2: Human Cannabinoid receptor 2 
  
 Identity:     (31.9%) 
 Similarity:   (43.9%) 
   
 
 
CB1         1 MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPL     50 
                                                                        
CB2         1                                                         0 
 
 
CB1        51 TSFRGSPFQEKMTAGDNPQLVPADQVNITEFYNKSLSSFKENEENIQCGE    100 
                                    .::..:||..|.|......|         
CB2         1                       MEECWVTEIANGSKDGLDSN--------     20 
 
              TM1       
CB1       101 NFMDIECFMVLNPSQQLAIAVLSLTLGTFTVLENLLVLCVILHSRSLRCR    150 
                 .::.:|:|:..|:.|:|||...||..:.|||:.||.:||.|..||.: 
CB2        21 ---PMKDYMILSGPQKTAVAVLCTLLGLLSALENVAVLYLILSSHQLRRK     67 
 
             TM2 
CB1       151 PSYHFIGSLAVADLLGSVIFVYSFIDFHVFHRKDSRNVFLFKLGGVTASF    200 
              |||.||||||.||.|.||:|..||::|||||..||:.|||.|:|.||.:| 
CB2        68 PSYLFIGSLAGADFLASVVFACSFVNFHVFHGVDSKAVFLLKIGSVTMTF    117 
 
        TM3                                    TM4 
CB1       201 TASVGSLFLTAIDRYISIHRPLAYKRIVTRPKAVVAFCLMWTIAIVIAVL    250 
              |||||||.|||||||:.:..|.:||.::||.:|:|...:||.::.:::.| 
CB2       118 TASVGSLLLTAIDRYLCLRYPPSYKALLTRGRALVTLGIMWVLSALVSYL    167 
 
               TM5 
CB1       251 PLLGWNCEKLQSVCSDIFPHIDETYLMFWIGVTSVLLLFIVYAYMYILWK    300 
              ||:||.|  ....||::||.|...||:.|:...:.|...|:|.|.::||| 
CB2       168 PLMGWTC--CPRPCSELFPLIPNDYLLSWLLFIAFLFSGIIYTYGHVLWK    215 
 
 
CB1       301 AHSHAVRMIQRGTQKSIIIHTSEDGKVQVTRPDQARM--DIRLAKTLVLI    348 
              ||.|..         |:..|  :|.:|    |..|||  |:||||||.|: 
CB2       216 AHQHVA---------SLSGH--QDRQV----PGMARMRLDVRLAKTLGLV    250 
 
     TM6               TM7 
CB1       349 LVVLIICWGPLLAIMVYDVFGKMNKLIKTVFAFCSMLCLLNSTVNPIIYA    398 
              |.||:|||.|:||:|.:.:...::..:|..|||||||||:||.|||:||| 
CB2       251 LAVLLICWFPVLALMAHSLATTLSDQVKKAFAFCSMLCLINSMVNPVIYA    300 
 
 
CB1       399 LRSKDLR-----------------------HAFRSMFPSCEG----TAQP    421 
              |||.::|                       .|.||.....|.    |..| 
CB2       301 LRSGEIRSSAHHCLAHWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWP    350 
 
 
CB1       422 LDNSMGDSDCLHKHANNAASVHRAAESCIKSTVKIAKVTMSVSTDTSAEA    471 
              ....:..|||                                         
CB2       351 DSRDLDLSDC                                            360 
 
 
CB1       472 L                472 
 
| = identical amino acid, : =similar amino acid, . =dissimilar amino acid, TM = 
transmembrane helix   129
A.7 Primers: 
 
CB1 receptor primers for baculovirus expression system 
 
CB1FBV  
 
5’ GC G GAT CC G ACC ATG GCG AAG TCG ATC CTA GAT GGC 3’  
 
CB1RBV  
       NotI                          
5’ GAA T GC GGC CGC  TCA CTT TTC GAA TTG AGG GTG CGA CCA  
    EcoRI 
GAA TTC AGC CTC GGC AGA CGT GTC TGT GGA 3’  
 
 
CB2 receptor primers for Baculovirus expression system 
 
CB2Forward 
 
5’ GC G GAT CC G ACC ATG GAG GAA TGC TGG GTG ACA 3’ 
 
CB2Reverse 
 
5’ CCA GAA TTC GCA ATC AGA GAG GTC TAG ATC 3’ 
 
 
CB1 receptor truncations 
 
 
CB1-417Rev: CB1 C-terminal 55 amino acids truncation 
 
5’ CCA GAA TTC GCC TTC ACA AGA GGG AAA CAT 3’ 
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A.8 Gαi1-CFP fusion protein 
 
 
 
 
PCRIGi: 
 
FwdGiI: 5’ GC GGA TCC ACC ATG GGC TGC ACG CTG AGC 3’ 
        BamHI 
 
RevGiI: 5’ TTC TCT AGA CAC CAT GGT TGA ATA ACC AGC TTC ATG 3’ 
                                XbaI                NcoI   
     
PCRIIGi: 
 
FwdGiII: 5’ ACC ATG GTG TCT AGA GAA GAG GAG TGT AAA CAA 3’ 
                            NcoI                XbaI 
 
RevGiII: 5’ GC GAA TTC TTA AAA GAG ACC ACA ATC 3’ 
                              EcoRI    
 
PCRCFP: 
 
CFPFwd: 5’ CAT ACC ATG GTG AGC AAG GGC GAG GAG 3’ 
                                      NcoI 
 
CFPRev: 5’ TTC TCT AGA CTT GTA CAG CTC GTC CAT 3’ 
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